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Abstract 
 
The concept of autoantibodies was developed at a time when, due to the limitations of culture-
based techniques, the human body was considered to be largely sterile. However, over the 
past few years, researchers in the emerging field of metagenomics have developed molecular 
tools that instead allow microbes to be identified by their genomic fingerprints. These tools 
have opened a door to an era of tremendous discovery. Homo sapiens has been shown to 
harbor thousands of species of microbes in tissue and blood that were previously undetectable. 
Today it is estimated that around 90% of the cells in the human body are microbial, and that 
the genes of these microbes outnumber our own by a factor of at least 10:1. The genomes of 
intracellular microbes can directly interact with our own genomes, meaning that humans may 
be best described as superorganisms. When populations of these microbes interfere too much 
with  the  metabolism  of  Homo  sapiens,  the  resulting  changes  in  the  proteome  can  lead  to 
disease. This suggests that the inflammation observed in "autoimmune" disease may instead 
result from an effort by the innate immune system to target pathogens and restore microbial 
homeostasis. Many intracellular microbes survive by dysregulating the expression of genes 
and antimicrobials via key nuclear receptors. The VDR nuclear receptor plays a critical role by 
expressing  cathelicidin  and  TLR2,  the  primary  intracellular  defenses.  It  appears  that  the 
pathogens  that  cause  autoimmune  disease  accumulate  during  a  lifetime,  with  individuals 
increasingly accumulating microbes as the innate immune response becomes incrementally 
compromised. One reason that autoimmune disease is more common in women may be that 
they have an additional site of VDR expression, in the cycling endometrium. Thus, they may 
more  easily  acquire  microbial  loads  than  their  male  counterparts.  The  interaction  of  many 
different microbes acting in concert is more likely to cause a particular autoimmune condition 
rather than, as Koch suggested, a single organism. This helps account for the high levels of co-
morbidity  observed  amongst  patients  with  autoimmune  conditions.  Autoantibodies  are 
increasingly  being  identified  as  the  body's  response  to  specific  pathogens,  with  collateral  
vi 
damage from these antibodies exacerbating the disease process. The possibility that microbes 
drive  the  autoimmune  disease  state  calls  for  a  re-evaluation  of  how  these  diseases  are 
routinely  treated.  While  the  standard  of  care  for  autoimmune  disease  remains  the  use  of 
medications that slow the immune response, treatments aimed at eradicating pathogens would 
attempt  instead  to  stimulate  the  body's  antimicrobial  defenses.  We  have  collaborated  with 
American and international clinicians to research a therapy designed to reactivate the innate 
immune  response  in  patients  with  autoimmune  disease.  Our  case  series  demonstrate  that 
patients  generally  report  symptomatic  improvement,  but  only  after  experiencing  temporary 
increases in inflammation and disease symptoms. This is likely due to immunopathology - a 
reaction in which the release of cytokines and cellular debris accompany microbial death. Thus 
we must reconsider the long-term consequences of using immunosuppressive substances. For 
example, the secosteroid vitamin D reduces inflammation, but may do so at the expense of 
slowing  the  innate  immune  response  and  its  ability  to  target  underlying  pathogens. 
Furthermore, the concept of vitamin D "deficiency" may itself be flawed. The low levels of 25-D 
in  many  patients  with  inflammatory  conditions  may  be  a  result  rather  than  a  cause  of  the 
disease  process.  Conventional  interpretation  of  other  out-  of-range  metabolites  must  be 
similarly re-examined. This work offers a novel framework with which to understand and treat 
inflammatory  disease,  with  broad  implications  across  many  disciplines.  Efforts  to  further 
validate this model are needed, taking researchers down entirely new avenues of exploration.  
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1 
General introduction 
 
In  2010,  Sapkota  used  16S  rRNA-based  taxonomic  microarray  to  show  that  bacteria 
persisted in five commonly smoked brands of cigarettes.
1 Such genomic sequencing tools as 
well as pyrosequencing and single cell sampling techniques can identify microbes by their 
genetic fingerprints and have proven vastly more effective than the culture-based techniques 
used for most of the past century. In fact, Sapkotaʼs method for identifying bacteria proved 
so powerful that she identified fifteen classes of bacteria and a broad range of pathogenic 
organisms in every cigarette tested – the vast majority of which have never been identified 
by in vitro technologies. While cigarette smoking has been linked to disease for some time, 
results like this imply that we must re-examine the hypotheses that underpin most of our 
research. By allowing for the identification and characterization of microbes in tissues once 
considered sterile, these new molecular tools allow much more compelling explanations for 
how disease develops and proliferates.    
 
Autoimmune  disease  is  widely  understood  to  be  a  form  of  illness  in  which  the  adaptive 
immune system loses tolerance and begins to create autoantibodies against self. Over the 
past decades, researchers have characterized the relentless and long-standing inflammation 
that defines these diseases and their relapsing/remitting nature, but have not conclusively 
proven causation. 
 
Numerous studies point to the chronic presence of microbes in patients with autoimmune 
disease,  suggesting  that  they  could  play  a  role  in  the  disease  process.  However,  the 
autoimmune community continues to rely heavily on culture-based methods for microbial 
detection  rather  than  use  molecular  tools.  Thus,  microbial  prevalence  and  diversity  are 
greatly underestimated in vivo. Tissue, blood, and cells continue to be regarded as largely 
sterile.  In  addition,  historical  assumptions  still  dominate  the  study  of  any  identified  
2 
pathogens. Researchers are expected to adhere to Kochʼs postulates and consequently the 
notion of “one microbe, one disease” continues to hold sway.  
 
Yet  at  the  same  time,  researchers  in  another  disparate  field  are  actively  re-defining  the 
human/microbe relationship. That field is metagenomics - a specialty in which researchers 
perform  genomic  analysis  of  the  microorganisms  present  in  a  specific  habitat  (a 
microbiome). In 2007, the NIH Human Microbiome Project was initiated, allowing dozens of 
research teams to identify previously undetected microbes and explore their ability to directly 
interact with the human genome.
2 Some commentators have gone so far as to refer to the 
human  body  as  a  superorganism  "whose  metabolism  represents  an  amalgamation  of 
microbial  and  human  attributes."
3  Thus,  metagenomic  studies  examine  the 
metatranscriptome, or the expressed genetic information of an entire ecosystem. 
  
It  is  now  accepted  that  over  90%  of  cells  in  the  human  body  are  bacterial,  fungal,  or 
otherwise non-human in origin. Only a fraction of these microbes have been characterized, 
much less identified. The sheer number of non-human genes represented by the human 
microbiota – 1,000,000+ compared to the meager 23,000 in the human genome – implies we 
have just begun to fathom the full extent to which microbes impact the human condition in 
both health and disease.  
 
Yet, as discussed above, most researchers in the field of autoimmunity have yet to apply 
these new findings to their work. This thesis represents an effort to cross-pollinate research 
from the field of autoimmunity with the copious data emerging from metagenomic studies.  
 
We expound a novel model, a pathogenesis for autoimmune disease that describes how the 
genomes of many intracellular pathogens can interact directly with the human genome in  
3 
order to cause the catastrophic metabolic dysbiosis associated with the autoimmune disease 
state.  
 
This pathogenesis centers on how communities of intracellular microbes can dysregulate 
gene expression by key nuclear receptors, particularly the vitamin D nuclear receptor (VDR), 
in order to promote their survival. Evidence is presented showing that microbial communities 
may act in concert to drive the inflammation characteristic of the autoimmune disease state 
and  even  the  production  of  what  are  currently  considered  “autoantibodies.”    These 
pathogens  are  acquired  gradually  over  a  lifetime  so  that  the  mix  of  species  acquired 
determines which autoimmune symptoms and syndromes a person may eventually develop.  
 
Chapter 1 introduces the VDR and 
its  vital  role  in  controlling 
components of the innate immune 
response  including  expression  of 
TLR2  and  the  beta-defensin  and 
cathelicidin antimicrobial peptides.  
It  also  expresses  important 
genes  involved  in  autoimmune 
and inflammatory disease processes (see Figure 1).  The chapter posits in silico research 
showing  that  the  sulphonolipid  capnine,  created  by  Lysobacter,  likely  dysregulates  the 
receptor  in  order  to  promote  its  survival.  By  chapter  4,  more  detailed  in  vitro  data  is 
presented showing that Mycobacterium tuberculosis, Borrelia, and Epstein-Barr virus also 
dysregulate  the  VDR.  Because  disabling  the  innate  immune  system  is  such  a  logical 
pathogenic  survival  mechanism,  other  yet  to  be  characterized  microbes  almost  certainly 
persist  in  a  similar  fashion.  Chapters  1  and  2  focus  on  the  flow-on  effects  of  such 
Figure 1.  Select proteins transcribed by the Vitamin D  
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dysregulation. Chapter 1 illustrates how VDR dysregulation may cause the active vitamin D 
metabolite  1,25-D  to  rise  and  subsequently  affect  expression  of  antimicrobial  peptides 
expressed by other key nuclear receptors such as thyroid beta. This may impact women 
more severely as the cycling endometrium provides an added site of VDR expression and 
subsequently potential dysregulation in females. Indeed, chapter 2 presents data showing 
that of 100 patients with autoimmune disease, 81% present with 1,25-D levels above the 
“normal” range. 
 
Chapter  3  explores  how  both  1,25-D  and  the  inactive  vitamin  D  metabolite  25-D  affect 
transcription  by  the  VDR  and  subsequently  activity  of  the  innate  immune  response.  The 
mechanisms by which vitamin D palliates autoimmune symptoms and the concept of vitamin 
D deficiency are both re-evaluated in a new light. A novel model of vitamin D metabolism is 
described  in  which  the  low  levels  of  25-D  often  observed  in  patients  with  autoimmune 
disease are a result rather than a cause of the inflammatory disease process.  
 
Chapter 4 introduces the novel concept of “successive infection.” Patients who present with 
autoimmune  disease  acquire  pathogens  in  numerous  ways  including,  but  not  limited  to, 
childhood infection, vaccines, blood transfusions, and parental exposure (such as microbes 
in the sperm and egg). Successive infection dictates that, because many of these pathogens 
likely slow AMP expression via the nuclear receptors, such patients become increasingly 
immunocompromised. This creates a snowball effect in which each pathogen that decreases 
immune activity makes it easier for the host to pick up other pathogens and so on. Chapter 5 
builds  on  this  hypothesis,  supporting  it  with  novel  data  and  describing  in  detail  how  the 
process may account for the high levels of co-morbidity and familial aggregation observed 
among  patients  with  autoimmune  disease.  Chapter  5  also  presents  substantial  data 
supporting  the  hypothesis  that  “autoantibodies”,  often  polyspecific,  are  created  when  the  
5 
innate  immune  system  responds  to  the  microbiota  and  a  cascade  of  cytokines  and 
chemokines  stimulate  the  adaptive  response.  Weaknesses  associated  with  a  Mendelian 
model of inheritance in autoimmune disease are also discussed.  
  
Chapter 6 introduces a therapeutic model for autoimmune disease that has formed the basis 
of our collaboration with United States-based and international physicians during the past 
eight years. The putative VDR agonist olmesartan is used to correct VDR dysregulation and 
prime the immune system to kill the intracellular pathogens driving the autoimmune disease 
process. Case series and histories are presented that examine the effects of the treatment in 
a variety of autoimmune diagnoses, most showing improvement and/or reversal of disease 
symptoms.  Unfortunately  increased  microbicidal  activity  results  in  immunopathology  -  a 
temporary rise in symptoms due to apoptosis and toxin release. Challenges associated with 
managing immunopathology are discussed.   
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   CONTEMPORARY CHALLENGES IN AUTOIMMUNITY
Dysregulation of the Vitamin D Nuclear
Receptor May Contribute to the Higher
Prevalence of Some Autoimmune Diseases
in Women
Amy D. Proal,a Paul J. Albert,b and Trevor G. Marshallc
aGeorgetown University, Washington, DC, USA
bWeill Cornell Medical College, New York, NY, USA
cMurdoch University, Perth, Australia
Researchershavenotedthattheincidenceofautoimmunediseases,suchasHashimoto’s
thyroiditis, is markedly higher in women than in men, but to date the reason for this
disparity has been unclear. The vitamin D nuclear receptor (VDR) is expressed in the
human cycling endometrium. Because the VDR controls expression of the cathelicidin
and  -defensin antimicrobial peptides (AmPs), dysregulation of the receptor greatly
compromises the innate immune response. Increasing evidence indicates the presence
of a chronic, intraphagocytic, metagenomic microbiota in patients with autoimmune
disease that may survive by dysregulating the VDR. VDR dysregulation, in turn, pre-
vents the breakdown of the active vitamin D metabolite 1,25-hydroxyvitamin D (1,25-D)
by CYP24. In silico data suggest that when 1,25-D rises above its normal range, it binds
the  /  thyroid receptors, the glucocorticoid receptor (GCR), and the androgen receptor
(AR), displacingtheirnative ligands and causing an array of hormonal imbalances. IfT3
is displacedfrom -thyroid,thyroiditismay result.Because theVDR, GCR, and ARalso
expressmultiplefamiliesofAmPs,expressionofthesenaturalantibioticsfurtherwanes
in response to dysregulation by 1,25-D. The end result is a system-wide drop in AmP
expression that may allow pathogens to spread with greater ease. Because women have
an extra site of VDR expression in the endometrium, the drop in AmP expression as-
sociated with nuclear receptor dysregulation may disproportionately affect them. This
would cause women to accumulate higher bacterial loads than their male counterparts,
particularly during early pregnancy when 1,25-D levels rise by 40%.
Keywords: vitaminDreceptor;metagenomicmicrobiota;1,25-dihydroxyvitaminD;an-
timicrobialpeptides;Hashimoto’sthyroiditis;autoimmunedisease;pregnancy;vitamin
D; olmesartan; women
Introduction
Systemic lupus erythematosus (SLE) and
multiple sclerosis (MS) were ﬁrst recorded over
100 years ago. Even at that time, it was noted
thatthediseasesaffectmorewomenthanmen.1
Today it is estimated that autoimmune disease
affects approximately 8% of the population,
Address for correspondence: Amy Proal, 400 East 71st Street,
Apartment 14A, New York, NY 10021. Voice: +917.848.0238.
amy.proal@gmail.com
78% of whom are women.2 Sex distribution
in autoimmune disease, such as rheumatoid
arthritis (RA), MS, and myasthenia gravis is
around 60–70%. The most striking sex differ-
encesareobservedinSjogren’ssyndrome,SLE,
and scleroderma; these sex differences come
from a spectrum of diagnoses in which the pa-
tient population is >80% women.1
Autoimmune thyroid diseases, such as
Hashimoto’s thyroiditis, fall into the latter
category. Beeson has reported that approx-
imately 85% of patients with Hashimoto’s
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Figure 1. Co-morbidity of Hashimoto’s thyroiditis
with other autoimmune diagnoses.
thyroiditis are women.3 This rate of incidence
isconﬁrmedbydataobtainedfromaretrospec-
tive trial in which a vitamin D nuclear receptor
(VDR)agonistandbacteriostaticantibioticsare
used to treat patients with various autoimmune
diagnoses. While members of both sexes were
allowed to participate in the trial, out of 100
subjects with autoimmune disease surveyed, 24
had Hashimoto’s thyroiditis and only three of
them were men (see Fig. 1) (J.C. Waterhouse,
personal communication, 2008).
Evidence for important interplays between
the endocrine and immune systems has
launched the new ﬁeld of neuroimmunoen-
docrinology, which has attracted the interest
of scientists and clinicians alike.4 Since autoim-
mune diseases often show preference for one
sex, attention has been given to the possible
role of sex hormones in affecting the disease
process.5,6
The sex hormonesactivateorrepress theac-
tivity of speciﬁc nuclear receptors, which form
homodimers and heterodimers that directly
bind DNA in order to regulate the expression
ofgenes.Giventhewidespreadrelevanceofthe
superfamily of nuclear receptors to almost all
aspects of normal human physiology and the
role they play in the etiology in human disease,
a detailed understanding of these systems has
major implications not only for human biology
but also for the understanding and develop-
ment of new therapies.7
However, the majority of the body’s nuclear
receptors are not activated by sex hormones.
The potential of gender-related differences in
the expression of these nonandrogenic nuclear
receptorstoaffecttheautoimmunediseasepro-
cess has received less attention. This chapter
focuses on how differential expression of the
VDR in females may contribute to the higher
prevalence of autoimmune disease in women.
It also examines how VDR dysregulation may
impacttheautoimmunediseaseprocessinboth
sexes.
The Vitamin D Receptor Is
Expressed in the Human Cycling
Endometrium
As discussed above, sex hormone expression
differs between males and females. But, the ac-
tivevitaminDmetabolite1,25-hydroxyvitamin
D (1,25-D) and its target nuclear receptor,
VDR, are also expressed in different quantities
in males and females. Both sexes express the
VDR in the keratinocytes, macrophages, and
body tissue.8 However, Vigano’s recent work
shows that 1,25-D and the VDR are expressed
in the human cycling endometrium, meaning
that women possess an extra site of VDR gene
expression when compared to their male coun-
terparts.9 Because the VDR plays a vital role
in activating the innate immune response, this
gender-based difference may have far-reaching
consequences.
The innate immune response serves as the
body’s ﬁrst line of defense against infection.
The VDR is activated by 1,25-D to directly
induce expression of the cathelicidin and  -
defensin antimicrobial peptides (AmPs).10 Fur-
thermore, 1,25-D activates the VDR to tran-
scribe (or repress) at least 913 genes.11 Several
of these genes expressed by the VDR in the en-
dometrium may well play a role in regulating
events related to pregnancy or the menstrual
cycle. They may also protect the fetus from
infection.
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Bacteria in Autoimmune Disease
A recent increase in autoimmune incidence
led Rose to express concern over the pos-
sible role that infection might play in exac-
erbating autoimmune disease, particularly in
women.2 Additionally, the Centers for Dis-
ease Control and Prevention has written that
chronic infectious agents are emerging as no-
table determinants, not just complications,
of chronic disease—stressing that infectious
agentslikelydeterminemorecancers,immune-
mediated syndromes, neurodevelopmental dis-
orders, and other chronic conditions than cur-
rently appreciated.12
Rookprovidedevidencethatseveraldiseases
usually regarded as “autoimmune” or “idio-
pathic,” including RA, Crohn’s disease, ulcera-
tive colitis, sarcoidosis, and psoriasis, may be
caused by infection with slow-growing bac-
teria.13 Similarly, Relman demonstrated evi-
dence of persistent infection in sarcoidosis, var-
ious forms of inﬂammatory bowel disease, RA,
SLE, diabetes mellitus, and primary biliary
cirrhosis.14
Wirostko described persistent bacterial
bioﬁlm-like inclusions inside the phagocytes
(monocytes, macrophages, neutrophils) of pa-
tientswithCrohn’sdisease,15 sarcoidosis,16 and
juvenile RA.17 Serological evidence for bac-
terial infection has been demonstrated in pa-
tients with Hashimoto’s thyroiditis.18,19 Water-
house et al. showed that 81% of a group of 54
patients representing 20 different autoimmune
diagnoses reported continual improvement af-
tertreatmentdurationsof18–53monthswitha
VDRagonistandantibiotics—furtherpointing
to bacteria as a causative agent in autoimmune
disease.20
The Human Microbiome—a
Metagenome
Recent advances in molecular techniques
now allow for the detection of bacterial
genomes of organisms that cannot be grown
in culture. The scientiﬁc community is just be-
ginning to comprehend the full impact of un-
culturable microbes upon human disease. The
global initiative known as the Human Micro-
biome Project currently estimates that the mi-
croorganisms that live inside or on Homo sapiens
outnumber somatic and germ cells by a factor
of 10.21 To this point, only approximately 1%
of this microbiota has been characterized and
identiﬁed.22 The combined genetic contribu-
tions of these microbes—in excess of 100,000
protein-coding genes—provide traits not en-
coded in our own genomes.23 Some of these
traits may well lead to autoimmune disease.
Researchers afﬁliated with the Human Micro-
biome Project aim to use an array of molecu-
lar sequencing techniques to characterize the
full Homo sapiens microbiota over the coming
years.23
Bacteriologists are increasingly examining
how the metagenome of complex microbial
communities may contribute to disease. Koch’s
postulates,whichrequirethatasinglepathogen
cause a single disease state, are being re-
examined.24 This suggests that autoimmune
disease results when patients concurrently ac-
cumulate a variety of different pathogenic
forms, such as those that exist in a persistent
metagenomic bioﬁlm or in intracellular com-
munities where they are better protected from
the host immune response.20
The human body, once considered to be
sterile, exists in symbiosis with the human mi-
crobiome. Recent studies show that chronic
pathogens persist in the endometrium. Eigh-
teen different taxa of microbes were recently
identiﬁed in the amniotic ﬂuid of women who
gave birth prematurely.25 Mycobacterium tuber-
culosis and inﬂuenza HSN1 have been shown
to cross the placental barrier.26,27 Infection
with Shigella has been proposed as an expla-
nation for the etiopathogenesis of endometrio-
sis,28 and invasion of the endometrium by
bacteria has been implicated in implantation
failure, spontaneous abortion, and preterm
birth.29
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VDR Dysregulation by the
Microbiota
While the expression of the VDR in the en-
dometrium should put a healthy woman at an
advantage by strengthening her ability to ﬁght
infectious agents, a dysregulated VDR leads to
a state in which women are less able to mount
an effective innate immune response. Among
othercompounds,bacterialligandsarecapable
ofdysregulatingtheVDR.Forexample,thesul-
fonolipid capnine, produced by gliding bioﬁlm
bacteria,isastrongVDRantagonist.30 Because
the creation of a VDR-dysregulating ligand
provides a persistent pathogen with an evo-
lutionary advantage, it is quite possible other
bacteria have developed equivalent survival
mechanisms.Ifthisisthecase,achronicmicro-
biota capable of dysregulating the VDR may
well be perverting what the body intends as a
protective environment during pregnancy and
menstruation into one that allows disease to
ﬂourish.
The likelihood of a VDR-dysregulating mi-
crobiotainautoimmunediseaseisstrengthened
by the data collected by Waterhouse et al. in
which subjects were routinely administered the
VDR agonist olmesartan in conjunction with
bacteriostatic antibiotics. He reported bacte-
rial death resulting from the release of endo-
toxinsandinﬂammatorycytokines,causingpa-
tients to experience an exacerbation in disease
symptoms caused by immunopathology, some-
times referred to as the Jarisch–Herxheimer
reaction.20
Patients administered the antibiotics with-
out olmesartan experienced weak, sometimes
negligible,increasesinimmmunopathology.By
contrast, when the same patients took the an-
tibiotics in conjunction with olmesartan, im-
munopathology often became so strong that
it had to be carefully controlled by palliative
measures. That this dramatic change in im-
munopathology correlates with administration
ofaVDRagonistaddsweighttothehypothesis
that VDR dysfunction is central to the patho-
genesis of autoimmune disease.
TABLE 1. Afﬁnities of Native Ligands and 1,25-D
for Various Nuclear Receptors
Nuclear Native Native 1,25-D
receptor ligand ligand (Kd) (Kd)
 -Thyroid T3 7.20 8.41
 -Thyroid T3 7.18 8.44
Glucocorticoid Cortisol 7.36 8.12
Androgen Testosterone 7.38 8.05
Progesterone Progesterone 7.53 8.09
The Effects of VDR Dysregulation
Not only does VDR dysregulation decrease
cathelicidinand -defensinexpression, itopens
a number of other pathways leading to hor-
monal imbalance. The activated VDR ex-
pressesCYP24,theenzymeprimarilyresponsi-
ble for breaking 1,25-D down into the inactive
vitamin D metabolites. This exerts a feedback
control on the maximum level that 1,25-D will
attain.30 However, CYP24 is suppressed in au-
toimmune disease, allowing 1,25-D to reach
unusually high levels.
In silico modeling demonstrates that besides
activating the VDR, 1,25-D also has a strong
afﬁnity for several of the body’s other nuclear
receptors. This indicates that at high concen-
trations it can displace their native ligands.30
Table 1 shows, for example, that 1,25-D has
a very high afﬁnity for the  -thyroid recep-
tor,suggestingthatitcankeeptriiodothyronine
(T3) out of the binding pocket (see Fig. 2).  -
Thyroid is similarly affected.
If 1,25-D prevents T3 from activating the
thyroidreceptors,geneswith -thyroidpromot-
ers will no longer be transcribed. The resulting
thyroid disease would explain why increasing
levels of exogenous thyroid hormone are nec-
essary to maintain thyroid homeostasis as the
disease progresses. Furthermore, since the type
1 nuclear receptors work as a group, if tran-
scription by the  -thyroid receptor is dysregu-
lated, a cascade of metabolic dysfunction will
result. It is instructive to note that excessive
1,25-D also potentially interferes with several
of the body’s other nuclear receptors. Table 1
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Figure 2. The thyroid-  receptor and its native ligand T3 [PDB:2H77], with 1,25-D super-
imposed in the ligand-binding pocket. Note how 1,25-D displaces T3 from binding to the key
receptor residues. Calculated Kd is 8.41 for 1,25-D and 7.20 for T3.
shows high Kd values for the glucocorticoid,
androgen, and progesterone receptors.
Secondary Effects of VDR
Dysregulation on Antimicrobial
Peptide Expression
If 1,25-D is able to dysregulate the nuclear
receptors, it would have detrimental effects on
system-wide AmP production. Just as the VDR
expresses cathelicidin and  -defensin, other
nuclear receptors also express AmPs. Brah-
machary has shown that the glucocorticoid re-
ceptor, the androgen receptor, and the vitamin
Dreceptor,areincontrolof20,17,and16fami-
lies,respectively,outofthe22analyzed.31 Thus,
VDRdysfunctioncausesﬂow-oneffectsviaglu-
cocorticoid, thyroid, androgen, and other nu-
clear receptors, which potentially disable the
bulk of the body’s production of AmPs.
Consequently, there is a strong relationship
between hormonal dysfunction and autoim-
mune disease. Indeed, most of the patients
with Hashimoto’s thyroiditis in the study re-
ported by J.C. Waterhouse (personal commu-
nication, 2008) had also been diagnosed with
other inﬂammatory or autoimmune diseases.
Only8%ofsubjectswithHashimoto’sthyroidi-
tis had Hashimoto’s thyroiditis alone. Similarly,
autoimmunethyroiditishasbeenreportedinan
elevated percentage of ﬁbromyalgia patients.32
Smith has described a proven association be-
tween Hashimoto’s thyroiditis and Addison’s
disease, type 1 diabetes mellitus, pernicious
anemia, celiac disease, dermatitis herpeti-
formis, MS, RA, SLE, and systemic sclerosis.33
Slokafoundthatinnearlyeverysubjectstudied,
hypothyroidism caused by autoimmune thy-
roid disease showed a tendency to be more
severe and more often present in patients with
MS.34 BothmenandwomensufferingfromMS
have been shown to manifest low-serum-T3
concentrations.35
Because women have an extra site of VDR
gene transcription—the endometrium—it is
likely that a greater variety of genes are ex-
pressed by the female VDR. Thus, as women
age, they may well be disproportionately af-
fected by VDR dysfunction, particularly when
it comes to AmP expression. It is likely they
would accumulate heavier bacterial loads than
their male counterparts. This might contribute
to the higher incidence of autoimmune disease
among females.
Elevated 1,25-D as a Marker
for Autoimmune Disease
When active, transcription of CYP24 by
the VDR keeps 1,25-D levels in the normal
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range.30 If the VDR is disabled by disease and
unable to express CYP24, patients should dis-
play higher than normal levels of 1,25-D. Stud-
ies on Crohn’s disease, ulcerative colitis, RA,
Sjogren’s, and other autoimmune diagnoses
conﬁrm a higher than normal level of 1,25-D
among study subjects.36 Blaney reported 1,25-
D levels well above the accepted range in the
majority of his cohort of 100 patients with au-
toimmune disease.37
Yet data on 1,25-D levels in autoimmune
disease remain relatively scarce because most
clinicians test only the inactive vitamin D
metabolite 25-hydroxvitamin-D (25-D) when
determining vitamin D status. Low levels of
25-D have been tied to a higher incidence of
autoimmune disease, leading to the consensus
that vitamin D “deﬁciency” may be a risk fac-
tor for autoimmune disease.8 However, the low
levels of 25-D often observed in autoimmune
disease must also be viewed in light of data
advanced by Marshall, Blaney, and others in
which low 25-D levels are the result of the au-
toimmune disease process rather than part of
its cause.32 According to this model, the likely
pathway for the downregulation 25-D arises
directly from the elevation of 1,25-D. Reduced
gene expression by the pregnane X nuclear re-
ceptor (PXR) inhibits expression of CYP27A1
and thus downregulates conversion of vitamin
D into 25-D.
Itisclearthatboth25-Dand1,25-Dmustbe
measuredinpatientswithautoimmunedisease,
as the presence of inhibited 25-D expression or
excessive 1,25-D expression both act as reliable
markers of the disease process and are best in-
terpreted in relation to one another.
Pregnancy
InMSandRA,womenexperienceperiodsof
palliation during gestation only to become in-
creasingly symptomatic after giving birth.38,39
Because 1,25-D production rises by 40% in
the early pregnant decidua,9 its ability to dys-
regulate the nuclear receptors and the AmPs
theyexpressisparticularlyprevalentduringthis
time.Ifawoman’sVDRexpressionhasalready
become dysfunctional because of pathogen-
induced 1,25-D dysregulation, the 40% surge
in1,25-Dduringpregnancywouldresultinad-
ditional substantial immunosuppression. Un-
der such conditions, immunopathology would
decrease,resultinginsymptomaticrelief.When
thesurgein1,25-Ddisappearsafterpregnancy,
AmPexpression andimmunopathologyshould
increase, leading to exacerbation of disease
symptoms.
Measuring both 25-D and 1,25-D may help
resolve the anomalies in symptomatic presen-
tation among MS, RA, and lupus.
Discussion
The conﬂuence of in silico, in vivo, and
in vitro data has elucidated a pathway in
molecular biology that can potentially con-
tribute to an understanding of the higher inci-
dence of autoimmune disease observed among
women.DysregulationoftheVDRbyachronic
intraphagocytic microbiota would cause sig-
niﬁcant hormonal disruption by allowing
1,25-D to accumulate and displace native lig-
ands from  -thyroid, glucocorticoid, andro-
gen, and other nuclear receptors. By reduc-
ing the ability of these same nuclear receptors
to express AmPs, accumulating 1,25-D would
also cause a system-wide drop in AmP expres-
sion,allowingpathogenstoproliferate.Because
1,25-D is expressed in the human cycling en-
dometriumandrisesby40%duringearlypreg-
nancy, women are disproportionately affected
by the potential drop in AmP expression asso-
ciated with VDR dysregulation and likely ac-
cumulate a more diverse microbiota than their
male counterparts.
The advent of highly parallel DNA se-
quencers, high-throughput mass spectrome-
ters, and other molecular techniques is ush-
ering microbiology into a new era—steering
focus away from the properties of isolated or-
ganisms to the manner in which a microbiota
can act as metagenome when causing disease.
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Researchers afﬁliated with the Human Micro-
biomeProjectarebeginningtocharacterizethe
milieu of unidentiﬁed bacterial organizations
that persist in Homo sapiens.
Their ﬁndings have the potential to greatly
expand our understanding of how chronic
pathogens contribute to autoimmune disease.
The potential role of persistent pathogens in
autoimmune disease mandates reconsideration
of the use of corticosteroids as a ﬁrst-line treat-
ment for many autoimmune diseases. Corti-
costeroids effectively reduce the ability of the
immune system to respond to pathogens, in-
cludingpersistentmicrobiota,whichiscounter-
productive to recovery. Waterhouse et al. report
that antibacterial therapy can induce recovery
from a variety of autoimmune diseases further
cautions against the overuse of corticosteroids.
Scientists and clinicians should be encour-
aged to test both 25-D and 1,25-D in their sub-
jects. A low 25-D and a high 1,25-D are both
useful markers of the disease process. Low lev-
els of 25-D are more likely a result rather than
a cause of disease progression.
While this model provides novel insight into
the manner in which pathogens may dysregu-
late the innate immune response and poten-
tially contribute to the autoimmune disease
process, much more research is needed. The
relationship between nuclear receptors and the
AmPs they express has been sorely under-
explored. Potential AmP expression by the es-
trogen or progesterone receptors has yet to be
studied, leaving a gap in our understanding of
how ﬂuctuations in estrogen and progesterone
during pregnancy and menstruation may also
affect the female immune response.
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Summary and link to next chapter 
 
In this first chapter, "Dysregulation of the Vitamin D Nuclear Receptor may contribute to the 
higher  prevalence  of  some  autoimmune  diseases  in  women",  we  have  explained  the 
importance of the Vitamin D Receptor (VDR). The receptor expresses at least 913 genes, 
several associated with autoimmune disease and cancer. In addition, the VDR controls key 
aspects of the innate immune response including expression of cathelicidin, beta-defensins, 
and TLR2. We have introduced the major concept that the VDR is linked to health status and 
have shown how pathogens are able to dysregulate the VDR in order to gain a survival 
advantage leading to a the development of a pathogenic microbiota.  
 
Autoimmune  disease  is  more  common  in  women  than  in  men.  The  reason  for  this 
discrepancy  remains  unclear.  However,  several  mechanisms  whereby  this  pathogen-
induced VDR dysregulation may contribute to the higher incidence of autoimmune disease in 
women were explored in Chapter 1. Specifically, we illustrated how VDR dysregulation may 
cause the active vitamin D metabolite 1,25-dihydroxvitamin D (1,25-D) to rise, as it is not 
broken  down  by  CYP24,  and  subsequently  affect  expression  of  antimicrobial  peptides 
(AMPs)  expressed  by  other  key  nuclear  receptors  such  as  β-thyroid.  This  may  impact 
women  more  severely  as  the  cycling  endometrium  provides  an  additional  site  of  VDR 
expression and subsequently potential dysregulation in females. Differential expression of 
the VDR in females may contribute to greater prevalence of autoimmune disease in women. 
Pregnancy associated with a 40% rise in 1,25-D levels correlates with a decrease in AMP 
expression, allowing for VDR dysregulation and microbiota survival advantage. Importance 
is placed on measuring levels of both 25-D and 1,25-D in patients as biomarkers of disease. 
 
We hypothesize that higher than normal levels of 1,25-D occur in patients with autoimmune 
disease  due  to  dysregulation  of  the  VDR  by  microbes.  Building  on  this  hypothesis,  we  
17 
studied  the  1,25-D  levels  of  100  Vancouver,  Canada-based  patients  with  a  variety  of 
autoimmune diagnoses, presented in Chapter 2, "Vitamin D metabolites as clinical markers 
in autoimmune and chronic disease".  
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Chapter 2: Vitamin D metabolites as clinical markers 
in autoimmune and chronic disease 
 
 
Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune 
and chronic disease. Ann N Y Acad Sci. 2009 Sep;1173:384-90. 
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RecentresearchhasimplicatedvitaminDdeﬁciency(serumlevelsof25-hydroxyvitamin
D <50 nmol/L) with a number of chronic conditions, including autoimmune conditions
such as multiple sclerosis, lupus, and psoriasis, and chronic conditions such as os-
teoporosis, osteoarthritis, metabolic syndrome, ﬁbromyalgia and chronic fatigue syn-
drome. It has been assumed that low levels of 25-hydroxyvitamin D (25-D) accurately
indicate vitamin D storage and vitamin D receptor (VDR)–mediated control of cal-
cium metabolism and innate immunity. To evaluate this assumption, 25-D and 1,25-
dihydroxyvitamin D3 (1,25-D) levels were measured in 100 Canadian patients with these
conditions. Additionally, other inﬂammatory markers (CK, CRP) were measured. Re-
sults showed a strong positive association between these autoimmune conditions and
levels of 1,25-D >110 pmol/L. However, there was little association with vitamin D de-
ﬁciency or the other inﬂammatory markers, meaning that the results challenge the
assumption that serum levels of 25-D are a sensitive measure of the autoimmune dis-
ease state. Rather, these ﬁndings support the use of 1,25-D as a clinical marker in
autoimmune conditions. High levels of 1,25-D may result when dysregulation of the
VDR by bacterial ligands prevents the receptor from expressing enzymes necessary to
keep 1,25-D in a normal range.
Key words: autoimmune disease; 1,25-dihydroxyvitamin D3; 25-hydroxyvitamin D;
C-reactive protein; creatinine kinase
Introduction
Thereisincreasinginterestintheroleofvita-
minDdeﬁciencyinanumberofchronichealth
problems, including autoimmune diseases.1–8
However, other studies have shown a deleteri-
ous or no beneﬁcial effect of vitamin D supple-
mentationoncertaindiseases.9–18 Theeffectsof
vitamin D are the result of genomic and non-
genomic actions mediated by the active form
of vitamin D, termed calcitriol, which is also
known as 1,25-dihydroxyvitamin D3 (1,25-D).
Yet most of the studies evaluating vitamin D
Address for correspondence: Greg P. Blaney, M.D., 4419 W. 10th
Ave., Vancouver, BC, Canada. Voice: 604-224-6583; fax: 604-224-6584.
gregblaney@shaw.ca
and its association with disease are based on
25-hydroxyvitamin D (25-D) serum levels and
not 1,25-D.
The deﬁnition of deﬁciency of 25-D is vari-
able. One author recently surveyed the litera-
ture and determined that 25-D deﬁciency be-
gins at or below 80 nmol/L.19 Still, a number
of studies have found levels below that to be
common in healthy subjects.20–24
Because of these ambiguities, an evalua-
tion of vitamin D metabolites was conducted
on 100 Canadian patients residing in the Pa-
ciﬁc Northwest who suffer from diseases that
have been associated with vitamin D deﬁ-
ciency.25 Two markers of inﬂammation, creati-
nine kinase26 and C-reactive protein, were also
measured.27,28
Contemporary Challenges in Autoimmunity: Ann. N.Y. Acad. Sci. 1173: 384–390 (2009).
doi: 10.1111/j.1749-6632.2009.04875.x c   2009 New York Academy of Sciences.
384
20Blaney et al.: Vitamin D Metabolites as Clinical Markers 385
Figure 1. Patients with a given diagnosis. Note
that many patients had multiple diagnoses. Abbrevi-
ations: FM, ﬁbromyalgia; CFS, chronic fatigue syn-
drome; PTLDS, post treatment Lyme Disease Syn-
drome; MD, metabolic disease; OA, osteoarthritis;
IBS, Irritable Bowel Syndrome; Psor Arthritis, Psori-
atic arthitis; MS, Multiple Sclerosis; SN arthritis, Sero-
negative arthritis.
Materials and Methods
Blood samples from 100 randomly se-
lected patients presenting with clinical criteria
indicating the presence of autoimmune and as-
sociated diseases were drawn and analyzed by
Lifelabs, located in Burnaby, British Columbia,
Canada.
Of the 100 patients, 26 were male and 74
were female and ranged in age from 20 to
67 years. Patients with classical autoimmune
disease totaled 30: nine with metabolic syn-
drome, 43 with chronic fatigue syndrome/
ﬁbromyalgia, 12 with post-Lyme disease syn-
drome,29 and six with osteoarthritis (see Fig. 1).
Patients were measured for the presence
of four blood markers: elevated levels of C-
reactive protein, elevated levels of creatinine
kinase,deﬁcientlevelsof25-Dandelevatedlev-
els of 1,25-D. Elevated levels of C-reactive pro-
tein were determined by a ﬁnding of 5 mg/L
or greater. Elevated levels of creatinine kinase
weredeterminedbyaﬁndingofabove300U/L
(males), 200 U/L (females). 25-D deﬁciency
was determined by the ﬁnding of levels at or
below 50 nmol/L.
Samples to be tested for 1,25-D were refrig-
erated and then frozen within 12 h after with-
drawal. 25-D was measured using the Diasorin
LIAISON chemiluminescence immunoassay.
1,25-D was measured using the Diasorin ra-
dioimmunoassay.
There appears to be a lack of consensus
as to the normal serum levels of 1,25-D (see
Table 1) with various authors citing ranges
from 39–110 pmol/L,30 33–160 pmol/L,31
60–156 pmol/L,32 47–162 pmol/L33 and 36–
108pmol/L.34 Thethresholdforelevated1,25-
Dwasselectedas110pmol/Lbasedontheob-
servation that all healthy patients in a clinical
care setting showed levels under this range.35
Furthermore, levels of 1,25-D have been
shown to drop below 110 pmol/L in patients
participating in later stages of a therapy in
which a VDR agonist and pulsed low-dose an-
tibiotics are used to eliminate bacteria thought
to cause the vitamin D dysregulation observed
in autoimmune disease.35
Results
Levels of 25-D ranging from a low of
20 nmol/L to 50 nmol/L were found in 26
patients (see Fig. 2). None had below-normal
levels of 1,25-D (<40 pmol/L). Interestingly,
1,25-Dratherthan25-Dservedasamoreaccu-
ratemeasureofachronicinﬂammatorydisease
state.
Elevated levels of 1,25-D ranging from
110 pmol/L to a high of 350 pmol/L were
found in 85 patients. Of these patients, 19 had
25-D levels below 50 nmol/L. The mean level
of1,25-Dobservedinoursample(143.46 +/ 
45.56 pmol/L) was signiﬁcantly higher than
the laboratory threshold value of 110 pmol/L
(P < 0.0001 by one-sample t-test).
Levels of C-reactive protein higher than
5.0 mg/L were observed in 17 patients, with
the highest being 62.67 mg/L.
Creatinine kinase above the normal refer-
ence range was observed in 12 patients, with
the highest being 1109 U/L in a male and 562
U/L in a female.
Indiagnosedautoimmunepatients,10outof
30werefoundtohave25-Dlevels<50nmol/L
while 27 out of 30 showed 1,25-D levels
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TABLE 1. Selected Research of Serum Values for 1,25-D
Population Age Value of Serum 1,25-D
100 normotensive male industrial
employees with no history of
disease30
25 to 64 years (range) 39–110 pmol/L
173 subjects) at high and moderate
risk for coronary heart disease31
Two groups analyzed:
63.3 ± 7.1 years; 29.5 ± 10.6
years
33–160 pmol/L
1,903 chronic kidney disease
patients who were not prescribed
vitamin D32
70.1 (mean) 60–156 pmol/L
10 healthy Inuit children34 5t o1 7y e a r s( r a n g e ) 3 6 – 1 0 8p m o l / L
1,384 premenopausal and 1,084
postmenopausal women48
33.1 ± 10.1 years (premenopausal);
65.4 ± 8.1 years (postmenopausal)
35.5 pg/mL (mean for premenopausal
women); 39.1 pg/mL (mean for
postmenopausal women)
Figure 2. 25-D versus 1,25-D in a cohort of 100 patients.
>110 pmol/L. Five out of 30 had C-reactive
protein levels >5.0 mg/L. Five out of 30 had
creatinine kinase levels above normal.
Levels of 25-D below the normal range
were observed in two out of nine patients with
metabolicsyndrome,whilesixhadelevatedlev-
els of 1,25-D.36,37 Of the nine patients, ﬁve
showed elevated levels of C-reactive protein,
while none showed elevated creatinine kinase
levels.
Of 43 patients with chronic fatigue syn-
drome/ﬁbromyalgia,38,39 10 had <50 nmol/L
of 25-D while 38 had >110 pmol/L of 1,25-D.
Eight patients had elevated levels of C-reactive
protein, while only one had an elevated level of
creatinine kinase.
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Post-treatment Lyme Disease syndrome40
patients may well represent a subcategory
of CFS. Of 12 patients tested three showed
25-D levels <50 nmol/L. Nine showed
1,25-D levels >110 pmol/L. Two patients had
Cr e a c t i v ep r o t e i n s>5m g / L ,w h i l et h r e e
had above-normal creatinine kinase levels.
In six patients with osteoarthritis (OA) and
degenerative disc disease (DDD),41 only one
patient had <50 nmol/L 25-D. However, all
sixpatientshad>110pmol/Lof1,25-D.None
had elevated levels of C-reactive protein. Two
had elevated levels of creatinine kinase.
Discussion
These ﬁndings show that vitamin D deﬁ-
ciency was not as common as speculated in
CanadianadultslivinginthePaciﬁcNorthwest
and was not found in the majority of patients
with diseases previously associated with vita-
min D deﬁciency. However, elevated levels of
serum 1,25-D were found in 85% of patients
examined.
Technically, high levels of 1,25-D down-
regulate, via the pregnane X receptor (PXR)
nuclearreceptor,theamountofvitaminDcon-
verted into 25-D, resulting in low levels of 25-D
in patients with autoimmune disease.42 That
25-D levels remained above range in the ma-
jority of our cohort suggests that subjects were
supplementingwithvitaminDorsimplyeating
a plethora of foods that are now artiﬁcially for-
tiﬁed with the secosteroid/hormone. So long
as this confounding variable continues to exist,
reliable data on how 25-D may be affected by
the disease process itself and is likely to remain
inconclusive.
Vitamin D supplementation leads to the for-
mation of 25-D rather than 1,25-D. High levels
of25-Ddonotappeartopreventinﬂammatory
disease, as 34 out of the 100 patients tested had
25-D levels above 80 nmol/L. This is consis-
tent with other poor results of vitamin D sup-
plementation in the treatment of inﬂammatory
disease, particularly over long periods of time.
Certainstudieshavedocumentedatherapeutic
effect of vitamin D over the short term; Lappe
etal.showedthatconsumptionofvitaminDap-
pears to be protective against colorectal cancer
in a four-year trial.43 However, a similar study
done on a larger cohort that lasted only an ad-
ditional three years found no such effect.44 In
fact, studies in which patients had been con-
suming vitamin D over the course of decades
have shown a negative effect of vitamin D sup-
plementation.45,46
Also, it is well documented that those
who supplement with vitamin D are qualita-
tively different than those who do not, hav-
ing higher socioeconomic status,47 better edu-
cation, stronger interest in health education,46
and presumably access to higher quality health
care. This should give one further pause when
assessing observational epidemiological studies
on vitamin D supplementation.
In contrast, 1,25-D appears to be a highly
sensitiveclinicalmarkerindiagnosisofautoim-
mune and associated diseases. It may be fruit-
ful to consider why levels of 1,25-D are ele-
vated in patients with autoimmune diagnoses.
One possibility is that the vitamin D receptor
(VDR) becomes dysregulated when exposed to
sufﬁcient quantities of substances created by
bacteria that antagonize or otherwise inhibit
the VDR. One such substance is the sulfono-
lipid ligand capnine.48 The protease caspase-3,
which is up-regulated by P. aeruginosa49 and H.
pylori,50 has a similar effect on the VDR, effec-
tivelyinactivatingitbycleavingit.51 Thepersis-
tentand difﬁcult-to-culture bacteria thatcreate
these substances may play a role in the patho-
genesis of autoimmune and related diseases.
As bacterial ligands compromise the activity
of the VDR, the receptor is prevented from ex-
pressing CYP24, an enzyme that breaks the
1,25-D down into its inactive metabolites.42
This allows 1,25-D levels to rise without a feed-
back system to keep them in check, resulting
in the elevated levels of the hormone as ob-
served in our cohort. Acquired hormone re-
sistance has also been recognized with insulin,
thyroid,steroid,andgrowthhormonereleasing
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hormone.52,53 Elevated levels of hormones are
seen in some of these conditions.54
Consistent with the hypothesis is that al-
though 85 out of 100 patients in our cohort
had a 1,25-D higher than 110 pmol/L and a
signiﬁcant number (38) had levels greater than
160 pmol/L, there were no apparent clinical
manifestations of hypercalcemia.
This suggests that although 1,25-D rises in
inﬂammatory disease, it is unable to actually
bind to the VDR and drive the expression of
genes associated with calcium absorption. This
could result because the receptor is already an-
tagonized by bacterial ligands.
This model is supported by data collected
fromatrialinwhichpatientswithautoimmune
diagnoses used a VDR agonist to restore VDR
activity. Over the course of therapy, 1,25-D
levels dropped into a normal range as inﬂam-
mation decreased. This suggests that tracking
1,25-D levels may also serve as a valuable clin-
ical marker of therapeutic response and efﬁ-
cacy of treatment modalities for autoimmune
disease.
Given the potential beneﬁts of serum 1,25-D
as a clinical marker both in the diagnosis and
monitoring of treatment response, further re-
search is warranted. If elevated levels of 1,25-D
continuetobeassociatedwithaninﬂammatory
disease state, 1,25-D could be used as a reliable
marker of the autoimmune disease process.
Due to the length of this chapter, we are un-
able to summarize all of the cutting-edge issues
that surround this research. For this reason, we
refer to the following recent literature on this
subject.55–59
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Summary and link to next chapter 
 
Chapter 2, "Vitamin D metabolites as clinical markers in autoimmune and chronic disease", 
explored how both 1,25-D and the inactive vitamin D metabolite 25-D affect transcription by 
the VDR and subsequent activity of the innate immune response. The mechanisms by which 
vitamin D palliates autoimmune symptoms and the concept of vitamin D deficiency are both 
re-evaluated in a new light. A novel model of vitamin D metabolism is described in which the 
low levels of 25-D often observed in patients with autoimmune disease are believed to be a 
result rather than a cause of the inflammatory disease process. 
 
We presented data showing that 85 of 100 patients with autoimmune disease present with 
1,25-D levels above the normal range (>110pmol/L). However, low 25-D levels were not as 
common as expected in patients with autoimmune disease, possibly confounded by factors 
such as Vitamin D supplementation. 
 
Many studies have noted that the secosteroid 25-D palliates the symptoms of autoimmune 
disease.  However,  the  mechanisms  behind  such  palliation  remain  unclear.  Chapter  3 
"Vitamin D: The alternative hypothesis" introduces a model that explores 25-D's actions in 
autoimmune disease at the molecular level.   
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Early studies on vitamin D showed promise that various forms of the “vitamin” may be
protective against chronic disease, yet systematic reviews and longer-term studies have failed
to con rm these  ndings. A number of studies have suggested that patients with autoimmune
diagnoses are de cient in 25-hydroxyvitamin D (25-D) and that consuming greater quantities
of vitamin D, which further elevates 25 D levels, alleviates autoimmune disease symptoms.
Some years ago,molecular biology identi ed 25 D as a secosteroid. Secosteroids wouldtypically
be expected to depress in ammation, which is in line with the reports of symptomatic
improvement. The simplistic  rst-order mass-action model used to guide the early vitamin
studies is now giving way to a more complex description of action. When active, the Vitamin D
nuclear receptor(VDR) affects transcriptionof at least 913 genesand impacts processes ranging
from calcium metabolism to expression of key antimicrobial peptides. Additionally, recent
research on the Human Microbiome shows that bacteria are far more pervasive than previously
thought, increasing the possibility that autoimmune disease is bacterial in origin. Emerging
molecular evidence suggests that symptomatic improvements among those administered
vitamin D is the result of 25-D's ability to temper bacterial-induced in ammation by slowing
VDR activity. While this results in short-term palliation, persistent pathogens that may
in uence disease progression, proliferate over the long-term.
© 2009 Elsevier B.V. All rights reserved.
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30vitamin D supplementation insist that various forms of the
“vitamin” can be protective against chronic disease, but
longer-term studies have failed to con rm these  ndings
[1]. Even among those who support widespread supplemen-
tation with the substance, there is wide acknowledgement
that the understanding of vitamin D metabolism is “impre-
cise” [1].
L.R. Karhausen wrote, “Actually, there is no experience of
causation:events do not wear theircausalcredentials on their
faces [2].”In this review, we discuss how theunderstandingof
vitamin D metabolism in chronic disease may be approaching
“black box epidemiology [2].”
We hope to show that although vitamin D is currently
viewed in a bene cial light, explanations for how it provides a
bene ta r es i m p l i s t i ca n di m p r e c i s e .W ew i l la d d r e s s
liabilities of the disease/de ciency model for vitamin D and
summarize an alternative theory that, if valid, would
necessitate rethinking systematic supplementation with
vitamin D.
2. Black box epidemiology
Black box epidemiology is a focus on risk factors related to
disease outcome without satisfactorily understanding patho-
genesis [3]. This is the case with autoimmune disease, of
which there remains widespread debate about what causes
the majority of these common illnesses [4].
There are a number of examples of how incomplete
understanding of the causative factors of disease can have
unfortunate rami cations. Double-blind and/or randomized
controlled trials (RCTs), as recently as 15 years ago, erro-
neously showed women taking combined hormone replace-
ment therapy (HRT) had a lower-than-average incidence of
coronaryheartdisease(CHD).ThisleddoctorstoproposeHRT
was protective against CHD.
As it was learned, those with higher socioeconomic status
were more likely to use HRT [5]. The increased incidence in
CHD caused by HRT could have been mitigated by other
factors also associated with elevated status: better medical
care, healthier eating habits, etc. Although we don't know the
mechanism by which HRT causes CHD, studies suggest, given
its widespread use, tens of thousands of women died
prematurely or suffered strokes or cancer. One commentary
asked provocatively, “Is this the death of observational
epidemiology?”[5].
RCTs are not without liabilities—especially not when an
intervention generates a short-term bene t, but is harmful
over the long-term. Multiple studies found the combination
therapy of fen uramine and phentermine (fen–phen)
improved various physiological measures of health—raising
HDL cholesterol, lowering triglycerides [6,7] and reversing
obesity over the short-term. Yet, when researchers  nally
gathered data on patients who had been taking the drug for
longer periods of time, it became clear fen–phen caused
pulmonary hypertension and valvular dysfunction [7].
The entire class of steroids seems to be especially
problematic. The  rst-line treatment for many autoimmune
diagnoses, the corticosteroid Prednisone, may temporarily
reduce symptoms of disease, but long-term use dramatically
increases the odds of disease relapse [8]. This  nding, as we
will see, may be true for the secosteroid 25-D.
3. The vitamin D receptor and the vitamin D metabolites
People obtain vitamin D through diet, supplements, and
exposure to sunlight. Vitamin D2 is found in plants and
fungi and vitamin D3 in meats. Vitamin D3 is also produced
endogenously when the eyes and skin are exposed to
ultraviolet light. Both vitamins D3 and D2 are hydroxylated
in the liver, becoming the secosteroid 25-hydroxyvitamin-
D( 2 5 - D ) .U n d e rh o r m o n a lc o n t r o lm e c h a n i s m s ,t h e
enzyme 1-alpha-hydroxylase further hydroxylates 25-D
into the main biologically active hormone/secosteroid,
1,25-dihydroxyvitamin-D3 (1,25-D). 25-D and 1,25-D
serve as the native or endogenous ligands for the vitamin
D receptor (VDR), a nuclear receptor found in immune and
other cell types [9].
The VDR is responsible for transcribing 913 genes and
probably many more [10]. Directly and/or indirectly, the
vitamin D endocrine system regulates 3% of the human
genome [11]. The VDR transcribes the beta-Defensin and
cathelicidin antimicrobial peptides, broad-spectrum antibac-
terials which target pathogens [12]. When active, the VDR
also transcribes TLR2, which recognizes gram-positive
bacteria.
Recent vitamin D studies seem to address two broad
observations regarding 25-D. First, serum levels of 25-D tend
to be signi cantly lower in patients with autoimmune disease
[13]. Second, subjects given vitamin D, even in controlled
studies, often seem to have lower rates of autoimmune
disease and fewer markers of in ammation [14].
These observations have led people to assume that
supplemental vitamin D is bene cial, because it decreases
in ammation and autoimmune disease symptoms. Therefore,
many researchers suggest, some more strongly than others,
that regular and systematic supplementation with vitamin D
alleviates autoimmune disease [9]. We will call this view the
de ciency/disease model.
However, these same observations can be interpreted
differently. Low 25-D levels in autoimmune disease may be a
result of the disease process itself, and the drop in in amma-
tion among individuals taking the secosteroid may stem from
its ability to slow immune function. We will call this view the
alternative model. Efforts to determine which of these models
is correct must examine how 25-D affects the VDR.
4. Liabilities of the de ciency/disease model
Vitamin D's mode of action at the molecular level remains
a matter of debate among those who espouse the de ciency/
disease model. Autoimmune diagnoses are widely explained
to be illnesses inwhich the immune system and subsequently
the VDR are overactive [15]. These researchers argue addi-
tional vitamin D calms the immune response, presumably by
deactivating the VDR. Shoenfeld et al note, “Vitamin D has
multiple immunosuppressant properties [15].”
In contrast, cancer, arteriosclerosis, and other in amma-
tory diagnoses are often characterized as illnesses in which
the immune system fails to function adequately, suggesting
decreased VDR activity. Such research theorizes that addi-
tional vitamin D activates the VDR after being converted into
1,25-D [16]. Researchers have even tried to treat cancer by
inducing autoimmune disease [17].
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31Autoimmune diseases and cancers are not mutually
exclusive. There is co-morbidity between the diseases, and
they share some physiological biomarkers. People with the
autoimmune diagnosis Crohn's disease are much more likely
to get certain forms of cancer, including colon/colorectal
cancer [18].
If a patient presents with both cancer and Crohn's, how
can vitamin D alleviate symptoms associated with both
diseases if it is expected to activate the VDR in one disease
state and slow its activity in another? Thus, the de ciency/
disease model for vitamin D metabolism leaves us without a
clear model for how the secosteroid works at the molecular
level and contradictory assumptions for how it exerts a
bene cial effect.
5. Insights emerging from the molecular biology
Recent molecular and clinical research forms the basis for
an alternative model of vitamin D metabolism, one that fully
accounts for clinical observations in autoimmune disease. If
valid, this theory signi cantly undermines any rationale for
giving supplemental vitamin D to patients with autoimmune
diagnoses. According to the alternative model, low levels of
25-D in patients with autoimmune disease are a result rather
than a cause of the disease process. Secondly, the reduction in
in ammation, clinical disease markers, and disease symp-
toms in patients taking supplemental vitamin D result from
temporary suppression of the innate immune response.
As previously discussed, research indicates the VDR is
ultimately a control system for the innate immune response.
In silico simulations show that while 1,25-D possesses the
residue necessary to agonize the VDR, 25-D does not (Fig. 1)
[19]. Thatthetwomainformsof vitaminDalternatelyactivate
or deactivate a receptor at the heart of several critical
feedback pathways makes sense from an evolutionary view-
point. Indeed, 25-D and 1,25-D share an almost identical
af nity for the receptor [19].T h eb o d yr e g u l a t e st h e
production of 1,25-D, and, in turn, the VDR, through a series
of intricate and carefully controlled feedback pathways,
mechanismsthatbeliethesimplicityofthede ciency/disease
model.
Understanding the alternative model for vitamin D
requires an appreciation for how the human microbiota has
evolved to slow the innate immune response in order to
facilitate its survival. Molecular data shows certain members
of the microbiota create ligands that block the transcriptional
pathways set in motion by an active VDR [20].
Relatively little is known about the 90% cells persisting in
Homo sapiens that are non-human; the genomes of only a
fraction of such microbes have been sequenced. While some
of these bacteria may contribute to well-being, others may be
pathogenic. Persistent and unique communities of microbes
have been detected in subjects with diseases ranging from
autism [21] to obesity [22].
The innate immune system responds to chronic pathogens
by secreting cytokines and chemokines in an effort to clear
them from the body. If it fails, the result may be a disease
stalemate that accounts for the chronic in ammation
observed in autoimmune disease. Furthermore, as the micro-
biota continues to dysregulate the VDR, transcription of key
enzymes is thwarted. VDR production of CYP24A1 decreases,
allowing 1,25-D to rise without a feedback system to check it.
As the hormone/secosteroid rises above a normal range, it
down-regulates, via the PXR nuclear receptor, the amount of
vitamin D converted into 25-D [19]. This results in the low
levels of 25-D characteristic of autoimmune diagnoses.
5.1. Explanation for effects of vitamin D supplementation
Substancescapable of slowing VDRactivityalso reduce the
innate immune response and subsequently the in ammation
associated with bacterial death. Since 25-D antagonizes the
VDR, it follows that as the secosteroid and bacterial ligands
accumulate, the innate immune system is less able to
effectively target pathogens—including those that may
further dysregulate the VDR. In the short-term, cytokine and
chemokine production by the innate immune system drops.
Fewer endotoxins and less cellular debris are created by
bacterial die-off, resulting in a decrease in in ammation and
overall disease symptoms. Yet, over the long-term, the
pathogens at the heart of the disease process spread with
greater ease. In this respect, the vitamin D in food and
supplements is not unlike corticosteroids—substances that
ameliorate disease symptoms in the short-term but exacer-
bate them over time.
We all can appreciate that the absence of disease
symptoms is not necessarily the same as the absence of
disease. The adverse effects of immunosuppressants some-
times take decades to be realized. Users of anabolic steroids,
which are immunosuppressive [23], feel well being and
euphoria when taking the drugs. However, researchers have
Fig.1. Thesecosteroids25-hydroxyvitaminD(yellow)and1,25-dihydroxyvitamin
D3 (purple). Note that although the secosteroids have nearly identical structures,
25-D lacks the extra hydroxyl group, serving to stabilize the helices of the VDR and
activate it [40].T h et w om e t a b o l i t e sh a v en e a r l yi d e n t i c a la f  nities for the VDR:
1,25-D has an estimated Kd of 8.48 while that of 25-D is 8.36.
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32documented higher rates of cardiovascular disease in former
users [24]. Use of corticosteroids, a  rst-line treatment for
many autoimmune diagnoses, signi cantly increases relapse
by a striking margin [8]. There are no studies that show that
corticosteroids improve long-term prognosis in the treatment
of illness. One author writes, “Remarkably, despite over
50 years of use, there is no proof of long-term (survival)
bene t from corticosteroid treatment [25].”
According to the alternative model, true recovery from
autoimmune disease involves an activated immune response
and a corresponding spike in symptoms due to bacterial die-
off—a phenomenon known as immunopathology [26]. Symp-
tomexacerbation in the face of an activatedimmune response
occurs in other diseases including AIDS, in which patients
exhibit Immune Reconstitution In ammatory Syndrome after
beginning antiretroviral therapy aimed at targeting opportu-
nistic infections. Syphillis, sarcoidosis [27], and a number of
additional diseases [26] also induce immunopathological-
type reactions during periods where the immune system
succeeds in targeting chronic pathogens.
Consequently, if patients with autoimmune disease suc-
ceed in killing bacteria associated with their disease state,
their symptoms should be expected to escalate, at least in the
short-term, as cytokines and endotoxins are generated [28].
Conversely, in cases in which the immune response has been
suppressed by supplementation with an immunosuppressant
such as the secosteroid 25-D, one would expect to see fewer
clinical manifestations of disease in the short-term, yet more
advanced disease in the long-term. At a certain point,
depending on the clinical symptom or physiological markers
of disease, patients supplementing with vitamin D would be
expected to approach a “crossover point” when additional
reduction of the immune response is eclipsed by the
advancing disease (Fig. 2). This outcome has been demon-
strated in longitudinal studies, with studies on sicker or older
patients taking less time to realize the effect.
The Iowa Women's Health study showed vitamin D intake
seemed to protect against breast cancer in the  rst 5 years
after it was taken. However, the effect began to reverse
betweenyears 5 and 10 and was completely lost after year 10,
trending towards an opposing effect [29].L a p p ee ta l
published work, conducted over 4 years, that seemingly
showed vitamin D might lower the incidence of colorectal
cancer [30]. In a similar study looking at a larger cohort and
over a longer period of time, Rossouw et al found no such
effect [31].
The arc of feeling better and then worse in patients
supplementing with vitamin D is one that seems to play–
depending on the extent to which the VDR is already blocked
by bacterial ligands–over the course of 20 years or more. After
multivariate analysis, Payne et al found that long-term
consumption of vitamin D was strongly associated with
increased brain lesions in the elderly (pb0.001) [32]. In
another longitudinal study, Hyppönen et al found atopy and
allergic rhinitis were higher in 31-year-old subjects whose
parents gave them vitamin D as infants and children [33].
Strong support for the validity of the molecular data
forming the backbone of the alternative model comes from an
open-label clinical trial in which hundreds of patients with a
variety of autoimmune diagnoses are reporting improvement
and recovery after taking a VDR agonist and subinhibitory
antibiotics over the course of several years [34]. Subjects in
the trial avoid vitamin D in an effort to increase VDR activity
and subsequently the innate immune response. The strength
of their resulting immunopathology indicates that lowering
vitamin D intake indeed allows the innate immune system to
more effectively target chronic pathogens.
6. 1,25-D and in ammatory disease
It is often assumed that administering supplemental
vitamin D will stimulate 1,25-D production. Manyalso believe
1,25-D can be raised to very high levels in patients with
autoimmune disease without exacerbating the disease state.
There are several problems with these assumptions.
First, 1,25-D is generally already well above a healthy
range in patients with autoimmune diagnoses due to the
inability of CYP24A1 to break down the active metabolite.
Unfortunately, since most researchers test only 25-D when
determining vitamin D status, this elevation is frequently
missed. One recent study of patients with autoimmune
diagnoses residing in cloudy Vancouver found that only 15
Fig. 2. Depiction of effect of vitamin D on chronic disease.
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33of 100 had serum values of 1,25-D below 110 pmol/L (46.2 pg/
ml) [35]. Inappropriately high levels of 1,25-D, de ned in
another study as greater than 60 pg/ml, were likewise
observed in 42% of patients with Crohn's disease [36].
Furthermore, even if 1,25-D levels could be elevated by
supplementation in autoimmune disease, the hormone/
secosteroid would be unable to effectively bind the VDR
since receptor binding pockets are already blocked by
bacterial ligands. The inability of 1,25-D to activate the VDR
in patients with autoimmune illness is supported by data
showing that many subjects with autoimmune disease who
present with higher than normal levels of 1,25-D do not
develop hypercalcemia [35]. Of the aforementioned cohort of
100 patients with autoimmune disease, 85 of which had high
1,25-D, none had signs of hypercalcemia. Oncologists have
noteda similareffect in cancer.An activeVDR hasbeenshown
to inhibit growth of cancerous cells and induce apoptosis in
tumors [37]. However, some cancer researchers have sug-
gested the VDR loses sensitivity to 1,25-D as the disease
progresses [37].
Third, up-regulation of 1,25-D in disease, even without
additional vitamin D supplementation, already interferes
with transcription by other receptors. Molecular research
showsthatexcessively high concentrations of 1,25-D interfere
with numerous hormonal pathways by displacing native
ligands from nuclear receptors such as PPAR-gamma and
alpha, the glucocorticoid receptor, and the androgen receptor
[38]. Since these receptors also express antimicrobial pep-
tides, when 1,25-D reaches unnaturally high levels, the innate
immune system's ability to eliminate pathogens is further
thwarted.
7. Conclusion
Uncertainties resulting from epidemiological studies
underscore the danger in recommending use of a substance
when the exact manner in which it works to ameliorate
disease is not fully understood.
Ioannidis wrote, “…for many current scienti c  elds,
claimed research  ndings may often be simply accurate
measures of the prevailing bias [39].” The literature has been
nearly unequivocal in its support for vitamin D supplementa-
tion in autoimmune disease, but the factors dictating the
autoimmune disease process are not empirically self-evident.
In this case, it is possible that the statistical analyses and
studies on which they are based are misleading, and a
reassessment may be warranted.
De nitive mechanisms by which vitamin D protects against
autoimmune disease have yet to be identi ed. Some argue that
low levels of 25-D exacerbate disease and can be remedied by
additional consumption of vitamin D. This explanation may be
overly simplistic. Researchers are recommending vitamin D
supplementation at historically unprecedented levels. Yet, by
most measures, rates of chronic diseases that ought to be
reduced by such supplementation continue to escalate.
A reconsideration of the de ciency/disease model is
warranted. The alternative model is based on the growing
possibility that persistent bacteria drive autoimmune disease.
Under such circumstances, 25-D, which inactivates the VDR,
palliates symptoms over the short-term, but allows chronic
pathogens to proliferate over time. If so, low 25-D in patients
with autoimmune diagnoses is the result, rather than cause,
of the disease process—further undermining any therapeutic
bene t from vitamin D supplementation.
Take-home messages
• Prevailing theories of vitamin D are imprecise and suggest
contradictory understandings of vitamin D metabolism.
• 25-hydroxyvitamin D is immunosuppressive.
• Supplementation of the secosteroid vitamin D temporarily
alleviates signs and symptoms of chronic disease but leads
to a long-term increase in morbidity.
• Molecular biology suggests that low levels of 25-D are a
result rather than a cause of the autoimmune disease
process.
• A microbiota of bacterial pathogens may survive in the
human body by secreting proteins that antagonize the VDR
and disable the innate immune response.
• Elevated levels of 1,25-D exist at the site of disease and are
an indication that the innate immune system is responding
to an infection.
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Ultrasonographic depiction of knee joint alterations in systemic lupus erythematosus
Inflammatory changes within the knee joint of systemic lupus erythematosus (SLE) patients are not rutinarly explored.
Ossandon A, et al. (Clin Exp Rheumatol 2009;27:329–32) intended to evaluate in ammatory changes within the knee joint of
SLE patientscomparedtoRheumatoidarthritis(RA)patientsandhealthysubjects(HS)byusingultrasonographicmethod(US).
US ndingswerecorrelatedwithdiseaseactivityparameters.Twenty-sixSLEpatientswereenrolledinthestudy,25RApatients
and15HSwereselectedascontrols.USwasperformedbytwodifferentexperiencedoperators,usinganAgilent-HPImagepoint
Hxmachineequippedwitha10MHzlineartransducer.PowerDoppler(PD)wasusedtodeterminelocalsynovialperfusion(PFR
700-1100 Hz; gain 60-65dB; low  lter). Knee joints were examined bilaterally. US  ndings, expressed after consensus of the 2
operators, were correlated to clinical and serological parameters of disease activity. Statistical analysis was performed by the
EPISTATprogram.TheyfoundthatinSLE,synovitiswasfoundin21knees(40%),jointeffusionin12(23%),synovialproliferation
in 12 (23%), positive PD signal in 5 (10%) and gastrocnemius-semimembranosus bursitis in 5 (10%). No erosions were detected.
Therewas a signi cant difference respect toRA for synovitis (pb0.003), synovial proliferation (pb0.002) and positive PD signal
(pb0.01). No correlation was found between US alterations and SLE disease activity parameters. In the HS group 1 patient
showedmildsynovial proliferation.Thisis the rststudythatinvestigateskneejointinvolvementinSLE byultrasonography.US
was able to depict in ammatoryalterations in the articular tissues of SLE patients, revealing some common characteristics with
RA, except for the presence of erosions. The authors concluded that US might be of help in the global evaluation of SLE patients
with in ammatory joint involvement, providing relevant information to the clinician.
HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms
Kawasaki disease (KD) is a pediatric systemic vasculitis of unknown cause for which a genetic influence is supposed. However
matching susceptible genes to KD with specific clinical manifestations remains controversial. The purpose of the study performed
by Lin YJ, et al. (Arthritis Rheum 2009; 60:604–610) was to identify possible genetic variants in the major histocompatibility
complex (MHC) region that are associated with KD and the development of coronary artery aneurysms (CAAs) in a Taiwanese
population.The168 genetic variantscoveringtheMHClocus wereanalyzedinanassociationstudyof a Taiwanesecohortof93KD
patients and 680 unrelated healthy children matched for sex and age with the study patients. They found that eleven single-
nucleotide polymorphisms (SNPs) were associated with the occurrence of KD. The SNP located at the 3'-untranslated region of
HLA-E (rs2844724) was highly associated (Pb1x10(-7)). In addition, the frequency of the C allele was higher in KD patients
without CAAs than in controls (Pb0.001) due to a signi cantly increased frequency of the CC and CTgenotypes. Plasma levels of
solubleHLA-Eweresigni cantlyhigherinKDpatientsthanincontrolsregardlessofthepresenceofCAAs.Furthermore,therewasa
trendtowardhigherplasma levelsofsolubleHLA-EinKDpatientswiththeCTandTTgenotypesof theHLA-Egenepolymorphism.
Their results suggest that the HLA-E gene polymorphism may play a role in the pathogenesis of KD.
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Summary and link to next chapter 
 
Controversy exists in relation to the benefits of vitamin D supplementation for health. In the 
chapter, "Vitamin D: the alternative hypothesis", we discussed how a dysregulated immune 
response may allow metagenomic pathogens that play a role in the autoimmune disease 
process to spread. Liabilities of the deficiency/disease model for vitamin D were presented 
and an alternative model was supported. 
 
Our alternative model can be summarized by the following points: 
 
1. Low levels of 25-D observed in many patients with autoimmune diagnoses are likely the 
result rather than the cause of the disease process. Under these conditions, the concept of 
"vitamin D deficiency" is no longer valid. 
 
2. 25-D's immunosuppressive properties may result from its ability to slow activity of the 
VDR  and  subsequently  the  innate  immune  response.  This  allows  for  symptomatic 
improvement  in  the  short  term.  However,  over  longer  periods  of  time,  any  microbes 
contributing to the disease state are able to proliferate much more easily. This ultimately 
results in long-term relapse.  
 
3. Most studies on vitamin D test only levels of 25-D and do not test levels of the active 
vitamin  D  metabolite,  1,25-D.  This  results  in  an  incomplete  picture  of  how  vitamin  D 
metabolism is altered by the autoimmune disease state.  
 
In the next chapter, "Autoimmune disease in the era of the metagenome", we examine the 
microbiota/disease  nexus  in  greater  depth.  We  further  explain  how  many  microbes  can  
37 
themselves slow activity of the VDR and other key receptors, thus controlling the innate 
immune response in order to gain a significant survival advantage. 
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Chapter 4: Autoimmune disease in the era of the 
metagenome 
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Studies of autoimmune disease have focused on the characteristics of the identi able
antibodies. But as our knowledge of the genes associated with the disease states expands,
we understand that humans must be viewed as superorganisms inwhich a plethora of bacterial
genomes – a metagenome – work in tandem with our own. The NIH has estimated that 90% of
the cells in Homo sapiens are microbial and not human in origin. Some of these microbes create
metabolites that interfere with the expression of genes associated with autoimmune disease.
Thus, we must re-examine how human gene transcription is affected by the plethora of
microbial metabolites. We can no longer assume that antibodies generated in autoimmune
disease are created solely as autoantibodies to human DNA. Evidence is now emerging that the
human microbiota accumulates during a lifetime, and a variety of persistence mechanisms are
coming to light. In one model, obstruction of VDR nuclear–receptor-transcription prevents the
innateimmune system frommaking keyantimicrobials, allowingthe microbesto persist. Genes
fromthesemicrobesmustnecessarilyimpactdiseaseprogression.Recenteffortstodecreasethis
VDR-perverting microbiota in patients with autoimmune disease have resulted in reversal of
autoimmune processes. As the NIH Human Microbiome Project continues to better characterize
the humanmetagenome, newinsights intoautoimmune pathogenesisarebeginning toemerge.
© 2009 Published by Elsevier B.V.
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1. Introduction
A decade ago microbiologists were generally con dent
thatmostof the bacterial species capableof persisting in oron
humans had already been identi ed. However, over the past
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40few years this perception has changed dramatically. Advances
in molecular genetic sequencing have revealed the presence
of a vast human microbiota, much of which de es detection
by culture-based methods.
Homo sapiens was once thought to be the product of one
genome. Now, humans are best described as superorganisms
in which a multitude of microbial genomes persist in concert
with our own [1].T h eg e n o m e si n t e r a c tb ya f f e c t i n g
translation, transcription, and DNA repair in the cytoplasm
of infected cells. It is essential that we examine how both
human and microbial metabolites (the Human Metabolome)
alter the expression of key genes associated with the
presentation and progression of autoimmune disease.
2. The human microbiota
According tothe NIH, a mere 10% of the cells that comprise
the organism known as H. sapiens are human cells. The
remaining 90% are bacterial in origin [2]. Thus, H. sapiens is
best described as a superorganism inwhich a large number of
different organisms coexist as one [3]. Previously occult
bacteria are being found in and on the human body. For
example, hydrothermal vent bacteriawere found in studies of
hip joints during revision arthroplasty [4].
To date, only a fraction of the human microbiota has
beengeneticallycharacterizedandidenti ed,leavinglargegaps
inourunderstandingofhowitcontributestohumanhealthand
disease. The NIH Human Microbiome Project aims to use
molecular genetic sequencing to catalog the balance of the
human microbiome over the coming years. This Project has
already succeeded in characterizing over 1000 novel bacterial
genomes [2]. These genetic “ ngerprints” allow for a better
trackingandunderstandingofspeciesandanymetabolitesthey
produce which might interact with the human genome.
Medicine is now comfortable with the bacterial popula-
tionsthatexistin thegutandareasof thebodyin contactwith
the external environment, such as the mouth, ears, nose and
skin. Yet, components of the human microbiota also likely
persist in many other body tissues, including those which
become in amed in autoimmune disease [5]. Such bacteria
canpersist inside the verycells of the immune systemthat are
supposed to kill them [6], or in bio lm communities in which
they are protected from the immune response by a self-
created polymeric matrix [7].
Thesebacteria rapidlyand frequentlyshare their DNAwith
their fellow species – even distantly related species – through
horizontal gene transfer. Homologous recombination further
muddles genomic coherence. As a result, the diversity and the
variability present in the human microbiota is much greater
than anticipated [8]. Some argue that the number of microbes
created through genetic recombination is so high that the
concept of distinct bacterial species may become obsolete [9].
For example, researchers associated with the European Tract
MetaInitiativeseektounderstandhowbacteriainthegutmay
contribute to obesity and in ammatory bowel disease. The
goal of the project is simply to examine associations between
bacterial genes and human phenotypes. “We don't care if the
name of the bacteria is Enterobacter or Salmonella. We want to
know if there is an enzyme producing carbohydrates, an
enzyme producing gas or an enzyme degrading proteins,”
explains Francisco Guarnerof the project [10]. Such efforts are
shifting the focus of microbiology away from the search for
single pathogens in a disease state [1]. Instead, an increasing
number of researchers are exploring how components of the
microbiota may cause disease by interacting together.
3. A metagenome
Because so many bacteria persist in H. sapiens,t h e
microbiota is currently estimated to harbor millions of
genes compared with the mere 31,897 [3] that comprise the
human genome. In fact, the human genome is barely larger
than that of the worm C. elegans (23,399 genes) or that of the
small  owering plant thale cress (29,388) [3].
Due to their small size, hundreds, or even thousands, of
bacterial cells can  t inside a human cell [6]. The combined
genetic contributions of these microbes inevitably provide
myriad gene products not encoded by our own relatively small
genomes.Thismeansthatthehumangenomeisonlyoneofthe
many genomes that affect H. sapiens function. In reality, the
organism we call H. sapiens is controlled by a metagenome, a
tremendous number of different genomes working in parallel.
Bacterial gene products can be very similar to our own. For
example, the metabolism of glucose-6-phosphate by both the
human body and E. coli is nearly identical, so that remarkably
similar metabolites are produced by both species [11].W i t ht h i s
in mind, the interaction between an E. coli genome and the
humangenome,astheyexchangenutritionandtoxins,increases
the complexity of transcription and translation for both species.
4. Bacteria alter the expression of genes that affect the
progression of autoimmune disease
When analyzing a genetic pathway, we must study how
bacterial and human genes interact, in order to fully under-
stand any process related to the H. sapiens superorganism.
Some of these pathways contribute to the pathogenesis of
autoimmune disease.
Fig. 1 illustrates some of these gene–disease relationships
[12].An u m b e ro fa u t o i m m u n ea n di n  ammatory diseases are
shown together with the genes that have been associated with
each illness. Note that the gene ACE is related to myocardial
infarction,renaltubulardysgenesis,Alzheimer's,theprogression
of SARS, diabetes mellitus, and sarcoidosis. ACE has been shown
to be down-regulated by a number of peptides created by Lac-
tobacillus and Bi dobacteria [13],s p e c i e so fb a c t e r i ac o n s i d e r e d
to be innocuous or “friendly.” No one would argue that these
species aren't present in the human body, yet there has been
little study of how they affect chronic in ammatory disease.
For example, PTPN22 is related to rheumatoid arthritis,
lupus, and diabetes mellitus. Yet PTPN22 has been shown to be
upregulatedaspartoftheinnateimmuneresponsetomycobac-
teria [14].O u rp o p u l a t i o ni sf a c i n gas u r g ei nl a t e n tt u b e r c u l o s i s
and an increased prevalence of Mycobacterium avium.S oi ti s
extremely important that we look at how the presence of in-
creasedPTPN22fromlatentinfection,oranyofthemycobacteria
in themicrobiota, might contribute tothe autoimmune process.
5. Capnine and the persistence of the metagenome
Created by the gliding bacteria that are present in bio lm,
the sulfonolipid Capnine provides a speci c example of how a
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41bacterial metabolite could manipulate human gene expression
in order to dramatically alter the progression of autoimmune
and other chronic diseases. Capnine has the capacity to disrupt
transcriptionbytheVDR,oneofthebody'smostproli cnu clear
receptors [15].
The VDR expresses at least 913 genes, many connected to
autoimmune conditions and cancers [16]. The receptor also
regulates expression of several antimicrobial peptides (AmPs)
that play a vital role in allowing the innate immune system to
target chronic pathogens [17]. Furthermore, it transcribes
TLR2, which enables the innate immune system to recognize
gram-positive bacteria [18, 19].
Thus, if Capnine was dysregulating the VDR, it would
greatlyhampertheinnateimmuneresponse.VDRdysfunction
would cause the active vitamin D metabolite 1,25-D to rise to
excessivelyhighlevelswhereitcouldinhibitexpressionbythe
bulk of the body's other nuclear receptors — including alpha
thyroid, the glucocorticoid receptor, and the androgen
receptor [20]. This would result in hormonal imbalances and
also interfere with expression of the dozens of other AmPs
expressed by these receptors. In vivo, the microbiota appears
to gradually shut down the innate immune response over a
person's lifetime, resulting in the increased accumulation of
chronic bacteria and other pathogens [21].
Eventually, genes from the accumulating microbial meta-
genome may determine a clinical disease symptomology such
as an autoimmune diagnosis, or simply drive the in ammation
associated with the aches and pains of aging [5].T h i sa c c u m u -
lation is an extremely logical evolutionary survival mechanism.
Components of the human microbiome have evolved to
dysregulate the VDR receptor that would otherwise activate a
potent immune response against its presence. As Royston
Goodacre comments in Journal of Nutrition, we are born with a
genome that, asidefrom thegenes of species that can survive in
the womb and endometrium [22],i sl a r g e l yh u m a n .B u tw e
inevitably die with a genome that is at least 90% bacterial [3].
This shift towards an increasingly diverse microbiota over a
lifetime is directly correlated with an increase in diseases and
symptoms driven by in ammation.
6. Antibodies may be generated in response to
microbial DNA
Autoimmune diseases are often regarded as illnesses in
which the immune system creates antibodies against itself [23].
Yet now that H. sapiens is understood to be the product of
multiple genomes, it is equally possible that the antibodies
observed in autoimmune disease result from alteration of
human genes and gene products by the bacterial metagenome.
It seems that autoimmune disease is largely the result of
the adaptive immune system gone awry. However, when a
disabled innate immune system is forced to respond to the
chronic microbiota the resulting cascade of cytokines and
chemokines will also stimulate an adaptive response. At this
point, the adaptive immune system may likely create
antibodies to fragments of DNA that have been generated by
phagocytosis or apoptosis of infected cells [5]. Yet, until a
much larger portion of the human microbiota has been
characterized, correlation of such antibodies with speci c
components of the microbiota remains dif cult.
7. The Human Metabolome is a product of its environment
The spectrum of metabolites found in H. sapiens is known
as the Human Metabolome [3]. Although many bacteria
produce substrates similar to those of their human hosts,
others produce metabolites that differ from the byproducts of
human metabolism. The human microbiota differs from
person to person depending on the unique species of bacteria
accumulated over a lifetime. This means that every person's
Fig.1. Relationships betweendiseases and genes,an excerptfrom the human disease network[12].Conditions thoughtto be autoimmuneare shaded orange. Other
in ammatory conditions are shaded red.
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42health is distinctly in uenced by the speci c byproducts
created by their particular microbiota. Changes in the metabo-
lome pool are the downstream results of gene expression [3].
Some of the human and microbial metabolites in the H.
sapiens superorganism will be manifested in serum and urine
samples. For example, mass spectroscopy has been used to
identify the non-human metabolites present in the urine of
subjectslivinginthreedistinctpopulations—theUnitedStates,
China, and Japan [24]. The study found that subjects in each
population produced very different non-human metabolites
[24]. Thus, genetic makeup, nutrition, healthcare, external
toxins – factors associated with the acquisition of a particular
microbiota – caused the three populations to become substan-
tially different. That environmental factors drive the metabo-
lome is supported by the observation that when  ve of the
Japanese subjects moved to America, their metabolomes
adapted to resemble those of the American population [24].
When evaluating the overall operation of H. sapiens, it is thus
clear that the composition of the microbiota is far more
important thanregional variationsin the human genome itself.
8. The microbiota can interfere with transcription
and translation
Persistent bacteria including Francisella tularensis [25],
Mycobacterium tuberculosis [26], Rickettsia massiliae [27],
Brucella spp. [28], Listeria monocytogenes [29], Salmonella
typhimurium [30] and others, use a variety of mechanisms to
evade the immune response and survive inside macrophages
and other phagocytic cells. Furthermore, various species of
bacteria have been detected inside the cells of patients with
juvenile rheumatoid arthritis [31], sarcoidosis [6], and other
in ammatory diseases [32].T h i ss u g g e s t st h a td i s e a s e -
causing microbiota largely persists in the cytoplasm of
nucleated cells, where it has access to both the DNA
transcription and protein translation machinery of H. sapiens.
For example, upon infecting a macrophage, Brucella spp.
down-regulates genes involved in cell growth and metabo-
lism, but up-regulates those associated with the in amma-
tory response and the complement system [33]. When
Shigella persists within a macrophage it modulates numerous
host signaling pathways, including those that inactivate
mitogen-activated protein kinases [34]. According to one
analysis, expressions of 463 human genes are changed during
an infection with Mycobacterium tuberculosis [35].
Microorganisms are also capable of integrating their DNA
with our own [36]. This result in alteration of the human DNA
by the microbiota over time, potentially leading to genetic
mutations associated with autoimmune diagnoses. Genetic
haplotypes observed in autoimmune disease frequently have
very low statistical signi cance, as would be expected based
on knowledge that the metabolome varies from population to
population and individual to individual.
In addition, host DNA repair mechanisms are susceptible
to modi cation by the products of the metabolome. In fact,
bacteria may hijack DNA repair mechanisms to generate
genetic diversity without losing genomic stability [37,38].I f
the rate of DNA damage or mutation by bacterial metabolites
exceeds the capacity of cellular repair, the accumulation of
errors can overwhelm the cell and result in early senescence,
apoptosis or cancer [39].
9. Discussion
It is becoming apparent that the body of H. sapiens consists
notonlyofthehumangenome,butalsogenomesofcommensal
bacteria,bacteriophages,andviruses.Consequently,thehuman
genome can no longer be studied in isolation. Genes known to
be associated with autoimmune conditions are susceptible to
modi cation by the myriad pathogenic metabolites. Thus their
activity in disease processes must be studied in the tissues in
which they are expressed.
Commensal microbes that were thought to be solely
bene cial to man are now known to create metabolites that
interfere with the expression of genes associated with
autoimmune disease. For example, peptides from of Lactoba-
cillus and Bi dobacteria affect expression of the ACE gene.
Those species that disable VDR gene expression secure their
survival by suppressing key antimicrobial peptides. Their
persistence may well cause the in ammation and antibody
production thought to result from autoimmune processes.
Species of pathogens that collect in an individual's microbiota
will affect disease presentation and progression. In particular
as the innate immune response is compromised by the
chronic infection, the bodyadditionally loses its ability to stop
the proliferation of opportunistic acute infectious agents.
Lifelong symbiosis between the human genome and
persistent components of the bacterial metagenome does
not simply result in modi cation of the metagenome. It
results in the accumulation of microbial metabolites in the
cytoplasm of infected cells that are capable of interfering with
DNA repair and transcription activity. Thus genetic abnorm-
alities such as those observed in autoimmune disease may
well be the result of metagenomic activity.
The use of a VDR agonist and subinhibitory antibiotics has
demonstrated the ability to restore VDR function and induce
recovery in diverse autoimmune diagnoses [21,40]. This sup-
ports a biological description inwhich a persistent pathogenic
component of the microbiota accumulates inside macro-
phages and other nucleated cells. The use of corticosteroids
slows the immune system's ability to target the cause of any
chronic in ammation resulting from this persistent infection.
This can at best result only in short-term palliation.
Take-home messages
• H. sapiens is a superorganism controlled by both the human
genome and a microbial metagenome.
• Bacterial metabolites can up-regulate and down-regulate the
expression of genes associated with autoimmune disease.
• TheHumanMetabolomevariesgreatlyfrompersontoperson
dependingonmicrobiotacomposition.Thus,itsabilitytoalter
gene expression varies greatly depending on the individual.
• The microbiota can survive by slowing VDR Nuclear Receptor
transcription,and subsequently the expression of ~913 genes
key antimicrobials for the innate immune response.
• The microbiota can persist in the cytoplasm of nucleated
cells where it has direct access to both the DNA transcrip-
tion and to the protein translation machinery of H. sapiens.
• We must necessarily study how the metagenome and the
human genome interact in order to fully understand any
process related to autoimmune disease.
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Summary and link to next chapter 
 
In  the  chapter,  "Autoimmune  disease  in  the  era  of  the  metagenome",  we  examined  the 
nature of the human microbiota in detail and introduced the novel concept of “successive 
infection.” Patients who present with autoimmune disease acquire pathogens in numerous 
ways  including,  but  not  limited  to,  childhood  infection,  vaccines,  blood  transfusions,  and 
parental exposure (such as microbes in the sperm and egg). Successive infection dictates 
that,  because  many  of  these  pathogens  likely  slow  AMP  expression  via  the  nuclear 
receptors, such patients become increasingly immunocompromised. This creates a snowball 
effect in which each pathogen that decreases immune activity makes it easier for the host to 
pick up other pathogens and so on.  
 
We have introduced the concept of the human superorganism in which microbial and human 
genes continually interact in both health and disease. Human microbiota accumulates during 
our  lifetime.  We  have  reexamined  how  human  gene  transcription  can  be  affected  by 
microbial  metabolites.  We  further  expanded  on  this  topic  and  discussed  how  antibodies 
generated in autoimmune disease may not be created solely in response to human DNA but 
may be primarily a response to the DNA of the microbiota. Finally, we briefly discussed a 
treatment aimed at targeting the VDR dysregulation. 
 
In summary we have clarified the following points: 
 
1. Homo sapiens is a superorganism controlled by both the human genome and a microbial 
metagenome. 
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2.  Bacterial  metabolites  can  up-regulate  and  down-regulate  the  expression  of  genes 
associated with autoimmune disease. 
 
3. The Human Metabolome varies greatly from person to person depending on microbiota 
composition.  Thus,  its  ability  to  alter  gene  expression  varies  greatly  depending  on  the 
individual's specific microbiota. 
 
4. The microbiota can persist in the cytoplasm of nucleated cells where it has direct access 
to both the DNA transcription and the protein translation machinery of H. sapiens. A special 
case is the nucleated phagocytic cells of the immune system. 
 
5.  We  must  necessarily  study  how  the  metagenome  and  the  human  genome  interact  to 
produce  a  spectrum  of  metabolites  in  order  to  fully  understand  any  process  related  to 
autoimmune diagnoses. 
 
In the next chapter, "Autoimmune disease and the human metagenome" we expand on all 
these points. We discuss the model of successive infection in greater depth. Furthermore, 
we provide a much more detailed description of where and how microbes that contribute to a 
pathogenic microbiota are acquired. We use our model of autoimmune disease to elucidate 
topics such as co-morbidity and familial aggregation. 
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Chapter 5: Autoimmune disease and the human 
metagenome 
 
 
Proal AD, Albert PJ, Marshall TG. Autoimmune disease and the human metagenome. In: 
Nelson KE, editor. Metagenomics of the Human Body: Springer; 2010. p. 231-75. 
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   Chapter 12
Autoimmune Disease and the Human
Metagenome
Amy D. Proal, Paul J. Albert, and Trevor G. Marshall
Background
In 1922, Ernst Almquist – a colleague of Louis Pasteur – commented, “Nobody can
pretend to know the complete life cycle and all the varieties of even a single bacterial
species. It would be an assumption to think so” (Mattman, 2000). While Almquist’s
work on idiopathic bacteria in chronic disease never received the plaudits accorded
to Pasteur’s work, Almquist foresaw the complexity that would later be inherent to
the ﬁeld of metagenomics – a ﬁeld that today forces us to examine how countless
microbial genomes interact with the human genome across disease states.
Yet in the decades before novel genomic technology made a metagenomic under-
standing of disease possible, bacteria could only be cultured in vitro on a limited
range of growth media. As most major diseases of the time – tuberculosis, pneumo-
nia, leprosy, and others – were linked to the presence of a handful of acute pathogens
able to grow under these constraints, a “game over” attitude toward infectious agents
dominated the thinking of much of the medical community. Little consideration was
given to the possible role of these pathogens in autoimmune and inﬂammatory dis-
ease states. Instead, for most of the twentieth century, the predominant feeling about
the treatment, control, and prevention of diseases with a possible infectious etiology
was optimism (Cohen, 2000).
Between 1940 and 1960, the development and successes of antibiotics and
immunizations added to this optimism and, in 1969, Surgeon General William
H. Stewart told the US Congress that it was time to “close the book on infec-
tious diseases” (Avila et al., 2008). With “victory” declared, increasing emphasis
was directed at the “noninfectious” diseases such as cancer and heart disease. In
many cases, research on infectious disease or activities on their prevention and con-
trol were de-emphasized and resources were reduced or eliminated. As recently
as the 1980s, pharmaceutical companies, believing that there were already enough
antibiotics, began reducing the development of new drugs or redirecting it away
from antibiotics.
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Despite this rosy narrative, some microbiologists were never convinced that
drugs like penicillin had ended the war between man and microbe. In 1932,
Razumov noted a large discrepancy between the viable plate count and total direct
microscopic count of bacteria taken from aquatic habitats (Razumov, 1932). He
found higher numbers (by several orders of magnitude) by direct microscopic count-
ing than by the plating procedure. In 1949, Winogradsky conﬁrmed Razumov’s
assessment and noted that many microbes are not satisﬁed with laboratory culti-
vation conditions. He remarked that readily cultivated bacteria in natural microbial
communities “draw importance to themselves, whereas the other forms, being less
docile, or even resistant, escape attention” (Relman, 1998). In 1985, Staley and
Konopka pointed to Razumov’s discrepancy and called it the “Great Plate Count
Anomaly” (Grice et al., 2008). Their review describes work in which they compared
the efﬁcacy of a ﬂuorescent dye versus standard plating procedures in detecting bac-
terial species in samples of water collected from Lake Washington. They found that
only approximately 0.1–1.0% of the total bacteria present in any given sample could
be enumerated by the plating procedure – causing them to conclude that, unless new
methods for detecting bacteria were employed, “No breakthrough in determining
species diversity seems likely in the near future.”
Meanwhile, some microbiologists continued their best efforts to alter the pH
and growth medium of their samples in an effort to look for previously undetected
bacteria in chronic disease states. Over the course of a career spanning almost 50
years, Lida Mattman of Wayne State University cultured wall-less forms of bacteria
from the blood samples of patients with over 20 inﬂammatory diagnoses includ-
ing multiple sclerosis and sarcoidosis (Almenoff et al., 1996). She authored an
entire textbook on novel approaches for in vitro cultivation of bacteria (Mattman,
2000). Over his 39-year career at Tulane University, Gerald Domingue published
dozens of papers and book chapters devoted to the role of chronic forms of bac-
teria in inﬂammatory disease. “It is unwise to dismiss the pathogenic capacities
of any microbe in a patient with a mysterious disease,” he wrote. “Clearly, any
patient with a history of recurrent infection and persistent disability is sending
the signal that the phenomenon [infection with chronic bacteria or viruses] could
be occurring. The so-called autoimmune diseases in which no organism can be
identiﬁed by routine testing techniques are particularly suspect” (Domingue and
Woody, 1997).
Yet, scientists like Mattman and Domingue faced serious challenges in trying to
convince the medical community that their work was valid. Other research teams
using less rigorous techniques often failed to duplicate their ﬁndings. Many of
their observations were dismissed on the premise that their samples could have
been contaminated. However, the greatest impediment toward the acceptance of this
work was a set of rules set in motion by the nineteenth-century German physician
Robert Koch. These rules, known as “Koch’s postulates,” stipulate that in order for
am i c r o b et ob ed e e m e dac a u s a t i v ea g e n to fad i s e a s e ,c e r t a i nc r i t e r i am u s tb em e t .
The same microbe must be identiﬁed in every person with a given disease; the spe-
ciﬁc microbe must be able to be grown on pure culture medium in the lab; and, when
reintroduced into a healthy animal or person, must produce the disease again.
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While Koch’s postulates may have offered certain clarity during the formative
stages of the ﬁeld of microbiology, the rules distracted scientists from considering
the possibility that multiple species could be responsible for the onset of a sin-
gle disease state. Even today, Koch’s notions about disease are regularly invoked
(Monaco et al., 2005) despite the emergence of a number of counter-examples.
Neither Mycobacterium leprae,w h i c hi si m p l i c a t e di nl e p r o s y ,n o rTreponema
pallidum,w h i c hc a u s e ss y p h i l i s ,f u l ﬁ l lK o c h ’ sp o s t u l a t e s ,b e c a u s et h e s em i c r o b e s
cannot be grown in conventional culture media. Viruses further invalidate Koch’s
postulates because most require another living cell in order to replicate (Walker
et al., 2006).
In the absence of clear connections between a single microbe and a single
disease, most microbiologists necessarily assumed that the body was a sterile com-
partment and that inﬂammation, which might well suggest the presence of microbes,
was attributed to an idiopathic causation. Unable to grow all but a fraction of bac-
teria found in the human body in the conﬁnes of a Petri dish, and constrained by a
lack of technology with which to detect new microbes, the theory of autoimmune
disease, in which the immune system loses tolerance and generates antibodies that
target self gained momentum in the 1960s.
Yet over the past decade, the role of infectious agents in autoimmune disease has
once again gained momentum. The 2004 International Congress on Autoimmunity
in Budapest was themed “Autoimmunity and Infection” with many subsequent con-
ferences and papers in the same vein. However, nearly all speakers discussed the
role of viruses in autoimmune disease, whereas only a few contemplated bacteria.
Autoimmune conditions were repeatedly attributed to easily cultured viruses such
as Epstein–Barr and Herpes 6. Where bacteria were discussed, most reports cen-
tered on select pathogens such as Chlamydia pneumoniae.Y e tb e c a u s en o n eo ft h e s e
pathogens has ever been detected in any one autoimmune disease state 100% of the
time, such researchers continue to paint autoimmune diseases as a mosaic – in which
the hallmarks of infection are continually present in bits and pieces but cannot be
drawn into a fully cohesive picture. Yet the emerging science of metagenomics is
beginning to unmask entirely new populations of microbes whose genomes allow
for a means by which to bridge these gaps. The following chapter examines how
this metagenomic microbiota can cause the dysfunction seen in a wide range of
autoimmune conditions.
Culture-Independent Methods for Identifying Microbes
In 2007, a study orchestrated by NASA announced that the surfaces of the sup-
posedly sterile “clean rooms,” in which technicians assemble spacecraft, host an
abundance of hardy bacteria (Moissl et al., 2007). Samples taken from clean rooms
at the Jet Propulsion Laboratory in California, the Kennedy Space Flight Center in
Florida, and the Johnson Space Center in Houston revealed the presence of almost
100 types of bacteria representing all the major bacterial phyla; 45% of the species
identiﬁed were previously unknown to science. The ﬁndings came as a shock to
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NASA ofﬁcials, who were left to wonder exactly how many unknown microbes
might have been taken to the moon and Mars.
These clean room bacteria had not been previously detected because they could
not be characterized by standard cultivation techniques. To ﬁnd them, the research
team had used a genomic approach – RNA gene sequence analysis – to character-
ize the genetic material of the bacterial species in the rooms previously touted as
sterile.
Similar culture-independent tools are beginning to revolutionize our under-
standing of autoimmune disease by allowing for a vastly more comprehensive
understanding of the microbes that persist in Homo sapiens, microbes that may
cause the generation of autoantibodies. Genomic sequencing techniques, including
16S RNA sequencing, PCR and, more recently, pyrosequencing, have made it clear
that only a fraction of those microbes that persist in the human body will grow on
the limited medium of a Petri dish. With the advent of these technologies, the ﬁeld of
metagenomics was born. Rather than focusing on the study of single microbes and
their genomes, metagenomics provides a means of analyzing aspects of microbial
communities through their underpinning genetics. The amount of novel microbial
genetic information that is generated on a daily basis by metagenomic analysis is so
great that multidisciplinary approaches that integrate statistics, bioinformatics, and
mathematical methods are required to assess it effectively.
Today, the National Institutes of Health (NIH) estimates that a mere 10% of the
cells that comprise Homo sapiens are human cells. The remaining 90% are bacterial
in origin. The number of Escherichia coli in a single human is comparable to the
entire human global population – approximately six billion people (Staley, 1997).
Such knowledge has forever changed the manner in which the human organism is
perceived. We may best describe the human being as a super-organism in which
communities of different organisms ﬂourish in symbiosis with the host. Yet, even
with the availability of technology to explore the microbial world in depth, to date,
only a fraction of the human bacterial microbiota has been genetically identiﬁed and
characterized. As of late 2009, approximately 1,100 published complete bacterial
genomes had been identiﬁed with 6,000 more under review (Liolios et al., 2008).
Nevertheless, there are still huge gaps in our understanding of how the microbiota
contributes to human health and disease.
Viruses (the virome) and phages are also key components of the microbiota.
Like bacteria, many of these microbes have yet to be fully characterized by high-
throughput genome sequencing. However, molecular analysis has revealed that
nearly all humans acquire multiple viruses, usually within the ﬁrst years of life,
viruses that generally remain with them throughout life. Polyomaviruses infect
between72and98%ofhumans,survivinginthekidney,lung,andskin(Virginetal.,
2009). Similarly, human herpes viruses are extremely persistent. Anelioviruses, as
well as adeno-associated virus, are now recognized to infect most humans by the
end of childhood. The role of these viruses is unknown, but a signiﬁcant number
of people who harbor them become symptomatic later in life, suggesting that they
may be capable of virulence under conditions of immune dysfunction. According
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to Herbert Virgin of Washington University, “We carry, for good or for ill, many
lifelong [viral] passengers” (Virgin et al., 2009).
In the next 5 years, researchers associated with the NIH Human Microbiome
Project (HMP) plan to use molecular genetic sequencing in an effort to catalog the
bacterial component of the human microbiome. This initiative promises to increase
our knowledge ofbacterial diversity. TheNIH hasfunded many moreHMPprojects,
with the goal that the diagnosis, treatment, and prevention of many inﬂammatory
diagnoses can be improved by examining how the microbiota differs between those
people with a disease and their healthy counterparts. Thus far, targeted conditions
include Crohn’s disease (CD), inﬂammatory bowel disease, vaginosis, psoriasis,
and other conditions now considered to be autoimmune. Early work has already
demonstrated fundamental discrepancies in microbial composition between health
and disease. Swidsinksi et al. found that patients with irritable bowel syndrome have
more bacteria from diverse genera attached to their epithelial gut surfaces than do
healthy controls. Some of these microbes, such as Bacteriodes, were found to pen-
etrate the epithelial layer, at times intracellularly (Swidsinski et al., 2002). Enck
et al. found that irritable bowel syndrome manifests with a relative decrease in pop-
ulations of biﬁdobacteria and signiﬁcant differences in a variety of other microbes,
including those that cause the production of gas (Enck et al., 2009).
Medicine has become comfortable acknowledging that bacterial populations
exist in the areas of the body in contact with the external environment, such as the
airways, gastrointestinal tract, mouth, skin, and vagina/penis. For example, anal-
ysis of the human oral cavity by Nasidze et al. identiﬁed 101 bacterial genera
in the mouth as well as an additional 64 genera previously unknown to science
(Nasidze et al., 2009). Yet, microbes have also been shown to persist in many other
body tissues, including joints and blood vessels. Some of the same bacteria identi-
ﬁed in the salivary microbiome, such as Actinobacillus actinomycetemcomitans and
Porphyromonas gingivalis – both of which cause tooth decay (Lamell et al., 2000)–
have also been identiﬁed in atherosclerotic plaque (Kozarov et al., 2005). Bacterial
DNA has been detected in the blood (Nikkari et al., 2001). Recently, 18 different
bacterial taxa were detected in the amniotic ﬂuid, which was previously believed to
be completely sterile (DiGiulio et al., 2008). Analysis using 16S rRNA sequencing
detected 28 distinct phylotypes on bioﬁlm removed from prosthetic hip joints during
revision arthroplasties – joints also removed from a body compartment also thought
tobesterile.Theprevalence ofhydrothermal vent eubacteria,whichwerepreviously
thought to persist only in the depths of the ocean since they were found at temper-
atures well above 176 F( 8 0  C), was higher than the prevalence of Staphylococcus
aureus,ac o m m o nb i o ﬁ l ms p e c i e s( F i g .12.1).
It is now more prudent to assume that tissues that become inﬂamed in dis-
ease most probably do so because of the actions of microscopic pathogens, rather
than idiopathic causation. Different microbial populations have been identiﬁed in
many nongastrointestinal autoimmune conditions including sarcoidosis (el-Zaatari
et al., 1996), ankylosing spondylitis (Liu et al., 2001), chronic fatigue syndrome
(Lombardi et al., 2009), rheumatoid arthritis, multiple sclerosis, Hashimoto’s
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Fig. 12.1 Bacterial species identiﬁed by 16S rRNA gene sequencing of clones from 10 prosthetic
hip joints (Dempsey et al., 2007)
thyroiditis, and others (Pordeus et al., 2008). These diseases share features of
microbial infection including widespread inﬂammation and periods of relapse.
Sarcoidosis and CD’ are characterized by granuloma. In more than a dozen infec-
tious diseases, granuloma is widely acknowledged to be a host-protective structure
and to occur when acute inﬂammatory processes cannot destroy invading agents
(Zumla and James, 1996).
The Human Metagenome
At only approximately 23,000 genes, the human genome is dwarfed by the thou-
sands of genomes of the bacteria, viruses, and phages that persist in and on humans.
Given the sheer number of microbial genes, it is no longer possible to study the
human genome in isolation. Rather, the human genome is only one of myriad
genomes that inﬂuence the Homo sapiens experience. Humans are controlled by
am e t a g e n o m e–at r e m e n d o u sn u m b e ro fd i f f e r e n tg e n o m e sw o r k i n gi nt a n d e m .
Because they are so small, thousands of microbial cells can persist inside a single
infected human cell (Wirostko et al., 1989). The combined genetic contributions of
these microbes invariably provide a vast number of gene products not encoded by
our own relatively small genomes.
There is considerable similarity between the functions of the bacterial organisms
and the human organisms. For example, humans and E. coli metabolize glucose-
6-phosphate in a similar fashion, producing almost identical metabolites (Kuroki
et al., 1993). Thus, the transgenomic interaction between an E. coli genome and the
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human genome, as they exchange nutrients and toxins, increases the complexity of
transcription and translation for both species. The dihydrofolate reductase (DHFR)
antagonist trimethoprim is such an effective antibiotic because, like humans, bacte-
rial species possess a folate metabolism. Bacteria in the distal intestinal tract of mice
have been shown to signiﬁcantly alter the composition of human blood metabolites,
including amino acids, indole-3-propionic acid (IPA), and organic acids containing
phenol groups, providing another example of the signiﬁcant interplay between bac-
terial and human metabolism. A broad, drug-like phase II metabolic response of the
host to metabolites generated by the gut microbiota was observed (Wikoff et al.,
2009), suggesting that the gut microbiome has a direct impact on the host’s capacity
for drug metabolism.
In the pre-genomic era, diseases were classiﬁed largely on the basis of symptom
presentation; while in recent decades, researchers have attempted to categorize them
based on common genes. Yet metagenomics dictates that we must also consider how
the many microbial metabolites affect expression of these genes. Some genes and
their related pathways have already been shown to inﬂuence the pathogenesis of
autoimmune disease. For example, Goh et al. has shown that PTPN22 is related to
rheumatoid arthritis, lupus, and diabetes mellitus (Goh et al., 2007). Yet expression
of PTPN22 is also modiﬁed by the bacterial metagenome – it has been shown to
be upregulated as part of the innate immune response to mycobacteria (Lykouras
et al., 2008). The importance of understanding how microbes affect PTPN22 across
multiple disease states has special impetus, given the increased rate of latent tuber-
culosis in the global population as well as studies showing high rates of infection by
Mycobacterium avium among autoimmune patients (Bentley et al., 2008).
Many of the most well-studied persistent pathogenic bacteria have evolved
mechanisms to evade the immune response and survive inside macrophages and
other phagocytic cells. These include Francisella tularensis (Hazlett et al., 2008),
Mycobacterium tuberculosis (Domingue and Woody, 1997), Rickettsia massiliae
(Monaco et al., 2005), Brucella spp. (Baldwin and Goenka, 2006), Listeria mono-
cytogenes (Birmingham et al., 2007), Salmonella typhimurium (Kuijl et al., 2007),
among others. This suggests that other disease-causing components of the micro-
biota may also persist in the cytoplasm of nucleated cells, where they have access
to both human DNA transcription and protein translation machinery (Hall et al.,
2008). When Shigella persists within a macrophage it modulates numerous host sig-
naling pathways, including those that inactivate mitogen-activated protein kinases
(Lutjen-Drecoll, 1992). Brucella spp. downregulates genes involved in cell growth
and metabolism, but upregulates those associated with the inﬂammatory response
and the complement system upon infecting a macrophage.
Additionally, there appears to be an entire intra-cytoplasmic microbiota within
phagocytic cells. Wirostko’s team at Columbia University in the 1980s and 1990s
used electron microscopy to identify entities within the cytoplasm of phagocytes
from patients with juvenile rheumatoid arthritis, sarcoidosis (Wirostko et al., 1989),
Crohn’s, and other inﬂammatory diseases (Wirostko et al., 1987). The wide variety
of elongated and globular formations, together with both the existence and absence
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of exoskeletons around the microbiota, would imply that the observed communities
are metagenomic, rather than due to any one single obligate phagocytic pathogen.
Microbial Complexity
The HIV genome consists of a single strand of RNA comprising nine genes, from
which are transcribed 19 proteins. Transcription is noncontiguous, and variations
abound. For example, “Tat” is transcribed in multiple pieces that are subsequently
joined. Yet 1,443 direct interactions (3,300 total interactions) have been identi-
ﬁed between just these 19 proteins and the human metabolome (Fu et al., 2009).
Consider that the average bacterial genome codes for hundreds or sometimes
thousands of proteins. According to one recent estimate, the average human gut
microbiota codes for 9 million unique genes (Yang et al., 2009). Factor in the pro-
teins created by viruses and phages, and efforts to understand how these proteins
affect the metabolome leave an observer with little more than stochastic noise, par-
ticularly since biological systems are replete with components showing nonlinear
dynamic behavior.
Subsequently, interaction between the metagenome and the human genome intro-
duces a new level of complexity to the study of autoimmune disease – complexity
that renders it nearly impossible to fully comprehend the vast number of the
interactions between the human genome and those microbial genomes capable of
inﬂuencing the pathogenesis of autoimmune disease. According to Bunge, the size
of a gene pool for a given environmental sample can be estimated by mathematical
modeling, but the size of the gene pool for a microbial biosphere, such as the human
body, may be beyond any current credible model (Bunge, 2009). While this com-
plexity poses a signiﬁcant challenge to systems biology and to Koch’s simplistic one
gene–one disease model, it does not impede the emergence of a better understanding
of the human super-organism and the processes that cause disease.
Lifelong symbiosis between the human genome and persistent components of
the metagenome has shifted the focus of microbiology away from the search for
as i n g l ep a t h o g e ni nad i s e a s es t a t e .M a n yr e s e a r c ht e a m sa r en o ws t r i v i n gt o
understand how components of the microbiota may cause disease. For example,
researchers with the European MetaHIT Initiative are studying how bacteria in the
gut may contribute to obesity and inﬂammatory bowel disease. The goal of the
project is simply to examine associations between bacterial genes and human phe-
notypes. “We don’t care if the name of the bacteria is Enterobacter or Salmonella.
We want to know if there is an enzyme producing carbohydrates, an enzyme pro-
ducing gas or an enzyme degrading proteins,” explains Francisco Guarner of the
project.
Studies focused on enzymes, proteins, and carbohydrates are studies of the
metabolome. Metabolomic approaches can be used to characterize entire compo-
nents of the microbiome that cannot easily be seen or studied directly. Because
the downstream results of gene expression manifest in the human metabolome,
the metabolome can be analyzed for the presence of those unique metabolites
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created under the inﬂuence of the microbiota. Dumas et al. used mass spectroscopy
to identify the nonhuman metabolites present in the urine of subjects living in
three distinct populations – the United States, China, and Japan (Dumas et al.,
2006). He found that subjects in each population produced very different nonhuman
metabolites.Thus,geneticmakeup, healthcare, nutrition,andexternaltoxins,factors
associated with the acquisition of a particular microbiota, caused the three popula-
tions to become signiﬁcantly different. Moreover, when ﬁve of the Japanese subjects
moved to the United States, their metabolomes changed to resemble those of the
American population. This suggests that the metagenome is indeed the product of
its environment, and that the composition of the microbiota is far more important
than regional variations in the human genome itself.
In another study, the INTERMAP epidemiological study used an 1HN M R - b a s e d
metabonomics approach to examine differences in the urine metabolite proﬁles for
each of 4,630 participants from 17 populations in the USA, UK, Japan, and China
(Stamler et al., 2003). Elevated blood pressure was associated with high levels of the
bacterial co-metabolite formate. Interestingly, low levels of hippurate and alanine,
which reﬂected gut microbial activities, were also found in subjects with high blood
pressure (Holmes et al., 2008). This suggests that certain microbial metabolites may
serve as useful biomarkers for a disease state.
The fact that components of the microbiota are seldom found as single entities
further complicates the complexity of transgenomic control in Homo sapiens. While
just a few decades ago, most of the bacteria in Homo sapiens were assumed to per-
sist on their own in a planktonic form, it is now understood that large components
of the microbiota persist in communities commonly called bioﬁlms; they are shel-
tered by a self-created polymeric matrix that better protects them from the immune
response. Hundreds of different microbes can persist in a single bioﬁlm community,
and individual bacteria often form a niche inside the bioﬁlm that allows them to pro-
mote their own survival and the chronic nature of the infection. For example, more
virulent bacteria may protect the bioﬁlm from outside intrusion whereas other less
innocuous species inside the bioﬁlm may focus on obtaining nutrients for the com-
munity. As the bioﬁlm forms and then develops, the collective genetic expression of
microbes in the bioﬁlm is altered dramatically. For example, the expression of 800
genes has been shown to be altered when a single bacterial species joins a bioﬁlm
(Sauer et al., 2002). Bioﬁlms are increasingly being detected in autoimmune dis-
eases where they were not known to previously exist. For example, Wolcott recently
used pyrosequencing to demonstrate that the infectious agents that drive the devel-
opment of diabetic leg, foot, and pressure ulcers are almost all in a bioﬁlm state
(Dowd et al., 2008).
Bacteria in bioﬁlm, their planktonic counterparts, viruses, and other microbes
rapidly and frequently share their DNA with other species, even distantly related
species, through horizontal gene transfer. Genomic coherence is further muddled
by homologous recombination. This further diversiﬁes the variability present in the
human microbiome. Horizontal gene transfer is now believed by many to occur so
frequently that it has been proposed as a means by which species can acquire new
genetic traits. Some argue that the number of microbes created through homologous
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recombination is so high that the concept of distinct bacterial species may become
obsolete (Doolittle and Papke, 2006).
Thus, the concept that a single pathogen could cause the human metabolism to
fail in the myriad of ways necessary to result in an advanced, systemic autoimmune
disease is increasingly recognized as an outdated nineteenth-century concept. The
postulates of Koch are no longer relevant in the era of the metagenome. Brock con-
tends in his proﬁle of Koch that attempts to rigidly apply Koch’s postulates to the
diagnosis of viral diseases may have signiﬁcantly impeded the early development of
the ﬁeld of virology (Brock, 1988). The same can be said for the ﬁeld of bacteriol-
ogy, where the postulates have long impeded researchers from considering that the
genomes of many different bacteria and other pathogens interact together to cause
the range of symptoms we associate with autoimmune diagnoses.
Toward a More Nuanced View of the Human Microbiota
In New science of metagenomics: revealing the secrets of our microbial planet, the
National Research Council writes, “The billions of benign microbes that live in the
human gut help us to digest food, break down toxins, and ﬁght off disease-causing
microbes” (Committee on Metagenomics and National Research Council, 2007).
While certain components of the microbiota clearly aid humans in these and other
ways, strictly classifying microbes as either commensal or pathogenic may sug-
gest too categorical a distinction. Emerging research suggests that bacteria are no
more “good” or “bad” than their human counterparts, particularly when a commen-
sal microbe can easily acquire a plasmid or virulence factor from another microbe.
According to Fredricks and Relman, “The mobile nature of virulence-associated
gene islands, transported between bacteria via plasmids or phages, creates the
potential for acquired virulence in previously innocuous microbes” (Fredricks and
Relman, 1998).
In September 2009, Malcolm Casadaban, an infectious disease researcher at the
University of Chicago, died suddenly. An autopsy showed no obvious cause of
death except Yersinia in his bloodstream. Dr. Casadaban, an associate professor at
the university, was studying the bacteria to create a better vaccine for plague. Yet
Casadaban was working with a strain of Yersinia that was supposed to be less viru-
lent that those strains considered lethal. Researchers postulated that there must have
been something unusual about the bacterium that caused it to be dangerous, such
as a mutation. The so-called “innocuous” strain of Yersinia may have acquired a
plasmid or gene that endowed it with newfound virulence.
Acquired virulence via horizontal gene transfer has been studied in anthrax.
Although Bacillus anthracis,w h i c hc a u s e sf a t a lp o i s o n i n g ,a n dB. cereus,w h i c h
causes nonlethal opportunistic infections, are generally classiﬁed as separate bac-
terial species, Hoffmaster discovered a B. cereus mutant that also causes a deadly
form of pneumonia. Analysis revealed that the B. cereus mutant (B. cereus G9241)
had acquired a plasmid with 99.6% sequence homology to pX01, B. anthracis’m o s t
virulent, toxin-encoding plasmid. Indeed, B cereus G9241 killed mice more quickly
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than B. anthracis. Bacillus cereus G9241 was deemed the product of horizontal gene
transfer, causing Hoffmaster to note that, depending on the extent of horizontal gene
transfer, nature could produce an unlimited number of variations and combinations
of any given pathogen.
The distinction between commensalism and pathogenicity is further blurred by
host-speciﬁc factors. For example, if a species of bacteria aids in the metabolism
of carbohydrates from the human intestinal tract, the presence of the microbe in the
intestines of famine victims could save lives. However, in many Western countries,
where rates of obesity are rising at an alarming pace (Wang and Beydoun, 2007),
the same microbe might contribute to excess weight gain.
Returning to the gene/disease network discussed above, the ACE gene is
related to myocardial infarction, renal tubular dysgenesis, Alzheimer’s, the pro-
gression of SARS, diabetes mellitus, and sarcoidosis. However, Lactobacillus and
Biﬁdobacteria,s p e c i e so fb a c t e r i ac o n s i d e r e dt ob ei n n o c u o u so r“ f r i e n d l y , ”a r e
capable of creating a number of peptides that downregulate expression of ACE
(Ramchandran and Shah, 2008). These species of bacteria are added to many of
our dairy products and are clearly present in the human body. Yet by altering the
expression of ACE, these “friendly bacteria” may well affect the progression of sev-
eral autoimmune and chronic inﬂammatory diseases, albeit in ways not yet fully
understood.
Pathogens Alter the Expression of Human
Genes and Receptors
Intracellular components create myriad metabolites that can interfere and alter the
correct transcription of human proteins. Some of these metabolites can also disrupt
cellular repair mechanisms, resulting in the accumulation of “junk” (e.g., proteins,
enzymes, and mRNA) in the cytosol. For example, Machado et al. reported that
Helicobacter pylori impairs central DNA repair mechanisms, inducing a transient
mutator phenotype, rendering gastric epithelial cells vulnerable to the accumula-
tion of genetic instability (Machado et al., 2009). If the accumulation of errors
can exceed the capacity for cellular repair, such dysregulation not only has the
potential to drive autoimmune processes, but can also result in early senescence
(Muller, 2006), apoptosis (Knodler and Finlay, 2001;Y i l m a ze ta l . ,2008), or
cancer.
One of the ways in which pathogens survive is by dysregulating the activity of
several of the body’s key nuclear receptors. The ability of a number of pathogens
to dysregulate the vitamin D receptor (VDR), a type 1 nuclear receptor, provides
an excellent example of how microbes alter human gene expression so as to gain a
survival advantage. Many of the nuclear receptors play a critical role in regulating
immune activity and hormonal expression.
The VDR expresses at least 913 genes, many connected to autoimmune con-
ditions and cancers. The receptor also regulates expression of several families of
key antimicrobial peptides (AMPs), including cathelicidin and the beta-defensins.
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These play a vital role in allowing the innate immune system to target intracellular
pathogens. For example, vitamin D-mediated human antimicrobial activity against
Mycobacterium tuberculosis is dependent on the induction of cathelicidin (Liu et al.,
2007). The VDR also transcribes Toll-like-receptor 2 (TLR2), which recognizes
bacterial polysaccharides.
The TACO gene, when expressed, inhibits mycobacterial entry as well as
survival. Mycobacterium tuberculosis (Mtb) downregulates the VDR, and thus
expression of TACO in order to survive. Xu et al. showed that the VDR was down-
regulated 3.3 times in monocytic cell lines infected with Mtb (Xu et al., 2003).
Borrelia,a sa s s e s s e db yB e a d C h i pm i c r o a r r a y ,h a sb e e ns h o w nc a p a b l eo fd o w n -
regulating VDR activity by a factor of 50-fold, with lysed Borrelia downregulating
the receptor by a factor of 8 (Salazar et al., 2009). We have previously shown
that at least one bacterial metabolite produced by gliding bioﬁlm bacteria is also
as t r o n gV D Ra n t a g o n i s t( M a r s h a l l ,2008). The HIV “tat” protein binds to the VDR
in order to use this receptor to recognize its long terminal repeat (LTR) promoter
region (Nevado et al., 2007). Thus, tat takes over the human VDR in order to tran-
scribe HIV’s own genome, so the HIV LTR can be recognized and express new
HIV RNA. Tat also recruits histone acetyltransferase activity, including the CREB
binding protein (CBP)/p300 complex, to acetylate the HIV LTR promoter region
(Romani et al., 2009).
Slowing the ability of the VDR to express elements of the innate immune func-
tion is such a logical survival mechanism that it is almost certain that the other less
studied components of the microbiota would have also evolved ways to dysregulate
the VDR, and the other nuclear receptors orchestrating the innate immune response.
Eukaryotic cells respond to the presence of the microbiota by activating signal-
ing cascades such as the NF-kappaB pathway. Induction of such pathways leads to
the upregulation of gene expression mediating pro-inﬂammatory and anti-apoptotic
effector proteins. Thus, in order for pathogens (and potentially, symbionts) to con-
tinue their life cycle, it is necessary to evade or repress these cellular responses. This
is especially true because acquisition of resistance to AMPs by a sensitive microbial
strain is surprisingly improbable. Furthermore, the extension of human life dur-
ing the past century now offers additional opportunity for microbes to evolve their
specialization in order to survive in man.
Indeed, Yenamandra et al. recently showed that Epstein–Barr virus (EBV) also
slows VDR activity (Yenamandra et al., 2009). Infection of human B cells with
EBV induces metabolic activation, morphological transformation, cell proliferation,
and eventual immortalization by altering the expression of a number of key nuclear
receptors. The team found that the expression of 12 nuclear receptors was down-
regulated in the longer-lasting, younger lymphoblastoid cells. Among them were
the VDR and the estrogen receptor beta (ERB), both downregulated by a factor of
about 15 times (Fig. 12.2).
EBV is found in many common chronic disease states. Indeed, EBV has been
detected in a subset of patients with nearly every autoimmune diagnosis, although
it has rarely been detected in 100% of patients with any given condition. In
some cases, infection with the virus is described as a “precipitating factor” for
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Fig. 12.2 Nuclear receptors mRNA expression is downregulated upon infection of B cells with
EBV (Yenamandra et al., 2009)
autoimmune disease. That EBV downregulates VDR and ERB expression may
explain this phenomenon. If a patient acquires EBV, the virus slows innate immune
activity to the point where the endogenous microbiota can become dominant.
This is particularly true because, in addition to reducing expression of cathe-
licidin and beta-defensin, VDR dysregulation opens a number of other pathways
that also inﬂuence immune activity and hormonal regulation. Blockage of the
VDR prevents transcription of CYP24A1, an enzyme that normally breaks down
excess levels of the active vitamin D metabolite 1,25-dihydroxyvitamin-D (1,25-
D). Activation of protein kinase A (PKA) by bacterial cytokines also causes
increased production of the enzyme CYP27B1, resulting in increased conversion of
25-hydroxyvitamin-D (25-D) into 1,25-D. Both processes result in a rise in 1,25-D.
High levels of 1,25-D in autoimmune disease have been conﬁrmed in a clinical
setting. Mawer et al. found that 1,25-D levels were particularly elevated in the syn-
ovial ﬂuid surrounding the joints of patients with rheumatoid arthritis (Mawer et al.,
1991). Abreu et al. found that in a cohort of 88 CD’ patients, 35 patients or 40%
had elevated levels of 1,25-D, which the authors deﬁned as above 60 pg/ml (Abreu
et al., 2004). Bell noted that patients with tuberculosis, pneumonia, AIDS, dis-
seminated candidiasis, leprosy, rheumatoid arthritis, silicone-induced granulomas,
Wegerner’s granulomatosis, Hodgkin’s disease, lymphoma, histocytic lymphoma,
T-cell leukemia, plasma cell granuloma, leiomyoblastoma, seminoma, and subcuta-
neous fat necrosis all tend to manifest with higher than normal levels of 1,25-D
(Bell, 1998). Blaney et al. found that of 100 patients with various autoimmune
diagnoses, 85% had 1,25-D above the normal range (Fig. 12.3)( B l a n e ye ta l . ,
2009). Yoshizawa et al. reported that in VDR knockout mice, a circumstance that
closely mimics extreme VDR dysregulation, 1,25-D levels increase by a factor of 10
(Yoshizawa et al., 1997). However, understanding 1,25-D’s role in various inﬂam-
matory disease states is complicated by the fact that most researchers determining
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Fig. 12.3 25-D vs. 1,25-D in a cohort of 100 autoimmune patients (Blaney et al., 2009)
vitamin D status test subjects only for levels of the inactive vitamin D metabolite,
25-D.
In silico research indicates that 1,25-D has a high afﬁnity for not just the VDR,
but many of the body’s other nuclear receptors (Proal et al., 2009). This suggests
that at high concentrations it will displace their exogenous ligands. Those receptors
affected by elevated 1,25-D include alpha thyroid, beta thyroid, the glucocorticoid
(adrenal) receptor, and the progesterone receptor (Fig. 12.4). For example, 1,25-D
has a very high afﬁnity for the thyroid beta, suggesting that it can displace T3 and
T4 from the binding pocket (Table 12.1)( P r o a le ta l . ,2009).
If 1,25-D prevents T3 from activating thyroid beta, then genes with thyroid beta
promoters will be less energetically transcribed. This would result in thyroid disease
and explain why increasing levels of thyroid hormone are necessary to maintain
thyroid homeostasis as chronic disease progresses. Furthermore, since the functions
of type 1 nuclear receptors are largely interdependent, if transcription by thyroid
beta is dysregulated, system-wide transcription is also affected.
This leads to disruption of system-wide AMP production. Just as the VDR
expresses cathelicidin and beta-defensin, other nuclear receptors also express
AMPs. Brahmachary et al. have shown that the glucocorticoid receptor, the andro-
gen receptor, and the VDR are, respectively, in control of 20, 17, and 16 families
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Fig. 12.4 The Thyroid-alpha nuclear receptor and T3, its native ligand [PDB:2H77], with the
bound conformation of 1,25-D superimposed. Since the XSCORE Kd for 1,25-D is 8.4, and for T3
is 7.2, it is apparent that 1,25-D is capable of displacing T3 from binding to key receptor residues
(shown here are Arg228, Asn179, Gly290, Leu292, Leu276, Ser277, Thr275, Ala263, Leu287,
Ala180, Phe218, and Arg162) (Proal et al., 2009)
Table 12.1 Afﬁnities of native ligands and 1,25-D for various nuclear receptors (Proal et al., 2009)
Nuclear receptor Native ligand Native ligand (Kd) 1,25-D (Kd)
Thyroid alpha T3 7.20 8.41
Thyroid beta T3 7.18 8.44
Glucocorticoid Cortisol 7.36 8.12
Androgen Testosterone 7.38 8.05
Progesterone Progesterone 7.53 8.09
out of the22 analyzed (Brahmachary et al.,2006). Thus, dysregulating VDRactivity
yields ﬂow-on effects that potentially disable the bulk of the body’s AMPs. A patient
affected in this manner would become increasingly immunocompromised, allowing
disease-causing components of the microbiota to proliferate with even greater ease.
This supports a disease model in which key components of the microbiota
responsible for autoimmune conditions gradually shut down the innate immune
response over a person’s lifetime as bacteria, and other pathogens, incrementally
accumulate into the microbiota. CD’ is already characterized by diminishing func-
tional antimicrobial activity, particularly when it comes to expression of cathelicidin
and the beta-defensins (Nuding et al., 2007). Eventually, genes from the accumulat-
ing microbial metagenome may instigate a clinical disease symptomology, such as
one of the autoimmune diagnoses, or simply drive the inﬂammation associated with
the aches and pains of aging. Indeed, the lifelong accumulation of an increasingly
diverse microbiota directly correlates with an age-related increase in diseases and
symptoms associated with inﬂammation. The term “inﬂammaging” has been coined
to explain “the now widely accepted phenomenon that aging is accompanied by a
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low-grade chronic, systemic up-regulation of the inﬂammatory response, and that
the underlying inﬂammatory changes are common to most age-associated diseases”
(Giunta, 2006).
Because 1,25-D is expressed in the human cycling endometrium and rises by
40% during early pregnancy, women may be disproportionately affected by the
potentialdropinAMPexpressionassociatedwithVDRdysregulation(Viganòetal.,
2006). This implies that females may more easily accumulate a more diverse micro-
biotathantheirmalecounterparts, whichcouldhelpexplain whywomensufferfrom
ah i g h e rr i s ko fm o s ta u t o i m m u n ed i a g n o s e s .
Successive Infection and Variability in Disease Onset
and Presentation
The makeup of a person’s microbiota is unique: humans may share as little as
1% of the same species (Eckburg et al., 2005). Given that the human microbiome
may play the principal causative role in autoimmune disease, it may not be by
accident that the uniqueness with which patients’ autoimmune disease symptoms
develop parallels the incredible variability of the human microbiome. Traditionally,
diseases have been understood to be discrete and have their own respective and
distinct pathologies, hence the emphasis on diagnosis. However, if the spectrum
of autoimmune disease were driven by a common factor – namely a person’s
microbial inhabitants – variability in disease could be explained by accounting for
how the human microbiota accumulates and develops in any one person. Enck
et al. recently analyzed fecal ﬂora of stool samples from 35,292 adults whose
ages ranged from 18 to 96 years of age in order to gauge the relative abundance
and composition of various bacterial species over time (Enck et al., 2009). He
found that while the number of bacteria in the fecal microbiota remained sta-
ble with age, the composition of the microbiota diversiﬁed as subjects became
older, with the oldest subjects measured (over 60 years of age) representing the
most profound changes. Older subjects were much more likely to have higher
prevalence of microbes associated with chronic disease such as Enterococcus and
E. coli.
An u m b e ro fm i c r o b e st h a ts l o wi m m u n ea c t i v i t yh a v ea l r e a d yb e e ni d e n t i -
ﬁed indicating that bacteria/viral-driven suppression of innate immune activity
may occur on a much larger scale than previously imagined. Each pathogen that
decreases immune activity makes it easier for the host to pick up other pathogens,
whichthemselvesmayfurtherslowimmuneactivity,creatingasnowballeffect.This
process is known as successive infection and offers us a framework for understand-
ing how not only diseases of the gastrointestinal tract develop, but also any number
of other autoimmune and inﬂammatory diseases. As human genes are upregulated
or downregulated by components of the microbiota, the body shifts farther and far-
ther away from its natural state of homeostasis. Infected cells increasingly struggle
to correctly produce human metabolites in the presence of numerous proteins and
enzymes being created by the pathogenic genomes.
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The ease with which a person acquires a pathogen from the environment, or
from another person, depends largely on the state of their immune system. Those
people who harbor low pathogenic loads and still have an active innate immune
system could be expected to kill the acute and chronic pathogens they encounter.
Conversely, those people with a compromised immune system will accumulate
pathogens over time. We have previously discussed how VDR dysfunction, along
with adrenal and androgen dysfunction, predispose to a weakened innate immune
system, but there are many other factors in play. For example, Bukholm and
team found that when the measles virus infects cell cultures, those cells are more
susceptible to a secondary bacterial invasion (Bukholm et al., 1986).
Stress has also been shown to impede immune function, by inhibiting natural
killer cell activity, lymphocyte populations, lymphocyte proliferation, antibody pro-
duction, and reactivation of latent viral infections (Webster Marketon and Glaser,
2008). Already identiﬁed consequences on health include delayed wound heal-
ing, impaired responses to vaccination, and development and progression of cancer
(Boscarino, 2004). Depending on the variety of stressful events that occur over a
lifetime, people may be more susceptible to picking up microbes at different times.
The immune response could be expected to be particularly weak after traumatic
events such as surgery, a car accident, or even a pregnancy (McLean et al., 2005).
People accumulate microbiota-altering pathogens in myriad different ways, the
most obvious being social contact. People in close proximity, particularly spouses
and children, inevitably pick up components of each other’s microbiomes (Wilhoite
et al., 1993). Healthcare workers have higher rates of certain autoimmune and
inﬂammatory conditions including breast cancer and malignant melanoma (Lie
etal.,2007). Merelyshakinghands causes thetransferofnumerous microbes (Fierer
et al., 2008). Genomic analysis of the bacteria on the hands of students leaving an
exam room contained 332,000 genetically distinct bacteria belonging to 4,742 dif-
ferent species. Forty-ﬁve percent of the species detected were considered rare. This
marked a 100-fold increase in the number of bacterial species detected over previous
studies that had relied on purely culture-based methods to characterize the human
hand microbiota.
Obesity is not currently accepted as an autoimmune condition, but Christakis and
Fowler recently used quantitative analysis of a densely interconnected social net-
work to conclude that obesity is transmitted among people (Christakis and Fowler,
2007).Aperson’sriskofbecomingobeseincreasesby57%iftheyhaveafriendwho
becomes obese, and by 37% if their spouse becomes obese. Although, as the team
concludes, people may mimic the behavior of friends or family in ways that could
cause them to gain or lose weight, it is also possible that the close proximity among
many of the subjects in the study would have allowed them to directly exchange
microbes. Since the composition of bacteria in the gut has, in several instances,
been linked to the development of obesity (Kinross et al., 2008)–p e r h a p s ,i ns o m e
cases, obesity is literally contagious. It seems likely the same could be said for any
autoimmune condition with an infectious etiology.
In some cases, pathogens may be acquired in the womb, particularly if the
mother already suffers from one or more autoimmune or inﬂammatory diagnoses.
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Similarly, bacterial species including Staphylococcus epidermidis, Streptococcus
viridans, E. coli, Staphylococcus aureus, Streptococcus faecalis, Proteus,a n do t h -
ers have been detected in sperm (Merino et al., 1995). Mycobacterium tuberculosis
and inﬂuenza HSN1 have been shown to cross the placental barrier. Already impli-
catedinimplantationfailure,spontaneousabortion,andpretermbirth,infectionwith
Shigella is now proposed to cause endometriosis (Kodati et al., 2008). DiGiulio
studied ribosomal DNA (rDNA) of bacteria, fungi, and archaea from amniotic ﬂuid
of 166 women in preterm labor with intact membranes. Fifteen percent of subjects
harbored microbes that together belonged to 18 different taxa – including Sneathia
sanguinegens, Leptotrichia amnionii, and an unassigned, uncultivated, and previ-
ously uncharacterized bacterium. A positive PCR was associated with histologic
chorioamnionitis and funisitis. The correlation between positive PCR and preterm
delivery was 100%.
Pathogens can also pass from mother to child during breast-feeding. For exam-
ple, Human papillomavirus type 16 (also called high-risk HPV-16), which has been
linked to cervical cancer, has been detected in human breast milk collected during
the early period after a woman delivers her baby (Sarkola et al., 2008). Pathogens
can also be transmitted from person to person through bodily ﬂuids released dur-
ing coughing, sneezing, and other intimate contact and are found nearly everywhere
in our environment. For example, nontuberculosis Mycobacteria and other oppor-
tunistic human pathogens are enriched to high levels in many showerhead bioﬁlms,
>100-fold above background water contents. Catheters used to treat urinary tract
infections and other conditions have, in some cases, been shown to harbor copious
amounts of bioﬁlm.
Early Infections Predispose a Person to Later Chronic Disease
Most of the bacteria implicated in autoimmune disease are slow-growing pathogens
whose effects will take decades to manifest (Davenport et al., 2009). In this sense,
bacteriaacquiredearlierinlifecanaltertheultimatemicrobiotainwaysthatmaynot
be recognized for decades. According to Merkler et al., “In genetically susceptible
individuals, early childhood infections seem to predispose them to [such disease as]
multiple sclerosis or Type 1 diabetes years or even decades before clinical onset”
(Merkler et al., 2006). A 2006 report by the Centers for Disease Control (CDC)
echoes this sentiment: “A person’s age at the time of infection – from intrauterine or
perinatal (the time period surrounding birth), through childhood and adolescence,
to adulthood and the elder years – may further inﬂuence the risk for chronic out-
come. For example, perinatal herpes virus infection dramatically increases the risk
of developing adult or pediatric chronic liver disease. Recurrent infections or per-
haps serial infections with certain agents might also determine a person’s risk for
chronic outcome” (O’Connor et al., 2006).
Thus, while medicine generally assumes that once a person has recovered from
an acute illness, they return to a state of complete health – the so-called “ster-
ilizing immunity” – in truth, the long-term consequences of acute infection are
6612 Autoimmune Disease and the Human Metagenome 249
somewhat poorly understood. Newborns who harbor certain types of bacteria in
their throats, including Streptococcus pneumoniae and Haemophilus inﬂuenzae,a r e
at increased risk for developing recurrent wheeze or asthma early in life (Bisgaard
et al., 2007). Approximately two-thirds of patients with Guillain–Barré syndrome, a
suspected autoimmune condition, have a history of an antecedent respiratory tract or
gastrointestinal infection (Kuroki et al., 1993). Prenatal infections such as rubella,
inﬂuenza, and toxoplasmosis are all associated with higher incidence of schizophre-
nia – with the children of those mothers exposed to inﬂuenza in the ﬁrst trimester
of gestation showing a seven-fold increased risk of schizophrenia (Brown, 2006).
Reactive arthritis (Reiter’s syndrome) is classically seen following infection with
enteric pathogens such as Yersinia, Salmonella, Campylobacter,a n dShigella (Hill
Gaston and Lillicrap, 2003). Acute gastroenteritis, resulting from infection with
the same pathogens, causes approximately 6–17% of patients to develop chronic
irritable bowel syndrome.
In an especially provocative experiment, a team including Doron Merkler and
Nobel Laureate Rolf Zinkernagel injected cytomegalovirus (CMV) into the brains
of mice that were only a few days old (Merkler et al., 2006). The innate immune
systems of the mice were able to eliminate CMV from most of the tissues except
for those of the central nervous system. As a result, the virus persisted in the brains
of the mice. Later in life, when the same mice were challenged by infection with a
similar virus, they developed a condition resembling a type of autoimmune disease
and died. The team referred to this concept as “viral déjà vu.”
Incidents of food poisoning also point to unresolved features of acute infections.
Siegleretal.notedthat10%ofpeoplewhosufferedfromE.colifoodpoisoninglater
developedarelativelyinfrequentlife-threateningcomplicationcalledhemolyticure-
mic syndrome (HUS) where their kidneys and other organs fail (Siegler et al., 1994).
According to the study, 10–20 years after patients recover, between 30 and 50% of
E. coli survivors will have some kidney-related problem, conditions that include
high blood pressure caused by scarred kidneys, slowly failing kidneys, or even
end-stage kidney failure requiring dialysis.
Microbes can also be transmitted by donation of blood, bone marrow transplants,
or organ donation, which, if pathogenic, can greatly disrupt the composition of the
microbiota over time. The term “donor-acquired sarcoidosis” refers to the develop-
ment of sarcoidosis in presumably naïve (nonsarcoidosis) transplant recipients who
have received tissues or organs from donors who were not known or suspected to
have active sarcoidosis (Padilla et al., 2002). Murphy studied over 8,500 people in
the United Kingdom who underwent heart surgery between 1996 and 2003 (Murphy
et al., 2007). Patients who had received red blood cell transfusions were about three
times more likely to suffer a heart attack or stroke and were at a higher risk for infec-
tion, readmission to hospital, and death compared with heart patients who did not
receive blood. The risks associated with blood transfusions were not inﬂuenced by a
patient’s age, hemoglobin levels, or the extent of their disability at the time of trans-
fusion. Writing in the journal Circulation,M u r p h ye ta l .c o n c l u d e d :“ R e db l o o dc e l l
transfusion appears to be harmful for almost all cardiac surgery patients and wastes
as c a r c ec o m m o d i t ya n do t h e rh e a l t hs e r v i c er e s o u r c e s ”( M u r p h ye ta l . ,2007).
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Comorbidity
Thus the catastrophic failure of the human metabolism we see in autoimmune dis-
ease – which at ﬁrst glance appears so diverse and so different among different
diagnoses–appearstobeduetoasingleunderlyingmechanism:aubiquitousmicro-
biota, much of which has evolved to persist in the cytoplasm of nucleated cells.
What differ among individuals as they gradually acquire a unique microbiota over
time are the virulence, location, and combination of those pathogenic species. The
high rate of comorbidity among inﬂammatory diagnoses (Anderson and Horvath,
2004)l e n d ss u p p o r tf o rt h i se x p l a n a t i o n .S u c hc o m o r b i d i t yb e t w e e ns e e m i n g l y
unrelated diseases cannot be explained by laws of average – the risk of autoimmune
disease is not evenly distributed. Figure 12.5 demonstrates the degree of comorbid-
ity seen among various inﬂammatory diagnoses. Each “spoke” represents a study
Fig. 12.5 Comorbidities among common inﬂammatory diseases. Each “spoke” of this wheel rep-
resentsapublished studyappearinginMEDLINE, whichshows asigniﬁcantstatisticalrelationship
between one disease and another
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from PubMed, which has demonstrated a signiﬁcant statistical relationship between
patients suffering from one inﬂammatory disease and the next.
Inthecaseofmultiplesclerosis,Barcellosetal.identiﬁedcoexistingautoimmune
phenotypes in patients with multiple sclerosis from families with several mem-
bers with the disease and in their ﬁrst-degree relatives (Barcellos et al., 2006). A
total of 176 families (386 individuals and 1,107 ﬁrst-degree relatives) were exam-
ined for a history of other autoimmune disorders. Forty-six (26%) index cases
reported at least one coexisting autoimmune disorder. The most common were
Hashimoto’s thyroiditis (10%), psoriasis (6%), inﬂammatory bowel disease (3%),
and rheumatoid arthritis (2%). One hundred and twelve (64%) families with a
history of multiple sclerosis reported autoimmune disorders (excluding multiple
sclerosis) in one or more ﬁrst-degree relatives. Hashimoto’s thyroiditis, psoriasis,
and inﬂammatory bowel disease were also the most common diagnoses occur-
ring in these family members. Such high rates of comorbidity support a model
for autoimmune conditions in which no two people with the same diagnosis ever
develop the exact same disease presentation; the interactions between an indi-
vidual’s genome and their unique metagenome are so varied that they are rarely
identical.
Note that Fig. 12.1 suggests that patients with autoimmune diagnoses are also
much more likely to suffer from mental conditions such as depression and anxiety.
Increasing clinical evidence, including that from our own study (Perez, 2008), con-
ﬁrms the involvement of microbiota in neurological disease states. This suggests
that both autoimmune and neurological diagnoses, which are currently balkanized
into separate medical specialties, most probably result from the same underlying
dysregulation of microbial populations.
Autoimmune and inﬂammatory conditions also suffer from specialty delineation.
For example, VDR dysregulation does not just impact the autoimmune disease state.
Researchers have reported epigenetic repression of VDR gene expression and activ-
ity in choriocarcinoma cell lines (Pospechova et al., 2009). Furthermore, the VDR
expresses genes involved in both autoimmune and inﬂammatory processes. It tran-
scribes insulin-like growth factor (IGFBP-3) (Wang et al., 2005), which inﬂuences
the development of diabetes, yet also expresses metastasis suppressor protein 1
(MTSS1), which plays a vital role in repressing the cell cycle and promoting apop-
tosis in cancerous cells (Wang et al., 2005). Drawing a line between autoimmune
and inﬂammatory disease makes these and other common mechanisms harder to
recognize and study.
Causation vs. Association
If most autoimmune and inﬂammatory conditions do indeed arise from the same
underlying disease process, then we must re-examine some of the cause and effect
relationships postulated to exist among inﬂammatory conditions. For example, it is
commonly believed that obesity is a causative factor in the development of diabetes
(Hibbert-Jones et al., 2004). In fact, patients with Type 2 diabetes are so likely to
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become morbidly obese that the two conditions are sometimes collectively referred
to as “diabesity” (Bailey, 2009). Obesity has been tied to microbial composition in
the gut (Turnbaugh et al., 2006), the result of a microbial process. Roesch et al.
found that the onset of Type 1 diabetes was tied to the presence of speciﬁc bac-
teria in the murine gut (Roesch et al., 2009). Additionally, at least one microbial
species, Streptomyces achromogenes,s e c r e t e sas u b s t a n c e ,s t r e p t o z o c i n ,w h i c hc a n
directly induce Type 1 diabetes (Bolzan and Bianchi, 2002). The diabetes disease
process would also make it substantially harder for the immune system to regu-
late microbial gut composition. In particular, species that are extremely effective at
extracting calories from food may thrive while their innocuous counterparts may
ﬁnd themselves out-competed. The expression of hormones that regulate appetite,
such as leptinor ghrelin, could also become dysregulated by thebacterial microbiota
(Fetissov et al., 2008). For example, H. pylori infection leads to a decrease in circu-
lating ghrelin through a reduction in ghrelin-producing cells in the gastric mucosa
(Weigt and Malfertheiner, 2009). In some cases, this could cause weight gain even
in the absence of excess calorie consumption (English et al., 2002). In light of the
above, obesity and diabetes might better be described as developing simultaneously.
Treatments aimed at addressing those underlying factors contributing to both disease
states might well prove the most effective.
The same dichotomy is found in other sets of parallel conditions such as tooth
decay and dementia, rheumatoid arthritis and uveitis, high cholesterol and heart
disease, and others. It is far more likely that both conditions arise from a common
metagenomic microbiota than that one condition is causal for the other.
Microbial Interaction and Disease
One of the more striking characteristics of nonobese diabetic (NOD) mice is that
exposure to Mycobacteriacanpreventtheonsetofdiabeteswhileprecipitatinglupus
inthesameanimal(Haradaetal.,1990;Ha wk eetal.,2003).Whilethisphenomenon
is difﬁcult to interpret by studying the murine genome alone, it may help to consider
the murine metagenome. If, as in humans, the murine metagenome causes disease
as it accumulates over time, then the interactions between various microbial species
may be telling. Even within the context of the ultimate example of symbiotic behav-
ior, the bioﬁlm, bacteria have been shown to compete with one another, sometimes
even “cheating” to do so (Dunny et al., 2008). We would not have many antibiotics
if it were not for competition among bacterial species. For example, the early tetra-
cycline antibiotics were derived from species of Streptomyces,a n da r et o x i ct oa
number of its competitors.
With the NOD mice, introduction of a new species of bacteria into the micro-
biota, Mycobacteria,a l t e r st h em i c r o b i o t ai ns u c haw a ya st ow i p eo u t ,o ra tl e a s t
diminish, the diabetes disease state. At the same time, the microbiota allows lupus
to proliferate or dominate. Similar competition between microbes may also explain
why lupus has been shown to inhibit the development of malaria (Plasmodium
falciparum)( Z a n i n ie ta l . ,2009).
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Autism, an inﬂammatory condition that has been associated with several unique
microbial populations (Nicolson et al., 2007)m a yh a v eac o m p a r a b l ed y n a m i ca t
work. In children diagnosed with autism spectrum disorder, fever associated with
intercurrent bacterial or viral infections – such as upper respiratory infections –
has been shown to temporarily decrease aberrant behavior such as irritability and
inappropriate speech (Curran et al., 2007).
Gastric surgery invariably alters the composition of the gastrointestinal micro-
biota. DePaula et al. found that after 39 diabetic type 2 patients in Brazil underwent
bariatric surgery all subjects no longer required insulin therapy (DePaula et al.,
2008). All subjects also experienced normalization of their cholesterol levels, 95.8%
had their hypertension controlled, and 71% achieved targeted triglyceride levels.
This correlates with data showing that the intestinal bacterial populations of normal
weight individuals, morbidly obese individuals, and people who have undergone
gastric bypass surgery are distinctly different. For example, Firmicutes were dom-
inant in normal-weight and obese individuals but signiﬁcantly decreased in post-
gastric-bypass individuals, who had a proportional increase of gammaproteobacteria
(Zhang et al., 2009).
Other microbial interactions can alter the pathogenicity of one or more species
involved. The pathogenic potential of Helicobacter hepaticus in a mammalian coli-
tis model is altered by the presence of different strains of Bacteroides fragilis. When
the bacterial polysaccharide PSA is expressed on the microbial cell surface of B.
fragilis,i ts u p p r e s s e sp r o - i n ﬂ a m m a t o r yi n t e r l e u k i n - 1 7p r o d u c t i o nt oH. hepaticus
(Mazmanian et al., 2008). Hoffman et al. found that when the bacterial species
Pseudomonas aeruginosa and S. aureus were incubated together, P. aeruginosa cre-
ated a protein, HQNO, which protected S. aureus from eradication by commonly
usedaminoglycosideantibioticssuchastobramycin(Hoffmanetal.,2006).Besides,
incasesofP. aeruginosa andS.aureusco-infectioninthepresenceofHQNO,small-
colony variants of S. aureus are selected for, making S. aureus more difﬁcult for the
immune system to target. Although we are far from understanding the full nature of
these microbial interactions, it is clear that a microbiota constantly evolves so that
the symptoms of any given disease are seldom static.
Familial Aggregation
The common disease–common variant hypothesis suggests that chronic diseases
are the product of anywhere from one to thousands of disease-causing alleles. The
HapMap single nucleotide polymorphisms (SNPs) cataloging project has identiﬁed
over 3.1 million SNPs, with many more expected to be found as the project con-
tinues. However, only a fraction of these SNPs confers any more than a minimal
statistically increased risk for disease (Chung et al., 2010). For example, in cancer,
for nearly all regions conclusively identiﬁed by genome-wide association studies
(GWAS), the per allele effect sizes estimated are lessthan 1.3. While over 85 regions
have been conclusively associated in over a dozen different cancers, no more than
ﬁve regions have been associated with more than one distinct cancer type (Chung
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et al., 2010). According to Stephen Chanock of NIH, “Nearly every candidate SNP
[associated with cancer] has failed in the long run – maybe ﬁve or six are real by
rigorous standards” (personal communication).
There appear to be factors at work other than just Mendelian inheritance.
The increased risk of chronic disease among nonrelations in close proximity – the
so-called “case clusters” – strongly implies an infectious dynamic at work. The
evidence that the autoimmune disease sarcoidosis is communicable is particularly
strong. A study of 215 sarcoidosis patients found that ﬁve husband-and-wife couples
both had the disease – a rate 1,000 times greater than could be expected by chance
(Rossman and Kreider, 2007). The NIH ACCESS research team also noted that the
risk for sarcoidosis increased nearly ﬁve-fold in parents and siblings of people with
the disease. A case-controlled study of residents of the Isle of Man found that 40%
of people with sarcoidosis had been in contact with a person known to have the dis-
ease, compared with 1–2% of the control subjects (Gribbin et al., 2006). Another
study reported three cases of sarcoidosis among 10 ﬁreﬁghters who apprenticed
together (Kern et al., 1993).
The literature contains many examples of unexpected familial associations
among seemingly distinct disease pathologies. For example, a 2008 study of par-
ents of children with autism found they were more likely to have been hospitalized
for a mental disorder than parents of control subjects, with schizophrenia being
more common among case mothers and fathers compared with respective con-
trol parents (Daniels et al., 2008). In the case of schizophrenia and autism, both
have been associated with prenatal viral infection (Fatemi et al., 2008). While a
fetus can acquire these and many other pathogens directly, successive infection dic-
tates that as children age they will manifest with inﬂammatory symptoms that may
differ from those of their parents. Major factors that would inﬂuence the devel-
opment of a discrete inﬂammatory diagnosis include the mix of species acquired,
the sequence in which the pathogens are acquired, the subsequent changes in gene
expression caused by the pathogens, and the profound effect on the body’s proteins,
enzymes, and metabolites caused by these changes. Because the adaptive immune
response in infants takes several weeks to develop, infants are particularly prone
to picking up pathogens during the ﬁrst weeks of life (Bisgaard et al., 2007). Such
pathogens could be acquired from any family or friends in contact with the child,
especially the grandparents, who probably harbor some of the highest pathogenic
loads. Palmer et al. found that infants pick up many of the species that make up
their gut ﬂora from family members within just a few weeks of birth, suggest-
ing that nongut bacteria may easily be acquired during this time as well (Palmer
et al., 2007).
Is Autoimmune Disease Predisposition Mendelian?
Two decades ago, the attention of the research community shifted toward a new
source in an attempt to explain the etiology of autoimmune disease: the human
genome. Begun formally in 1990, the US Human Genome Project was a 13-year
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effort coordinated by the US Department of Energy and the NIH. Its primary goal
was to determine the sequence of chemical base pairs that make up DNA and to
identify the genes of the human genome from both a physical and a functional
standpoint. A working draft of the genome was released in 2000 and a complete
version in 2003, with further analyses yet to be completed and published (Collins
et al., 2003). Meanwhile, the private company Celera Genomics conducted a parallel
project (Venter et al., 2001).
Early in the aftermath of the sequencing of the human genome, many geneticists
advocated the common disease–common variant hypothesis, expressing certainty
that the ﬁeld would quickly determine genetic haplotypes that would correlate with
and explain the bulk of chronic diseases. Dr. Francis Collins’ 2001 statement was
typical: “It should be possible to identify disease gene associations for many com-
mon illnesses in the next – 7 years” (Collins and McKusick, 2001). Researchers
hoped that by dissecting the human genome, patients could be informed that they
had “the gene” for breast cancer, sarcoidosis, rheumatoid arthritis, or any of the
other autoimmune diagnoses. Targeted gene therapies could then be developed to
effectively eradicate these conditions.
It may be too early to call human genomic research an unqualiﬁed failure
(Buchanan et al., 2006), but it is difﬁcult to ignore a lack of utility in identiﬁca-
tion of disease. Recently, the limited progress in the genetic analysis of common
diseases has begun to be acknowledged (Davey Smith et al., 2005;R i s c h ,2000).
Certainly there have been no widely successful gene therapies to date, and genome-
driven personalized medicine has yet to live up to its early promise. To identify
what some researchers refer to as the “missing heritability,” geneticists have pro-
posed GWA studies with historically unprecedented sample sizes. In the past year,
researchers have publicly contemplated “daunting” sample sizes exceeding 500,000
subjects in concert with studies that would be conducted over periods as long as 45
years (Burton et al., 2009).
Ewald et al. argue that evolutionary forces that would cause a serious disease to
be weeded from the population would also cause those people whose immune sys-
tems are prone to self-attack to be eliminated from the population (Cochran et al.,
2000). An exception would occur if the disease offers a survival advantage. For
example, the genetic disorder cystic ﬁbrosis may confer resistance to tuberculosis
(Poolman and Galvani, 2007). The Mendelian disorder sickle cell anemia is com-
mon in tropical countries because it confers resistance to malaria. With malaria,
researchers can quantify the rate by generation at which the gene for sickle cell ane-
mia is dropped from the population in the absence of an evolutionary advantage –
as is the case when people migrate away from malaria-infested areas. However,
no autoimmune diagnosis has been shown to confer any sort of beneﬁcial survival
trait. Under these circumstances, one would expect any faulty gene or network of
genes associated with an autoimmune condition to be selected against, especially
since many autoimmune conditions strike during the reproductive years. Chronic
diseases have existed for thousands of years with manifestations of both arterioscle-
rosis (Azer, 1999)a n dc a r d i a cd i s e a s eo b s e r v e di nm u m m i e so fa n c i e n tE g y p t
(Miller et al., 2000). Ötzi the Neolithic Iceman who lived around 3300 BC had
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arthritis, allowing ample time for any alleles associated with autoimmune disease
to be eliminated via natural selection (Dickson et al., 2003). Instead, the prevalence
of autoimmune conditions seems to have remained essentially constant until quite
recently.
SNPs and Autoimmune Disease
After noting that among his cohort of 31 patients with abdominal aortic aneurysm,
SNPs in the gene BAK1 were different in aortic tissue than in blood samples
from the same patients (Gottlieb et al., 2009) Gottlieb remarked, “Genome-wide
association studies were introduced with enormous hype several years ago, and
people expected tremendous breakthroughs. Unfortunately, the reality of these
studies has been very disappointing, and our [own] discovery certainly could
explain at least one of the reasons why.” The conundrum that Gottlieb’s study
has exposed is that the human genome appears to vary between the tissue
and plasma compartments. Medicine has always assumed that human DNA is
homogeneous throughout the human body. We now need to explore the mech-
anisms whereby these different genetic sequences could arise through selec-
tive pressure in different tissues such as would exist if the tissue harbored a
microbiota.
One of the mechanisms proposed for genetic predisposition states that genetic
haplotypes predispose for disease processes. Because it is a highly polymorphic
genomic region, MHC has served as the preferred axis for studying susceptibil-
ity to immune diseases. Major changes have been detected within the HLA class I
and class II genes related to various populations across the globe. For example, in
Type 1 diabetes, the most common haplotype in the Western world is AH8.1 (HLA-
A1-B8 DR3-SC01). However, this haplotype is almost nonexistent in the Indian
population and has been supplanted by the variant AH8.1v, which differs from the
Caucasian AH8.1 at several gene loci (Mehra et al., 2007). Moreover, there are
additional HLA-DR3 haplotypes HLA-A26-B8-DR3, HLA-A24-B8 DR3 (AH8.3),
A2-B8-DR3 (AH8.4), and A31-B8-DR3 (AH8.5) that occur largely in the Indian
population alone.
Similarly, the FCRL3-169T-C polymorphism, which is signiﬁcantly associated
with rheumatoid arthritis (RA) in East Asian populations is not associated with RA
in Caucasians of European decent (Begovich et al., 2007). Interestingly, the fre-
quency ofthers7528684 minor alleleassociated withFCRL3- varies asmuch within
each of the two ethnic groups as it does between them. Furthermore, a recent large
case-controlled study found that FCRL3-169T-C was not signiﬁcantly associated
with RA in Korean patients (Begovich et al., 2007).
Thus, no diagnostic certainty can be obtained by measuring genes on the HLA
axis. None of the HLA haplotypes causes disease 100% of the time and none causes
any one immune disease consistently. Patterns of haplotype variation are more sug-
gestive of a regional infectious model rather than a model in which an illness is
caused by widespread inherited variation of HLA haplotypes.
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Potential Systematic Errors in the Interpretation
of the Metagenome
Primers selected for most epidemiological studies are chosen without considera-
tion for whether they might amplify DNA from the genomes of any intracellular
microbes. As artist Pablo Picasso once remarked, “Computers are useless. They
can only give you answers.” If a software program fails to make provision for
the possibility that a metagenome might also be present, the chances of a false-
positive increase signiﬁcantly during the process of genomic analysis. Similarities
between bacterial and human genes will likely cause the analysis software to not
assemble the genomic data properly. The likelihood of error is not minuscule
as there is growing evidence of molecular mimicry, homology between bacterial
and human proteins. For example, signiﬁcant sequence homology exists between
human carbonic anhydrase II and alpha-carbonic anhydrase of H. pylori (Guarneri
et al., 2005). Moreover, the homologous segments contain the binding motif of the
HLA molecule DRB1 0405. The group A streptococcal carbohydrate antigen N-
acetyl-glucosamine is able to cross react with cardiac myosin (Cunningham, 2003).
Microbes including E. coli, H. pylori, P. aeruginosa,C y t o m e g a l o v i r u s ,a n dH.
inﬂuenzae share sequence homology with human pyruvate dehydrogenase complex-
E2, which has been tied to the development of primary biliary cirrhosis (Bogdanos
et al., 2004). The core oligosaccharides of low-M(r) LPSs of C. jejuni serotypes that
are associated with the development of Guillain–Barré syndrome are homologous
to neural gangliosides.
Before we can be certain that all measured SNPs and HLA haplotypes are a prod-
uct of only the human genome and not the metagenome, researchers must begin
to actively choose PCR primer pairs that are unlikely to amplify microbial DNA.
Primers need to be certiﬁed not only to amplify a unique sequence in the human
genome, but also as not likely to amplify genes from any of the thousands of bacte-
rial and viral genomes in the metagenomic databases. Although PCR ampliﬁcation
usually involves more than one stage of genomic selectivity, the increasing use of
arrays of RNA probes increases the likelihood that a fragment of metagenomic RNA
will unexpectedly match a probe, and increases the possibility of a false-positive
being signaled for the particular SNP being sought.
Antibodies in Response to Microbial DNA
Autoimmune diseases are characterized largely by the presence of autoantibodies.
Although autoantibodies were reported over a century ago, many scientists at the
time were unwilling to accept the possibility that the immune system attacks its
own cells. Ehrlich argued that autoimmunity was not possible and proposed the the-
ory of horror autotoxicus to describe the body’s innate aversion to immunological
self-destruction by the production of autoantibodies. Now that humans are under-
stood to be the product of multiple genomes, increasing evidence supports Ehrlich’s
view. When an innate immune system is forced to respond to a chronic microbiota,
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the resulting cascade of chemokines and cytokines will also stimulate an adaptive
response. Antibodies are notoriously polyspeciﬁc, and the likelihood that antibodies
generated to target metagenomic fragments will also target human proteins (target
“self”) is ﬁnite.
Al i t a n yo fr e s e a r c hi m p l i e sar e - e v a l u a t i o no ft h e“ a u t o a n t i b o d y . ”R e c e n t l y
researchers have shown that certain autoantibodies are created in response to sev-
eral well-studied pathogens. “Lupus-speciﬁc autoantibodies” such as RO, La, or
dsDNA are often generated in response to EBV (Barzilai et al., 2007). Similarly,
anti-EBNA-1 antibodies are able to bind lupus-speciﬁc autoantigens such as Sm or
Ro (Harley and James, 2006). Casali and Slaughter found that, in humans, EBV is a
polyclonal B cell activator, and in vitro transformation with EBV results in produc-
tion of rheumatoid factor (RF) (Casali et al., 1987;S l a u g h t e re ta l . ,1978). Possnett
et al. argues that high titers of RF are not only associated with severe rheumatoid
arthritis but also appear in a number of other diseases including viral, bacterial, and
parasitic infections (Posnett and Edinger, 1997). Maturation of RF can be initiated
by chronic infections (Djavad et al., 1996). For example, patients with subacute bac-
terial endocarditis, which is frequently tied to the presence of Streptococcus,a l s o
often present with high levels of RF (Russell et al., 1992). Williams et al. showed
that once the offending infectious agent is removed with antibiotic therapy, the RF
disappears (Williams and Kunkel, 1962). Similarly, the autoimmune disease throm-
bocytopenic purpura (ITP) is mediated by what are considered to be anti-platelet
autoantibodies. However, Asahi et al. found that eradication of H. pylori is effective
in increasing platelet count in nearly half of ITP patients infected with the bac-
terium (Asahi et al., 2006). Barzilai and team also found that Hepatitis B shares
amino acid sequences with different autoantigens, further suggesting that the so-
called autoantibodies may actually be created in response to pathogens (Barzilai
et al., 2007). Autoantibodies have been detected in patients without autoimmune
disease during periods of infection. Berlin et al. collected sera from 88 patients
with acute infections (41 bacterial, 23 viral, 17 parasitic, and 7 rikettsial (Berlin
et al., 2007)). Elevated titers of autoantibodies including annexin-V, prothrom-
bin, ASCA, ANA, or antiphospholipid antibodies were detected in approximately
half of the subjects, with 34 individuals harboring elevated titers of at least two
“autoantibodies.”
EBV, E. coli, Salmonella, and other pathogens discussed above are easily
detected by culture-based methods that may explain why their presence has already
been tied to “autoantibody” production. Yet the vast majority of the human micro-
biota is understudied. This means that what we now consider to be autoantibodies
in many autoimmune diagnoses may also indicate the presence of pathogens, but
pathogens that have yet to be fully characterized and named. Thus, in addition to
looking for antibodies to well-characterized pathogens, it is also important that we
look for antibodies indicating the presence of the underlying chronic microbiota,
some of which we may also be mistaking for autoantibodies. Like the pathogens
that may create them, many of these antibodies may not yet be detected by standard
testing. If this is the case, hundreds of pathogen-induced antibodies may exist and
impact the autoimmune disease state, but the possible detection and correlation of
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such antibodies with speciﬁc components of the microbiota remains difﬁcult until a
much larger portion of the microbiota has been characterized.
Because many antibodies demonstrate a high degree of polyspeciﬁcity, it is pos-
sible that in some cases, antibodies initially directed against pathogens could also
attack human tissue (Christen et al., 2010). According to Bozic, oxidative alter-
ations, affecting either the hypervariable region or the receptor site of IgGs, may
inﬂuence their functions (Bozic et al., 2007). Similarly, McIntyre reported the
appearance and disappearance of antiphospholipid antibodies subsequent to oxi-
dation reactions in human blood (McIntyre, 2004). Dimitrov et al. have shown
that a fraction of antibodies present in all healthy individuals begin to recog-
nize large number of self-antigens only after a transient exposure to certain
protein-destabilizing conditions, including low or high pH, high salt concentration,
chaotropic factors, and redox-active agents (Dimitrov et al., 2008). This points to at
least one mechanism whereby the oxidative stress that accumulates in inﬂamed tis-
sue could be at least partly responsible for the apparent polyspeciﬁcity of antibodies
and autoantibodies.
Molecular mimicry, in which peptides from pathogens share sequence or struc-
tural similarities with self-antigens, may also contribute to autoantibody production.
Lekakh et al. found that autoantibodies with polyspeciﬁc activity in the serum of
healthy donors were able to cross react with DNA and lipopolysaccharides (LPSs)
of widespread species of bacteria including E. coli, P. aeruginosa, Shigella boydii,
and Salmonella (Lekakh et al., 1991). CD’ is classiﬁed as an autoimmune condition
based largely on the presence of perinuclear anti-nuclear cytoplasmic antibodies
(pANCAs) in patients with the disease. Yet recently two major species of pro-
teins immunoreactive to pANCA were detected in bacteria from anaerobic libraries,
implicating colonic bacteria as a possible trigger for the disease-associated immune
response.
We previously discussed how factors other than calorie consumption may con-
tribute to the weight gain often associated with autoimmune or inﬂammatory
conditions. Fetissov et al. studied healthy women for the presence of IgG or
IgA autoantibodies directed against 14 key regulatory peptides and neuropeptides,
including ghrelin, leptin, vasopressin, and insulin (Fetissov et al., 2008). They
found numerous cases of sequence homology among these peptides and the protein
structures of over 30 microbes including Lactobacilli, H. pylori, E. coli, Yersinia
pseudotuberculosis,a n dListeria monocytogenes,s u g g e s t i n gt h a tt h e“ a u t o a n t i b o d -
ies” were actually the result of molecular mimicry. In the presence of certain
pathogenic bacterial species, the production of IgG autoantibodies directed against
ghrelin was upregulated, suggesting a complex interplay between autoantibody lev-
els and microbial antigens. This suggested that these so-called “autoantibodies”
might not only have physiologic implications in pathways that regulate hunger and
satiety but also represent a key link between the gut and the brain.
An increasing number of studies also show that what are currently perceived
as autoantibodies can often be detected in the so-called healthy individuals years
before the full presentation of an autoimmune disease state. Many researchers now
espouse that early detection of these antibodies can help predict whether or not
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such a “healthy” person will develop an autoimmune disease. For example, in an
8-year prospective study, Swaak et al. examined the diagnostic signiﬁcance of anti-
double-stranded deoxyribonucleic acid (anti-dsDNA) determination in a group of
441 patients without systemic lupus erythematosus (SLE) whose sera were found
to contain antibodies to dsDNA on routine screening (Swaak and Smeenk, 1985).
Within 1 year, 69% (304) of these patients fulﬁlled the preliminary American
Rheumatism Association (ARA) criteria for SLE. Eighty-two of the remaining 137
patients were followed up for several years. At the end of the study, 52% of these
patients had also developed SLE. The team concluded that about 85% of patients
without SLE with anti-dsDNA in the circulation would develop SLE within a few
years.
Another recent study of blood from 441 healthy Portuguese blood donors
found autoantibodies for rheumatoid factor, anticyclic citrunillated peptides, anti-
mitochondria, anti-Sacharomyces cerevisiae,A N A ,a n t i - T T G ,a n da n t i - B e t a 2 -
glycoprotein (Tavares-Ratado et al., 2009). More than 30% of the blood contained
one or more of the antibodies, 4% exhibited two antibodies, and nearly 1% had three
or more antibodies present. It is clear that sub-clinical autoimmune disease is much
more common than previously thought.
This gradual presentation of an increasing number of the so-called “autoanti-
bodies” in the years before a patient meets the ofﬁcial criteria for an autoimmune
diagnosis supports the model of successive infection described earlier – pathogenic
components of the microbiota gradually accumulate over the course of a lifetime
until bacterial, viral, and phage load reaches a level at which a diagnosis can be
made. It also supports the contention that individuals perceived as “healthy” may
still harbor and accumulate pathogenic microbes that will eventually lead to an
inﬂammatory diagnosis, or a process associated with “aging.” Indeed, it is pos-
sible that any antibodies that damage “self” do so as an unintended polyspeciﬁc
consequence of their activity against the metagenomic pathogens.
Therapies in the Era of the Metagenome
At the 2008 International Conference on Metagenomics in La Jolla, CA, James
Kinross of the Imperial College of London began his speech with the following
statement: “We surgeons have been operating on the gut for literally thousands of
years and the microbiota has just been this extraordinary elephant in the room. We
seem to have completely ignored the fact that we’ve co-evolved with thousands of
bacteria over millions of years and that they somehow may be important to our
health. As doctors, we routinely do terrible things to the microbiota and I’m sure
this has implications for our health.”
Although most physicians are undoubtedly well intentioned, Kinross is correct
in that many clinicians are generally not offered training that would keep them up
to date with advances in metagenomics. The result is that many doctors still believe
that nonmucosal surfaces of the body are largely sterile and that bacteria and other
pathogens are not driving factors in the autoimmune processes. Instead, the standard
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of care for patients with autoimmune disease continues to be corticosteroids and
TNF-alpha blocking medications. According to a 2008 report, TNF-alpha inhibitors
accounted for 80% of RA drug sales in the United States, France, Germany, Italy,
Spain, the United Kingdom, and Japan. Use of these immunosuppressants is still
grounded in the theory that autoimmune disease results from an overly exuber-
ant immune response and these drugs are administered without consideration for
the presence of a metagenome. Whether helpful or harmful, there is no question
that by dramatically slowing the immune response, such therapies must necessar-
ily and profoundly affect the composition, development, and stability of the human
microbiota.
Despite the copious use of these immunosuppressant drugs in autoimmune con-
ditions,theyprovide,atbest,short-termpalliation.Gottliebetal.showedthatsteroid
use causes relapse in sarcoidosis (Gottlieb et al., 1997). Additionally, there are no
deﬁnitive studies showing corticosteroids improve long-term prognosis in the treat-
ment of chronic inﬂammatory illness, nor is there any demonstrated reduction in
mortality. Van den Bosch and Grutters write, “Remarkably, despite over 50 years of
use, there is no proof of long-term (survival) beneﬁt from corticosteroid treatment”
(Grutters and van den Bosch, 2006). On the contrary, one of the side effects of TNF-
alpha inhibitors is an increased risk of tuberculosis. Several studies have shown that
TNF-alpha production is required for the proper expression of acquired speciﬁc
resistance following infection with M. tuberculosis (Allie et al., 2008;A r e n de ta l . ,
2003). So if we inhibit TNF-alpha expression, we would expect a long-term increase
in the prevalence of not only tuberculosis, but also in any of the autoimmune or
inﬂammatory diseases already associated with chronic forms of mycobacteria and
other bacteria (Bull et al., 2003;B u r n h a me ta l . ,1978).
The failure of these ﬁrst-line therapies to cure “autoimmunity,” and the range of
detrimental side effects associated with their use, suggests that slowing the immune
response of patients with autoimmune disease is counterproductive, allowing micro-
bial populations to develop unchecked. Now that autoimmune conditions are more
widely understood as illnesses in which myriad pathogens may trigger or drive
the disease process, efforts to target the root cause of autoimmune disease should
insteadbetargetedtowardactivating theinnateimmuneresponse,notsuppressingit.
Our own work (Perez, 2008)o f f e r sa ne x a m p l eo ft h er e s u l t so fs t i m u l a t i n g
rather than suppressing the innate immune response of patients with autoimmune
disease. Over the past 7 years, we have observed the effects of an experimen-
tal therapy for autoimmune disease that uses the VDR agonist olmesartan to
reverse pathogen-induced VDR dysregulation. Subjects are also administered sub-
inhibitory bacteriostatic antibiotics, which weaken bacterial ribosomes so that
pathogens can more easily be targeted by the reactivated immune system. Nearly all
of the hundreds of patients to start the therapy reported the predicted increase in spe-
ciﬁcsymptomsoftheirautoimmunediagnosis.Aftermonths,orsometimesyears,of
dealing with these symptomatic ﬂares, the very symptoms that waxed and waned in
synchronismwithantibioticadministrationbegantodisappear,resultinginimprove-
ment and, in many cases, eventual resolution of the disease process. This response
has been noted in the widely varying diagnoses of sarcoidosis, rheumatoid arthritis,
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lupus, Type 2 diabetes, uveitis, Hashimoto’s thyroiditis, ankylosing spondylitis,
chronic fatigue syndrome, and ﬁbromyalgia among others. The often dramatic ele-
vations in disease activity observed among study subjects – particularly during the
early stages of therapy – cannot be attributed to side effects of the protocol medi-
cations, as individually the drugs are well known and unremarkable (Schwocho and
Masonson, 2001). Additionally, when healthy individuals have been administered
the same medications they do not suffer any similar symptoms.
The most viable hypothesis for these temporary surges in disease symptoms and
inﬂammatory markers is that treatment medications allow the immune system to
mount an effective attack on an intracellular microbiota, such as the microbiota
observed by Wirostko et al. It is reasonable to expect that when intraphagocytic
pathogens are killed, some of the host cells will also undergo apoptosis, phago-
cytosis, or simply disintegration, leading to an increase in inﬂammation. For over
100 years, researchers have noted that the death of acute and persistent pathogens
is accompanied by a surge in inﬂammation. They have attributed the temporary
rise in inﬂammation to an increase in endotoxin and cytokine release upon bacte-
rial death. Known as the Jarisch–Herxheimer reaction, or immunopathology, this
phenomenon has been previously demonstrated after antibiotic administration in
diseases including tuberculosis (Cheung and Chee, 2009), borreliosis (Vidal et al.,
1998), tick-borne relapsing fever (Mitiku and Mengistu, 2002), multiple sclerosis
(Kissler, 2001), Whipple disease (Peschard et al., 2001), and syphilitic alopecia
(Pareek, 1977), among others. Zinkernagel also observed immunopathology in the
mice he had infected with a persistent neuro-active virus (Zinkernagel et al., 2009).
Similarly, immune reconstitution inﬂammatory syndrome (IRIS) is a condition seen
in some cases of AIDS following the use of antiretroviral drugs. As the immune
system begins to recover, it responds to previously acquired opportunistic infections
with an overwhelming inﬂammatory response that, like the immunopathological
reaction we observe, makes the symptoms of the infection temporarily worse
(Shelburne et al., 2002). At this point in time, the exact species or forms of bac-
teria potentially killed by any one subject in our own study cohort remain unknown.
As the focus of the HMP moves beyond the mucosal surfaces, and catalogs L-forms
andother intracellularspecies withinbodytissues,aclearerpictureofdiseasepatho-
genesis will emerge. However, as long as patients continue to report improvement
and recovery, determining the exact nature of pathogens being targeted by the ther-
apy has not been a high priority, given the limited resources currently allocated to
this research team.
Some subjects in the cohort have reported drops in viral titers, suggesting that
once the immune system is no longer burdened by the pathogenic components of the
bacterial microbiota, it may regain the ability to target chronic viruses as well. This
suggests that treatments that reverse immunosuppression caused by the bacterial
microbiota might also prove useful in mitigating viral virulence.
Our research suggests that while some people report being “allergic” to cer-
tain bacteriostatic antibiotics, what they perceive as an “allergy” may actually
be immunopathological reactions. For example, there are reports of minocycline
“inducing lupus” (Geddes, 2007). A more logical explanation may be that certain
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patients harbor persistent bacterial species that predispose for sub-clinical lupus.
When minocycline is administered, some of these bacteria are killed, result-
ing in immunopathological reactions that are mistakenly interpreted as clinical
manifestation of the disease.
What we have initiated needs further testing. However, the reports of pro-
found immunopathological reactions in autoimmune subjects imply the need to
re-examine whether palliative drugs actually provide long-term beneﬁt for patients
with autoimmune disease. Whether at the doctor’s ofﬁce or the health food store,
patients withautoimmune conditions continually seek out palliative drugs or supple-
ments that successfully reduce symptoms by lowering inﬂammation. Yet, if bacteria
drive the pathogenesis of autoimmune inﬂammation, and chronic bacterial death
invariably results in temporary increases in discomfort, then treatments that mitigate
symptoms may well do so at the expense of proliferation in pathogenic compo-
nents of the microbiota. Commonly used immunosuppressive compounds include
vitamin D, which, although its immunosuppressive properties have now been iden-
tiﬁed (Arnson et al., 2007), is now viewed as the ultimate inexpensive wonder
drug (Holick, 2008). Frequent use of vitamin D, as well as other substances that
slow immune activity, could at least partially account for the recently increased
prevalence of nearly every autoimmune disease (Luque et al., 2006).
L-Form Bacteria: An Often Overlooked Component
of the Microbiota
Certain stages of the bacterial life cycle result in the loss of the cell wall. L-form
bacteria are often less than 0.2 µmi nd i a m e t e r( D o m i n g u ea n dW o o d y ,1997) and
are therefore difﬁcult to view with a standard optical microscope. Not only do these
L-form variants fail to succumb to antibiotics that target the bacterial cell wall,
but those antibiotics also encourage the formation of L-forms. “Treatment with
penicillin does not merely select for L-forms (which are penicillin-resistant) but
actually induces L-form growth,” states Josep Casadesus of the University of Sevilla
(Casadesus, 2007). In fact, researchers deliberately culture classical forms of bac-
teria in conjunction with various beta-lactam antibiotics in order to create L-forms
(Mattman, 2000). The ability of the L-form to ﬂourish in the face of treatment with
thebeta-lactamantibioticspointstoamechanismbywhichacutebacterialformscan
mutate into latent mutants that may cause disease at a later time. Some researchers
have deemed the conversion into the L-form state to be a universal property of
bacteria (Gumpert and Taubeneck, 1983).
Joseleau-Petit et al. showed that classical forms of bacteria transform into the
L-form only if they are denied the ability to form a normal cell wall (Joseleau-
Petit et al., 2007). The beta-lactam antibiotics work toward this end by blocking the
creation of penicillin-binding proteins (PBPs) – proteins responsible for forming
the cross-linked chains associated with a peptidoglycan-derived cell wall. When
the ability of the PBPs to create a full cell wall is blocked, the cells also become
spherical and osmosensitive. Recently, Glover et al. performed the ﬁrst systematic
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genetic evaluation of genes and pathways involved in the formation and survival of
unstable L-form bacteria (Glover et al., 2009). Microarray analysis of L-form versus
classical bacterial colonies revealed many upregulated genes of unknown function
as well as multiple overexpressed stress pathways shared in common with persister
cells and bioﬁlms. Dell’Era et al. also observed cell division and changes in gene
expression in stable L. monocytogenes L-forms (Dell’Era et al., 2009).
Since the discovery of the L-forms in 1935 (Kleineberger-Nobel, 1951), they
have been described in hundreds of publications. Yet because researchers are only
just beginning to use molecular tools to study the L-form, they are still seldom
factored into the mix of microbes that compose the human microbiome. However,
over the years, L-forms have been implicated in dozens of diseases of unknown
etiology, including RA, multiple sclerosis, sarcoidosis, glomerulonephritis, idio-
pathic hematuria, interstitial cystitis, rheumatic fever, and syphilis – as well as a
large number of chronic and relapsing infections (Domingue and Woody, 1997;
Mattman, 2000).
A Research Consideration: Men Are Not Tall Mice
Without Tails
The emerging role of the human microbiota implies a reconsideration of certain
long-standing and frequently invoked models of disease. According to Javier Mestas
of University of California, Irvine, “There has been a tendency to ignore differ-
ences and in many cases, perhaps, make the assumption that what is true in mice
is necessarily true in humans. By making such assumptions we run the risk of
overlooking aspects of human immunology that do not occur, or cannot be mod-
eled, in mice” (Mestas and Hughes, 2004). Murine models are still used in an effort
to understand most autoimmune and inﬂammatory conditions, despite the obvious
differences between the murine and human immune systems.
For example, there are major differences in the Toll-like receptors. TLR1-9 exists
inbothmouseandman, although TLR8detectssingle-strandedRNA inmanandhas
no known function in the mouse. TLR10 exists in humans only; it is a degenerative
pseudo-gene in the mouse. TLR11, 12 and 13 in mice do not exist in man and their
function is not yet well deﬁned.
Analysis of the human and murine VDR offers other examples of discord
between man and mouse. Marshall’s molecular dynamics emulation showed that
the drug olmesartan, a putative VDR agonist, binds into a different conformation in
the murine VDR to that of Homo sapiens (Marshall, 2008), calling into question the
whole concept of drug safety testing in murine models.
While the human VDR transcribes dozens of genes necessary for a robust innate
immune response, including many key AMPs, the VDR does not similarly control
the murine innate immune system.
The murine innate immune response is dependent on a cascade of nitric oxide
functions in a manner yet to be fully understood (Bogdan, 2001). Although mice
have VDRs, the homology differs, and they express different genes than the human
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VDR. For example, the gene encoding the calcium-binding protein osteocalcin is
“robustly” transcribed by the VDR in humans, but not in mice.
Brahmachary et al. showed that the rat VDR does not express the cathelicidin
AMPs, marking an important difference in the way the two species target invad-
ing pathogens (Brahmachary et al., 2006). Gombart et al. recently expanded on the
ﬁnding by providing evidence of an evolutionarily ﬁxed, Alu-mediated divergence
in steroid hormone nuclear receptor gene regulation between humans/primates and
other mammals (Gombart et al., 2009). This divergence, which placed the cathe-
licidin pathway under VDR control only in humans and closely related primates,
remained under purifying selection for the past 55–60 million years, and yet even
cathelicidin in primates is not identical to that in man. Eventually, the pathway
evolved to become a key component of a novel innate immune response unique
to human infection. Because the murine VDR does not express cathelicidin, there
is less of an evolutionary incentive for components of the murine microbiota to
dysregulate its expression. This suggests that the survival mechanisms employed
by the human and murine microbiotas may be very different. Thus, the intermin-
gling of murine and human biologies in the literature hinders our ability to fully
understand nuclear receptor control of the AMPs and other key aspects of innate
immunity.
Discussion
The prevailing theory of autoimmune disease, which dictates that the body cre-
ates autoantibodies that attack its own cells, was developed during an era when
culture-based methods vastly underestimated the number of microbes capable of
persisting in and on Homo sapiens.T h ea d v e n to fc u l t u r e - i n d e p e n d e n tt o o l ss u c h
as 16S RNA sequencing, single cell sampling, and pyrosequencing has opened the
door to an era of discovery. Rather than a sterile compartment, the human body is
now known to teem with thousands of species of bacteria, viruses, and phages. In
addition to persisting on the body’s external surfaces, these microbes survive in the
blood and in many of the tissues, which become inﬂamed during autoimmune dis-
ease, suggesting that what were once thought to be “autoimmune” processes may
instead result from the presence of persistent microbes. Metagenomics is allowing
us to study these microbes in the tissues within which they naturally persist, where
they can be examined in the context of other microbes in their community. A more
exact understanding of how networks of microbes can interact to cause disease has
superseded Koch’s postulates, which stipulate that a single microbe causes a single
disease.
While diseases were once categorized largely on the basis of symptom pre-
sentation, they can now be classiﬁed based on their underlying genetics. Yet the
expression of key human genes is continually altered by a plethora of micro-
bial metabolites through an almost imponderable number of interactions. These
metabolites, some of which are created by bacteria considered to be “friendly” or
innocuous, can directly drive the pathogenesis of autoimmune disease by altering
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the expression of genes such as ACE and PTN22, genes associated with diag-
nosesincludingrheumatoidarthritis,lupus,diabetesmellitus,myocardial infarction,
renal tubular dysgenesis, and Alzheimer’s. It is becoming apparent that autoim-
mune processes cannot be fully understood if the human genome is studied in
isolation. An understanding of the interactions between the human genome and the
metagenome calls for a more nuanced understanding of the microbiota. Classifying
certain microbes as purely commensal may underrepresent the full spectrum of their
actions. Indeed, harmless species of bacteria and viruses can easily acquire virulent
plasmids via horizontal gene transfer or homologous recombination.
The microbiota has persisted in and on the human body for millennia. It has
evolved to slow the host immune response in order to ensure microbial survival.
Pathogens such as M. tuberculosis, Borrelia,E B V ,a n dH I Vh a v ee v o l v e dt od y s -
regulate the VDR nuclear receptor, inhibiting expression of the beta-defensin and
cathelicidin AMPs along with TLR2. Flow-on effects from VDR dysregulation
can further alter AMP expression via (at least) the alpha-thyroid, androgen, and
glucocorticoid nuclear receptors. This may result in the immunosuppression and
hormonal imbalances characteristic of many autoimmune diagnoses.
The bacteria that cause autoimmune disease likely accumulate over a lifetime,
with individuals picking up pathogens with greater ease over time, as the immune
response becomes increasingly constrained. Successive infection dictates that even
people with the same autoimmune diagnosis are unlikely to present with identical
clusters of symptoms and helps explain the high levels of comorbidity observed
among these patients. Common autoimmune comorbidities include inﬂammatory
conditions such as cardiovascular disease, along with mental diagnoses such as
depression or anxiety, suggesting these conditions may also be driven by the micro-
biota. Thus, insights gained from studying microbial composition in autoimmune
disease can accelerate research in other areas of medicine. Recently, several studies
have shown the presence of “autoantibodies” in autism with antinuclear antibody
seropositivity showing a signiﬁcant positive association with disease severity, men-
tal retardation, and electroencephalogram abnormalities. Rather than assign autism
to the end of a growing list of autoimmune diagnoses, this knowledge might be
better used as a basis on which to further explore the role that components of the
microbiota may play in driving the pathogenesis of disease.
Analyzing autoimmune disease through the lens of metagenomics calls for a re-
evaluation of the autoantibody. Polyspeciﬁc autoantibodies are increasingly being
associated with elements of the microbiota, making it likely that the term “autoim-
mune” will soon lose its diagnostic utility. When a disabled immune system is
forced to respond to the presence of a chronic microbiota, the resulting cascade of
cytokines and chemokines will stimulate an adaptive immune response. The adap-
tive immune system will then proceed to generate antibodies to fragments of DNA
generated by apoptosis or phagocytosis of infected cells. This is supported by stud-
ies showing that the so-called autoantibodies such as RO, La, dsDNA, and RF can
be created in response to various bacterial and viral pathogens. Autoantibodies are
often observed before a patient becomes fully symptomatic with an autoimmune
diagnosis, reﬂecting the gradual accumulation of persistent microbes.
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Rather than focusing on phenotypes and subsets of the metagenome, microbiome
research may instead beneﬁt from broader approaches geared toward understand-
ing shared mechanisms of persistence. Translational medicine should aim at cutting
through barriers among specialities, even between biologists and clinicians, so that
more of the pieces of the emerging jigsaw of disease etiology can drop into place,
and autoimmune disease patients can fully beneﬁt from the insights gained from
metagenomic science.
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Summary and link to next chapter 
 
While previous chapters emphasized that an inflammatory disease state results from the 
interaction  of  both  human  and  microbial  genes,  "Autoimmune  disease  and  the  human 
metagenome", further explored this topic. In Chapter 5, we built on our alternative model 
hypothesis, supported with novel data and described in detail how the process may account 
for the high levels of co-morbidity and familial aggregation observed among patients with 
autoimmune disease. Any one autoimmune disease is likely to be due to many different 
microbes within the metagenomic microbiota. We presented substantial data supporting the 
hypothesis that “autoantibodies”, often polyspecific, are created when the innate immune 
system responds to the microbiota and a cascade of cytokines and chemokines stimulate 
the adaptive immune response. Thus autoantibodies are produced in response to chronic 
infection with microbes.  
 
Weaknesses associated with a Mendelian model of inheritance in autoimmune disease were 
also  discussed.  We  showed  how  genetic  predisposition  for  autoimmune  disease  is  not 
necessarily Mendelian and questioned whether primers selected for most epidemiological 
studies  are  chosen  without  consideration  for  whether  they  might  amplify  DNA  from  the 
genomes  of  any  intracellular  microbes.  Finally,  Chapter  5  expanded  on  the  therapy 
discussed in the previous Chapter "Autoimmune disease in the era of the metagenome," a 
therapy  which  attempts  to  stimulate  rather  than  suppress  the  immune  response  in 
autoimmune disease.  
 
In  the  next  chapter,  “Immunostimulation  in  the  era  of  the  metagenome”,  we  introduce  a 
therapeutic  model  for  autoimmune  disease  which  has  formed  the  basis  of  our  past 
collaboration  with  American  and  international  physicians.  Unfortunately  increased 
microbicidal  activity  results  in  immunopathology,  a  temporary  rise  in  symptoms  due  to  
95 
apoptosis and toxin release by destroyed pathogens. Challenges associated with managing 
such treatment-induced immunopathology will be discussed. 
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Chapter 6: Immunostimulation in the era of the 
metagenome 
 
 
Proal  AD,  Albert  PJ,  Blaney  GP,  Lindseth  IA,  Benediktsson  C,  Marshall  TG. 
Immunostimulation in the era of the metagenome. Cellular & molecular immunology. 2011 
May;8(3):213-25. 
 
    
97 
Attribution 
 
AP developed the concept, reviewed the literature, wrote the manuscript, interpreted the 
findings, and helped design the figures. PA reviewed the literature, edited the manuscript 
and helped design the figures. TM supervised and critically revised the manuscript. GB and 
IL collected case data, and CB for edited the manuscript. All authors critically reviewed and 
approved the final version. 
AP: 55% 
   REVIEW
Immunostimulation in the era of the metagenome
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1
Microbes are increasingly being implicated in autoimmune disease. This calls for a re-evaluation of how these chronic inflammatory
illnesses are routinely treated. The standard of care for autoimmune disease remains the use of medications that slow the immune
response, while treatments aimed at eradicating microbes seek the exact opposite—stimulation of the innate immune response.
Immunostimulation is complicated by a cascade of sequelae, including exacerbated inflammation, which occurs in response to
microbial death. Over the past 8 years, we have collaborated with American and international clinical professionals to research a
model-basedtreatmentforinflammatorydisease.Thisintervention,designedtostimulatetheinnateimmuneresponse,hasrequireda
reevaluation ofdisease progression andamelioration. Paramountis the inherent conflictbetween palliation andmicrobicidal efficacy.
Increased microbicidal activity was experienced as immunopathology—a temporary worsening of symptoms. Further studies are
needed, but they will require careful planning to manage this immunopathology.
Cellular & Molecular Immunology advance online publication, 31 January 2011; doi:10.1038/cmi.2010.77
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INTRODUCTION
Ten years ago, the first draft of the human genome was published,
opening a window into the detailed operation of the healthy human
body, which, even today, is only just beginning to reveal its secrets.
However, it is the subsequent understanding of microbial genomes,
the emerging field of metagenomics, which is allowing us to start
deciphering many of the secrets of human disease.
1
While the extent of the relationship between microbes and disease
has yet to be fully characterized, provocative data are accumulating
which suggests a complete re-examination of the factors driving
chronic inflammatory disease. We can now begin reappraisal of key
assumptions that have guided the assessment, management and treat-
ment of autoimmune conditions.
THE HUMAN BODY IS AN ECOSYSTEM OF MICROBES
A decade ago, Chiller et al. concluded ‘The skin is a poor media for
bacteria given the large number of inherent defense mechanisms’.
2
This assessment was undermined seven years later by Fierer et al.’s
work, which found that the average human palm harbors at least 150
bacterial species—an order of magnitude greater than previous esti-
mates.
3 A 2009 Science study expanded on this understanding of
microbial diversity in skin, showing that forearms and underarms,
though located just a short distance apart, are as ‘ecologically dissim-
ilar as rainforests are to deserts’.
4
Until quite recently, efforts to characterize the human microbiota,
such as those of Chiller, had to rely upon in vitro cultivation of micro-
bial species. Today we understand that these conditions scarcely
mimic those of the human body. In order to obtain his results,
Fierer used 454 pyrosequencing, one of several novel molecular tools
thattodayallowresearcherstoidentifymicroorganismsbasedontheir
DNA signatures with a very high degree of accuracy. These tools,
which also include 16S rRNA sequencing, shotgun sequencing and
single-cell sampling, are revolutionizing microbiology, providing
researchers with unprecedented capability to perform hypothesis-dri-
ven analyses of uncultured microorganisms. They have even allowed
researcherstounderstandtheinteractionsamongindividualmicrobes
in communities within living tissues.
It is now understood that microbial cells vastly outnumber our own
human cells, by a factor of at least 10:1. The genes of these microbes
number in the millions, dwarfing the paltry 23 000 genes comprising
the human genome.
5 Many microbiologists have begun to replace the
concept of ‘human being’ with a ‘human superorganism’ in an effort to
reflect the emerging reality that the human genome is one of the myriad
genomes dictating the human experience in both health and disease.
6
Viruses (comprising the virome) and phages are also key compo-
nents of the human microbiome. Like bacteria, many viruses have yet
to be fully characterized by high-throughput genome sequencing.
However, molecular analysis has revealed that nearly all humans
acquire multiple persistent viruses within the first years of life, viruses
that generally remain with them throughout life. A team led by
Gordon recently analyzed the fecal virome of monozygotic twins
and their mothers. This study found that 81% of the reads generated
from this virome do not match any known viruses.
7
In concert with a number of privately funded groups, two major
multisite collaborations, the US-based NIH Human Microbiome
Project and MetaHIT, an EU consortium, have begun the process of
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5,8 Thus far, the Human Microbiome
Project has committed itself to collecting sequence data from several
keybodysites:thegastrointestinaltract,oralcavity,urogenital/vaginal
tract, skin, respiratory tract and, to a lesser extent, the blood.
5
One of the primary goals of these studies has been to compare
populations of microbes in healthy individuals with equivalent popu-
lations of microbes in their diseased counterparts. Such studies have
quickly shown that patients with a given autoimmune or inflammat-
ory diagnosis tend to present with microbial profiles that differ sub-
stantially from those of healthy subjects.
A 2008 study of psoriatic skin not only found 84 novel species never
before known to persist in skin, but also doubled the proportion of
microbes from the Firmicutes phylum in psoriatic patients, as com-
pared to healthy controls.
9 Distinct microbial profiles have been fur-
ther demonstrated in obesity
10 as well as inflammatory bowel
conditions. For example, the presence of methanogenic bacteria has
now been shown to be an independent predictor of higher body mass
index in obese adults.
11 Communities of bacteria in the gut of patients
with diabetes mellitus type 2 were recently reported to differ substan-
tially from those of their healthy counterparts. Using real-time quant-
itative PCR researchers determined that the proportions of phylum
Firmicutes and class Clostridia were significantly reduced in the dia-
betic group compared to the control group, among other differ-
ences.
12 Further, the ratio of Bacteroidetes to Firmicutes as well as
the proportion of Bacteroides–Prevotella group to Clostridium coc-
coides-Eubacterium rectale group correlated positively and signifi-
cantly with plasma glucose concentration but not with body mass
index. Gophna et al. showed that Crohn’s patients had a significantly
higher proportion of Proteobacteria and Bacteroidetes in their gut as
compared to healthy subjects.
13 Yap et al. showed that autistic chil-
dren had several urinary metabolites that were highly significant as
compared to controls.
14 In a murine model, Lee and her California
Institute of Technology colleagues recently found that specific intest-
inal bacteria have a significant role in affecting the nervous system
during multiple sclerosis.
15
However, the human microbiome is not confined to mucosal sur-
faces. An increasing number of scientific teams are using molecular
techniques to re-evaluate the sterility of internal body cavities—with
eye-opening results. The amniotic fluid, previously considered com-
pletely sterile, was shown to harbor uncultivated, previously unchar-
acterized taxa of bacteria, the presence of which was robustly
correlatedwithprematurebirth.
16Molecularcharacterizationofpros-
thetic hip joints removed from body tissues was found to harbor a
plethora of diverse bacteria, including species such as hydrothermal
vent eubacteria never previously thought capable of persisting in
man.
17 We now know there is a microbiome in the lungs, the com-
position of which differs in health and disease.
18
COMMUNITIES OF MICROBES DRIVE AUTOIMMUNE DISEASE
Discrete pathogens such as human herpesvirus-6 (HHV-6), cyto-
megalovirus, Epstein–Barr virus (EBV) and Chlamydia pneumoniae,
have been repeatedly identified in association with autoimmune dis-
ease. However, none of these microbes has been detected in 100% of
patients with any single autoimmune disease state. The evidence for
causality has been lacking. We now understand how these conditions
can be polymicrobial in nature.
1 Pathogens are capable of working in
concerttocausediseaseandentireecosystemsofmicrobescanbecome
dysregulated by the pathogenic genomes. These discoveries have
caused a total reevaluation of Koch’s postulates, which, over a century
ago, theorized that one microbe would cause one disease.
1
These andotherfindings additionally challengethetraditional view
that a largely sterile human body can create antibodies against self.
Insteadit isbecoming increasingly likely that,in autoimmune disease,
the body is not targeting its own tissues, but is generating antibodies
against fragments of these metagenomic communities of microbes.
1
One of the most effective survival mechanisms involves pathogens
that enter host cells, especially the phagocytic cells.
19 Earlier work has
demonstratedthat intracellular pathogens are indeedpresent in patients
with a variety of autoimmune conditions.
20–22 Intracellular microbes
living within nucleated cells can interfere with DNA transcription and
repair mechanisms, which allows them to create much of the systemic
dysfunction often associated with autoimmune diagnoses.
An increasing number of studies are providing support for the view
that ‘autoantibodies’ can be generated in response to the persistent
presence of a pathogenic microbiota. While high titers of rheumatoid
factor (RF) are associated with severe rheumatoid arthritis, they also
appear in a number of other diseases including viral, bacterial and
parasitic infections.
23 Maturation of RF can be initiated by chronic
infections.
24 For example, patients with subacute bacterial endocard-
itis,whichisfrequentlytiedtothe presence ofStreptococcus,alsooften
present with high levels of RF.
25 A 2007 study examined blood sera
from 88 patients with acute infections (41 bacterial, 23 viral, 17 para-
sitic and 7 rikettsial).
26 Elevated titers of autoantibodies including
annexin V, prothrombin, anti-Saccharomyces cerevisiae antibody,
antinuclear antibody (ANA) or antiphospholipid antibodies were
detected in about 50% of the subjects, with 34 individuals harboring
elevated titers of at least two autoantibodies.
Many proteins from pathogens share significant sequence or struc-
tural similarities with human proteins, and these can also contribute to
autoantibody production. Lekakh et al. found that autoantibodies with
polyspecific activity in the serum of healthy donors were able to cross-
react with DNA and lipopolysaccharides of widespread species of bac-
teria including Escherichia coli, Pseudomonas aeruginosa, Shigella boydii
and Salmonella.
27 Furthermore, since human antibodies are polyspeci-
fic, it is likely that some antibodies created to target pathogens may
mistakenly target human proteins, causing ‘collateral damage’.
1
IMMUNOSTIMULATION
While the standard of care for chronic inflammatory disease remains
the use of medications that slow the immune response, our bodies
themselves seek to do the exact opposite; they strive to stimulate the
immune system (immunostimulation) when they sense intracellular
pathogens. Current exogenous intervention is focused on immuno-
suppression. It therefore seems prudent to re-evaluate the manner in
which inflammatory conditions, including autoimmune conditions,
are routinely treated.
A fully activated immune response should be capable of clearing
common pathogens from the body, yet, in autoimmune disease, this
does not appear to be the case. The answer may lie in the way that
pathogens have evolved to slow the defenses of the innate immune
system—the very branch of the immune response that would other-
wise work to kill them. Indeed, some of these persistent pathogens
have long been implicated in autoimmune disease.
One of the key mechanisms by which microbes achieve this
immunosuppression is by subverting one of the body’s most prolific
nuclear receptors, the vitamin D receptor (VDR). Defects in VDR
signaling transduction have previously been linked to bacterial infec-
tion and chronic inflammation.
28
This is not surprising as the VDR is responsible for expression
of several families of key endogenous antimicrobials, including
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the innate immune system to target intracellular pathogens. Auvynet
and Rosenstein have argued that antimicrobial peptides ‘seem to par-
ticipate in every facet of it [modulating immunity] by boosting the
immune response to prevent infection, and also by suppressing other
proinflammatory responses to avoid uncontrolled inflammation’.
29
Indeed, the activated VDR, which also increases CD14 and TLR2
synthesis, has been described as a critical regulator of the innate
immune response.
30 Perversion of VDR function would clearly ease
pressure on intracellular microbial communities, thus making it an
obvious evolutionary selection.
It should be noted that the antimicrobial peptides also play a role in
mitigating the virulence of the virome and other non-bacterial infectious
agents. In addition to its antibacterial activity, alpha-defensin human
neutrophil peptide-1 inhibits HIV and influenza virus entry into target
cells.
31 It diminishes HIV replication and cani n a c t i v a t ec y t o m e g a l o v i r u s ,
herpes simplex virus, vesicular stomatitis virus and adenovirus.
29 In addi-
tion to killing both gram positive and gram-negative bacteria, human
beta-defensins HBD-1, HDB-2, and HBD-3 have also been shown to kill
the opportunistic yeast species Candida albicans.
32 Cathelicidin also pos-
sesses antiviral and antifungal activity.
33,34
In 2005, Wang et al. demonstrated that the VDR expresses at least
913 genes, many connected to autoimmune conditions and cancers.
35
Last year a UK-based team used chromatin immunoprecipitation fol-
lowed by massively parallel DNA sequencing (ChIP-seq) to identify
2776 binding sites for the VDR along the length of the human gen-
ome.
36 Significantly, the binding sites were unusually concentrated
near a number of genes associated with susceptibility to autoimmune
conditions. Such genes include IRF8 (multiple sclerosis) and PTPN2
(Crohn’s disease and type 1 diabetes).
In 2007, Marshall used in silico emulation to show that the sulfo-
nolipid capnine, which is created by biofilm bacterial species in the
genera Cytophaga, Capnocytophaga, Sporocytophaga and Flexibacter,
37
could bind to and slow the activity of the VDR.
38 This work suggested
that microbes may beable to directly alter VDRligand binding pocket
occupancy, and subsequently VDR expression, in order to gain a sur-
vival advantage.
Xu et al. used an early cDNA microarray to study cellular gene
expression altered by Mycobacterium tuberculosis infection. VDR
expression was downregulated.
39 This was not unexpected as the
VDR expresses TACO, a protein critical to intraphagocytic survival
of M. tuberculosis.
40 Borrelia burgdorferi, another obligate pathogen,
also reduces expression of VDR.
41 HIV uses the VDR to recognize its
own long terminal repeat promoter region in order to transcribe its
own genome.
42
In addition, EBV, which has been associated with many auto-
immune diseases, very effectively downregulates expression of VDR
in immature lymphablastoid cell lines.
43 This is an especially elegant
persistence mechanism.
Key metabolic changes within the nucleated cells
When microbial ligands dysregulate the VDR, the receptor fails not
onlytotranscribekeyantimicrobialsbutalsoCYP24A1,awell-studied
enzyme whichbreaks downexcess 1,25-dihydroxyvitamin D (1,25-D)
into 25-hydroxyvitamin D. Thus, when activity of the receptor is
thwarted, 1,25-D levels rise.
Indeed, Bell has pointed out that a number of infectious diseases—
tuberculosis, AIDS with Pneumocystis carinii pneumonia, and AIDS
with cytomegalovirus infection, disseminated candidiasis—have high
levels of 1,25-D leaking into the bloodstream.
44
A cross-sectional analysis of 100 patients with autoimmune disease
showed that a similar dynamic seems to occur in autoimmune dis-
ease.
45 Confirmation of this observation has been demonstrated in
Crohn’sdisease
46andrheumatoidarthritis,
44withKavathiaetal.tying
higher levels of 1,25-D to greater disease severity in sarcoidosis
patients,
47andMaweretal.findingthat1,25-Dlevelswereparticularly
elevated in the synovial fluid surrounding the joints of subjects with
rheumatoid arthritis.
48
We have previously predicted, based on molecular in silico emu-
lation,thatathigherconcentrations,1,25-Dinterfereswithexpression
of several of the body’s other key nuclear receptors, including the
glucocorticoid receptor, the androgen receptor andthe thyroid recep-
tor.
49 These receptors also express various families of AmPs—20, 17
and15families,respectively,outofthe22analyzedbyBrahmachary.
50
Astheconcentrationof1,25-Daccumulateswithinthenucleatedcells,
our model predicts that it would increasingly occupy the ligand-bind-
ing pockets of these receptors, displacing their endogenous ligands.
Forexample,inthecaseofalpha-thyroid,theagonistT3wouldhaveto
compete with the antagonist 1,25-D for access to the receptor ligand-
bindingpockets. Asthe levels of1,25-D continue torise,expression of
the AmPs by alpha-thyroid would be downregulated. Glucocorticoid
receptor and androgen receptors would be similarly affected, leading
to a profound suppression of the innate immune system’s ability to
respond to the intracellular attack.
Thus, dysregulation of the VDR by pathogenic components of the
microbiota couldcauseflow-oneffectsthateffectivelydisablethebulk
of the body’s AmPs, leaving the host increasingly immunocompro-
mised. The same phenomenon could explain, at least in part, why
many autoimmune diseases are characterized by dysregulated hor-
monal expression—a symptom that often becomes exacerbated as
the disease progresses.
The complete set of mechanisms by which persistent intracellular
microbes slow innate immune activity has yet to be definitively deter-
mined. However, it likely occurs on a much broader scale than prev-
iously supposed, as most of the human microbiome is still
understudied. Each pathogen that decreases VDR expression makes
it easier for other pathogens themselves to slow immune activity even
further, creating a snowball effect.
Successive infection
We refer to this dynamic state, in which the host microbiome shifts
further and further away from a natural homeostatic state, as success-
ive infection. Human genes are up- or downregulated by acquired
components of the microbiota, and infected cells progressively
struggle to correctly produce human metabolites in the presence of
the numerous proteins, enzymes and metabolites generated by the
pathogenic genomes. Indeed, Kanchwala et al. showed that patients
with sarcoidosis expressed the antimicrobial peptide cathelicidin less
than healthy subjects, and that the sickest sarcoidosis patients
expressed it least of all.
51 In patients with Crohn’s disease, Wang
et al. also demonstrated a decline in levels of cathelicidin,
52 while
Wiken et al. showed reducedTLR2 mRNA expression in patients with
Lofgren’s syndrome.
53
After acertainlevelofdysbiosishas occurred,peoplemaywellreach
the point where they can be diagnosed with an autoimmune/inflam-
matory condition. Many, however, incrementally present with aches
and pains often attributed to ‘normal aging’. For example, mice lack-
ing the cathelicidin gene, which is robustly transcribed by the VDR,
have longer periods of wound healing than their wild-type counter-
parts.
29 The absence of this key AmP in a murine model might be
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54 The
term ‘inflammaging’ has been coined to explain ‘the now widely
accepted phenomenon that aging is accompanied by a low-grade
chronic, systemic upregulation of the inflammatory response, and
that the underlying inflammatory changes are common to most
age-associated diseases’.
55
Further support for successive infection comes from the recent
metagenomicstudiesthatshowthattheredoesnotappeartobeacore
microbiome across people.
56 Even among relatively homogeneous
populations of fewer than 100 individuals, only a ‘tiny fraction’ of
the microbial species inhabiting the gut are shared by other commun-
ity members.
56,57 Similar variability has also been identified in the
skin.
3Theseunanticipateddiscrepanciesinmicrobialinhabitantspar-
allel the variability in presentation of chronic inflammatory disease.
Over 100 years ago, Theobald Smith commented ‘[i]t is what bac-
teria do rather than what they are that commands attention, since our
interest centers in the host rather than in the parasite’.
58 That many of
the pathogens driving the autoimmune disease state may survive by
gradually slowing the immune response adds additional weight to the
contentionthatimmunostimulation ratherthanimmunosuppression
is more likely to facilitate reversal of these chronic conditions.
IMMUNOPATHOLOGY
Unfortunately, immunostimulation in infectious disease is compli-
cated by a cascade of reactions, including inflammation, which
occur as part of the immune response to microbial death.
59 As
others have done, we use the term ‘immunopathology’ to refer to
a systemic inflammatory response consistent with elevated immune
activation.
60,61
Itiswellunderstoodthatthesymptomsoftheflu,oranyotheracute
microbial illness, stem from an inevitable battle between man and
microbe, a clash that ensues as the immune system releases a host of
cytokines and chemokines in an attempt to eradicate offending infec-
tiousagents.
62Additionally,thedeadmicrobialdebrismustbecleaned
up, placing an additional load on the immune system.
63
Thus, pathogens driving an infectious disease state cannot be killed
without, at the very least, a temporary increase in patients’ symptoms,
inflammatory markers or both. While patients may be administered
with some palliative medications, they must endure the burden of
inflammation if the host immune system is to prevail.
Thisisconsistentwiththeautoimmunediseaseprocessbeingdriven
largely by the presence of chronic pathogens. Autoimmune diseases
are characterized by a relatively continuous inflammatory process.
This suggests that the uninterrupted effort by the immune system to
secrete cytokines and chemokines is an attempt to keep pathogenic
loadundercontrol.
64Microbialdeathleadstothereleaseoftoxinsand
debris into the bloodstream. The death of intracellular pathogens is
particularlydifficultforthehosttomanage,asthebodymustdealwith
both the by-products of entire human cells undergoing phagocytosis
and apoptosis, as well as the microbes that once inhabited them. In
addition, innate immune activity is signaled to the adaptive immune
system, initiating the generation of antibodies from the scraps of both
cellular and pathogenic debris.
In chronic inflammatory disease, the conflict between man and
microbe rarely ends. Perhaps, because chronic microbes appear so
effectiveatprogressivelyandcumulativelyslowingtheinnateimmune
response,thebodyultimatelyseemsunabletoreversethediseasestate.
What results is a stalemate, where the immune system strives to target
the persistent microbes but never fully succeeds, and the initial low-
grade inflammation becomes continuous. As far back as 1929, Boas
and Michelson commented ‘[w]hen the battle waged between the
invadingorganismandthebody’sresistiveforcesbecomesastalemate,
chronicity results’.
65
Therefore, once a patient with autoimmune disease has accumu-
latedahighenoughmicrobialload,periodsofreliefmayparadoxically
correspond to times when the immune system is most compromised,
unable to mount an effective immune response against pathogens.
Autoimmune diseases are often characterized by patterns of relapse
punctuated by periods of remission. Indeed, remission may actually
signal a kind of exhaustion on the part of the immune system. On the
other hand, relapse, which is often accompanied by a new infection or
stress, may represent the immune system’s best effort at a response.
This suggests that, if efforts are made to restore the immune res-
ponse in these immunocompromised patients, any subsequent
renewed attack against pathogens will lead to symptom exacerbation.
The literature offers a number of examples of therapies that delib-
erately stimulate the immune response in an effort to target chronic
pathogens, and, in the process, generate an increase in symptoms as
part of a microbial die-off response. This reaction was first described
by Jarisch and Herxheimer during therapy of secondary syphilis using
mercury,andbecameknownastheJarisch–Herxheimerreaction.
66In
the 100 years since Jarisch and Herxheimer, researchers have noted
this reaction in a broad spectrum of infectious diseases such as relaps-
ing fever, Lyme disease, leptospirosis, brucellosis, tuberculosis,
Vincent’sanginaandAfricantrypanosomiasis.
1,60,66Symptomexacer-
bationvariesdependingonthenatureofthepathogenstargeted,butis
generally accompanied by a complex clinical reaction including
reports of abrupt onset of fever, chills, myalgias, headache, tachycar-
dia, hyperventilation and hypotension.
Immune reconstitution inflammatory syndrome (IRIS)
Morerecently,atypeofimmunopathologyhasbeenobservedinHIV/
AIDS patients. During IRIS, HIV/AIDS patients experience the wor-
sening or onset of systemic inflammatory clinical signs and symptoms
following treatment with highly active antiretroviral therapy
(HAART). This syndrome results when HAART allows for partial
recovery of the immune response. This causes renewed and exuberant
host immunological responses towards opportunistic infectious
agents, agents that the host accumulated during prior periods of
immunosuppression.
67
A number of well-known readily cultured pathogens have been
conclusively linked to IRIS: the herpes viruses, cytomegalovirus, hep-
atitis B and C, M. tuberculosis, Mycobacterium avium complex and
Cryptococcusneoformans.
68However,manymoremicrobeslikelycon-
tribute to the reaction since AIDS clinicians do not yet have access to
the metagenomic tools. Certainly, the existence of IRIS in culture-
negativeHAARTpatientssuggeststhatmoremicrobesmaybepresent
than the few that have already been isolated.
69
Interestingly, patientsexperiencing IRISoften ‘develop’ autoimmune
conditions as a manifestation of immune restoration. These include
sarcoidosis and other granulomatous reactions,
70,71 diabetes mellitus,
rheumatoid arthritis,
72 systemic lupus erythematosus,
73 Guillain–Barre
syndrome,
74 Graves disease
75 and autoimmune thyroid disease.
68,76
This suggests that these patients accumulated microbes that are directly
involved in the pathogenesis of these disease states.
Our therapeutic approach
Over the past 8 years we have developed a therapy for autoimmune
disease that appears to strongly activate the innate immune response.
Treatment is based on the use of a putative VDR agonist, olmesartan
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101medoxomil, which, by re-activating the receptor, appears to gradually
restore expression of the numerous AmPs, Toll-like receptors (TLRs)
and other antimicrobials expressed by the VDR.
Olmesartan medoxomil was developed as a mild hypotensive, an
angiotensin II type 1 receptor antagonist. Typically it is dosed 20–
40 mg once a day. However, this drug has a unique affinity for the
VDR nuclear receptor, for which it is most probably a partial ago-
nist.
38,77 In order to be effective in this targeting, the dosing has to be
more frequent as the VDR’s half-life is only 4–6 h before it is broken
apart by caspase-3, and protease activity.
78 Thus, when dosed at 4- to
8-h intervals, VDR stimulation persists between doses.
Olmesartan has at least two identified effects on the immune sys-
tem. Byinhibiting angiotensin II binding toits receptor, which occurs
undermostdosingregimes,theexpressionofnuclearfactor-kappaBis
reduced.
79 This lowers the cell’s production of inflammatory cyto-
kines. We have found that as the dosing interval shortens, immune
activation becomes noticeable above about 20 mg every 8 h, achieving
saturation at about 40 mg every 6 h. Patients have reported a further
palliative effect at even higher doses, but the exact mechanism for this
has not yet been validated.
Itshouldbenotedthatolmesartanisconsideredaverysafedrug,
80–83
for which the US FDA has not dictated any unsafe dosing level.
However, there are definite sequelae that some might consider to be
‘adverseevents’—autoimmunepatientsinitiatingthistherapyappearto
experience immunopathology, sometimes severe immunopathology.
Theygenerallyreportconsistentincreasesinoverallmalaise,particularly
thoserelatedto the specificsymptoms of their disease.At thesametime,
markers of inflammation rise. It should be noted that healthy people
administered with the same medications experience no such reaction.
80
After months, or sometimes years of dealing with these symp-
tomatic flares, the very symptoms that wax and wane in accordance
with administration of olmesartan begin to disappear, resulting in
reports of symptomatic improvement and, in some cases, eventual
resolution of the symptoms. Inflammatory markers generally return
to their normal range.
For example, LZ is a 58-year-old female diagnosed with rheum-
atoid arthritis in 1996. In the 5 years that followed, she was admi-
nistered with high-dose antibiotics along with frequent cortisone
injections. Despite treatment, her disease progressed and she had
joint damage in hands and feet. In 2001, LZ began 2000–5000 IU of
vitamin D daily, dehydroepiandrosterone, armor thyroid, hydro-
cortisone and bioidentical hormone supplementation. In August
2004, LZ’s measured levels of ANA were 1:160. Following the test,
patient stopped vitamin D and was administered with 40 mg of
olmesartan four times daily. Over the course of several years, she
was prescribed rotating combinations of certain subinhibitory anti-
biotics including minocycline, azithromycin and clindamycin. This
caused transient increases in symptoms of depression, gastro-
intestinal distress and joint pain. In March 2005, ANA antibodies
were measured at 1:320 while in August of the same year, this
measure declined to 1:160. By August 2006, LZ was able to dis-
continue both Celebrex and all hormone therapy. One year later,
LZ reported being able to hike with reduced joint pain. In
November 2006 and in eight subsequent tests, the patient tested
negative for ANA antibodies (Figure 1). In December 2007, LZ
discontinued all antibiotics but continues to take olmesartan.
Consistent with an activated immune response to microbes, LZ
clearly experienced increased discomfort, particularly during the earl-
ier stages of treatment. Because the medications with which she was
administered have benign safety profiles, it would be difficult to
attribute her symptom fluctuations to treatment side effects, particu-
larly when these ‘adverse events’ diminish over time.
ThesamewastrueforJH.This50-year-oldmalewasdiagnosedwith
ankylosing spondylitis in 1984. JH was subsequently diagnosed with
chronic prostatitis, and irritable bowel syndrome and complained of
depression and fatigue. In February 2005, JH commenced 40 mg of
olmesartan four times daily and subinhibitory doses of combinations
of minocycline, clindamycin and azithromycin. His erythrocyte sedi-
mentation rate (ESR) was 25 mm/h, his C-reactive protein (CRP) was
17.1 mg/l and his bath ankylosing spondylitis disease activity index
(BASDAI) was 8.8 (Figure 2). After 26 months (April 2007), the two
markers and index rose. ESR went up to 25 mm/h, CRP climbed to
21.6 mg/l and his BASDAI was 9.2. Three years later in April 2010, a
total of more than 5 years since starting the therapy, ESR declined to
4 mm/h, CRP fell to 6.7 mg/l and BASDAI descended to 5.3. In addi-
tion to improvement in markers of ankylosing spondylitis, JH
reported a decline in ankylosing spondylitis symptoms, as well as less
depression and improved irritable bowel syndrome.
It may seem unrealistic that a VDR agonist could cause what
appears to be immunopathology, let alone eventual improvement in
patients with so widely differing disease states. Yet, we have been
collecting many reports of improvement of patients with a wide range
of autoimmune and inflammatory conditions.
The antimicrobial peptides activated by the therapy are able to
target vastly different pathogens under very different circumstances.
Some even have activity against certain species of antibiotic-resistant
bacteria.
84 Zasloff concludes ‘Acquisition of resistance by a sensitive
microbial strain against antimicrobial peptides is surprisingly
improbable’.
85
Becauseitcanbedifferentiallyspliced,thecathelicidinproteinitself
can respond to a range of very different microbial challenges. In
humans,thecathelicidinantimicrobialpeptidegeneencodesaninact-
ive precursor protein (hCAP18) that is processed to release a 37-
amino-acidpeptide(LL-37)fromtheC-terminus.LL-37issusceptible
to proteolitic processing by a variety of enzymes, generating many
different cathelicidin-derived peptides, each of which has specific tar-
gets. For example, LL-37 is generated in response to Staphylococcus
aureus, yet LL-37 represents ,20% of the cathelicidin-derived pep-
tides,withthesmallerpeptidesbeingmuchmoreabundantandableto
target even more diverse microbial forms.
29
Beta-defensin expression is modulated in response to bacteria-
derived molecules and/or cytokines and chemokines produced by
the immune system and damaged cells. For example, in immune cells,
Figure 1 ANAs in a 58-year-old female with rheumatoid arthritis. ANA, anti-
nuclear antibody.
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102its production is upregulated following exposure to bacteria,
lipopolysaccharides, interferon-gamma and interleukin-beta among
others.
29 So again, the beta-defensin response will differ depending
on the presence and abundance of these and other factors that are,
in turn, determined by the unique nature of every individual’s
microbiota.
Olmesartan appears to potentiate pulsed subinhibitory antibiotics
Antibiotics may be generally ineffective at generating immunopathol-
ogy if a patient is immunocompromised. Under these conditions, the
immune system may not be able to potentiate the actions of the anti-
biotics in a manner that would allow them to generate significant
microbial die-off. The following case history illustrates how, when
certain subinhibitory antibiotics are taken in conjunction with the
immunostimulant olmesartan, patients generally become much more
sensitive to these antibiotics.
BG is a 56-year-old male who was first diagnosed with rheum-
atoid arthritis in June 2002. He also complained of fatigue and
depression. In February 2004, BG was administered with 200 mg
of minocycline every other day, 200 mg of Celebrex daily and Advil
as needed. BG reported improvement in all major symptoms within
weeks. In April 2005, Celebrex was lowered to 100 mg every day. At
this point, BG reported being ‘unaware’ of rheumatoid arthritis
symptoms. On a scale of 1–10, with 10 being the most severe, he
rated his overall well-being as a 1. In September 2005, he was
administered with 40 mg of olmesartan four times daily. His symp-
tom levels remained constant. After 2 weeks, 25 mg of minocycline
every other day was introduced. Within 48 h, BG reported exquisite
photosensitivity, complaining that daylight ‘hurt his eyes’ and
‘made him feel ill’. Over the course of several weeks, his symptoms
increased greatly to the point where he rated his overall well-being
as an 8.5. After 5 weeks, BG discontinued olmesartan and resumed
200 mg of minocycline every other day. He reported immediate
relief. In September 2005, BG resumed olmesartan four times daily
and 25 mg of minocycline on alternate days. He experienced a spike
in symptoms once more. Over a few months, immunopathology
gradually decreased on this dose. At present, BG has been on the
treatment for over 4 years. In September 2010, BG reported overall
well-being at a 2.
Neurological comorbidities
Since our therapy was originally developed, an increasing number of
mental diseases have been tied to microbes. In a seminal 2010 study, a
team of Harvard researchers showed that amyloid beta can act as an
antimicrobial peptide, having antimicrobial activity against eight
common microorganisms including Streptococcus, S. aureus and
Listeria.
86 This led study author Rudolph E. Tanzi to conclude that
amyloid-beta is ‘the brain’s protector’. A large subset of autism spec-
trum disorder patients show evidence of bacterial and/or viral infec-
tions
87 with Nicholson’s group showing unique urinary metabolites
associated with the disorder.
14 Thus, it is not implausible that an
immunostimulatory treatment could cause mental in addition to
physical immunopathology.
For example, AW is a 59-year-old male who was diagnosed
with severe depression in 2000. In 2004, he went on total disability
due to severe depression. AW also suffered from several comor-
biditiesincludingchronicfatiguesyndrome(CFS).CFS/myalgicence-
phalomyelitis is now believed by many to be an autoimmune illness.
88
Between 2000 and 2007, AW was administered with the psychotropic
medicationsCelexaandRitalinwithlimitedclinicalimprovement.He
was weaned from Celexa and Ritalin in January 2007. The patient
began 40 mg of olmesartan four times daily in October 2007. In the
following month, AW noted increased symptoms associated with his
CFS. In the following years, symptoms of depression and fatigue were
further exacerbated upon administration of clindamycin and azithro-
mycin.AWtemporarilydiscontinuedtreatmentstartinginNovember
2009 through June 2010. In June 2010, he started olmesartan again,
40 mg four times daily. AW’s CFS symptoms persisted but symptoms
of depression improved. The patient’s supervising psychologist
reported in June 2010 that AW’s ‘functioning and emotional adjust-
ment has improved considerably’ which the psychologist ‘attributed
to treatment of underlying medical issues’. In September 2010, AW
remains on the treatment and disability due to his CFS but no longer
complains of depression.
When our treatment was first administered in 2001, we were sur-
prised to receive reports of significant neurological immunopathol-
ogy. However, we have now grown accustomed to receiving frequent
reports in which not just depression, but obsessive compulsive dis-
order, anxiety, dyslexia, cognitive dysfunction and mania all fluctuate
Figure2 BASDAI,ESRandCRPina50-year-oldmalewithankylosingspondylitis.BASDAI,bathankylosingspondylitisdiseaseactivityindex;CRP,C-reactiveprotein;
ESR, erythrocyte sedimentation rate.
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olmesartan and, in some cases, pulsed subinhibitory antibiotics.
Subclinical infection
Clinicians have long reported a phenomenon known as ‘minocycline-
induced lupus’ in which certain patients administered with minocy-
cline appear to develop the autoimmune condition.
89 In fact, there is
no plausible mechanism that explains how minocycline can cause
lupus—oranyotherdisease.
90Amorelogicalexplanation maybethat
certain patients harbor persistent bacterial species that predispose for
subclinical lupus. When minocycline is administered, some of these
bacteria arekilled, resulting in immunopathological reactions that are
mistakenly interpreted as clinical manifestation of the disease. As
Krawitt has argued, the same is likely true for ‘minocycline-induced
hepatitis’.
91 Many of the patients on our immunostimulative therapy
have also reported the temporary development of new symptoms,
suggesting that the unmasked subclinical infections may be more
common than currently supposed.
JM is a 54-year-old female diagnosed with endometriosis (diag-
nosed in 1986), chronic fatigue syndrome (2000) and a number of
comorbidities. In January 2006, JM was administered with 40 mg of
olmesartan four times daily. In April, she was also administered
with 25 mg of minocycline every other day. JM reported increases
in symptoms including but not limited to the following: body pain,
fatigue, lightheadedness, insomnia, photosensitivity, anxiety and
depression. In August 2009, she developed acute shingles with dis-
tribution of the left greater occipital nerve branch. Shingles were
managed with oral and topical Valtrex. By November 2009, JM’s
symptoms were stable and tolerable, although she reported an
increase in fatigue after beginning 125 mg of Bactrim DS every
other day. In March 2010, JM discontinued taking all antibiotics
but remained on 40 mg of olmesartan four times daily. By April
2010, JM reported global improvement.
Most of thesymptoms that JMfound exacerbated upon olmesartan
and subinhibitory antibiotic administration were symptoms that she
had previously experienced before starting therapy. However, JM had
never reported any history of shingles infections. It is likely that her
activated immune response unmasked a previously subclinical infec-
tion. This same phenomenon, including treatment-induced appear-
ance of shingles, has also been reported in IRIS.
92
Potential severity of immunopathology
We have found very strong immunopathology to be quite common,
particularly among patients who have been ill for decades and/or have
taken immunosuppressants for extended periods of time. Physicians
must be aware that helping severely ill patients manage immuno-
pathology may present a significant clinical challenge.
PF is a 65-year-old female diagnosed with metabolic syndrome
(diagnosed in 1995), osteopenia (2004), fibromyalgia (2002) and
undiagnosed gastrointestinal symptoms. By 2004, she was taking
1200 IU of vitamin D a day for several years, which she discontinued
in March 2005. PF was administered with olmesartan four times daily
starting in March 2005. In June 2005, she was also administered with
50 mg of clindamycin every other day. In November 2008, PF experi-
enced acute and severe diarrhea and dehydration, which required
hospitalization for several weeks. Tests were negative for acute infec-
tions including Clostridium difficile. Due to these severe bowel symp-
toms, olmesartan was discontinued. PF was finally stabilized on
ramipril and losartan after 2 weeks. After taking 20 mg of olmesartan,
she experienced nausea, vomiting and diarrhea within 2 h.
This patient was not able to stay on our immunostimulatory treat-
ment despite the fact that she was able to tolerate the immunopathol-
ogy associated with her diabetes and CFS. Instead, her physician was
forced to terminate therapy because of her severe bowel immuno-
pathology. PF is an example of a patient who was simply too ill to
tolerate immunopathology that at a lower level might otherwise have
allowed for eventual improvement or recovery. Even so, over the
course of the treatment, PF did experience significant improvement
in bone density. Between June 2004 and the June 2010, the patient’s
total hip bone mineral density increased 4.8%, while anterior/poster-
ior spine (L1–L4) decreased 1.3% since baseline.
CaseslikethatofPFemphasizetheimportanceofactivelymanaging
immunopathologywiththegoalthatapatient’ssymptomsremainina
tolerable range. Patients would almost certainly die from sepsis if it
were somehow possible that their entire pathogenic microbiota could
be targeted at once. Indeed the literature has several reports of fatal
reactions among patients with syphilis in which too strong a Jarisch–
Herxheimer reaction was induced.
93–95 Our treatment protocol
encourages physician and patient to work together to adjust levels of
olmesartan and antibiotics in order to continually achieve a tolerable
level of immunopathology.
Many patients experience an inflammatory reaction for several
years before reporting significant improvement. While we expected
immunopathology as a result of olmesartan administration to occur
for at least several months, we did not anticipate how profound and
prolonged the reaction could be. In our experience, patients with
severe illness often manage immunopathology for 4–7 years before
presentingwithobjective markersindicatingsignificantimprovement
or disease resolution.
The length of time it takes seriously ill patients to report symptom
remission on this therapy has some medical precedent. The preferred
regimen for the treatment of latent tuberculosis is 9 months of iso-
niazid—which is also intended to kill intracellular pathogens.
96
Notably, both treatments may involve an immunopathological-style
reaction.
97,98However,isoniazidtreatmentisaimedatkillingonlyone
major pathogen whereas patients with autoimmune disease may be
targeting multiple phyla of pathogenic microbes. By contrast, treat-
mentslikeHAARTinHIVpatientstargetpolymicrobialcommunities
of opportunistic infections including viruses, fungi and bacteria.
Beatty has noted that symptoms of IRIS among these patients can
occur as long as 3 years after initiating treatment.
99
The long periods of immunopathology experienced by some
patients on our treatment could speak to the possible inadequacies
associated with the therapy. However, it may also reflect the sheer
number and virulence of the pathogenic microbes present in auto-
immune disease.
Recently diagnosed patients
Conversely, patients who start our treatment early after disease onset
andhavenotpreviouslybeenadministeredwithimmunosuppressants
often find that their immunopathology is much easier to tolerate and
experience faster symptom improvement.
At the age of 34 years, in January 2007, AC was diagnosed with her
first inflammatory condition, mixed connective tissue disease. Several
months later, she had ANA of 1:2520 and RF of 12. Several other
diagnoses followed in the next 2 years including neuropathy,
Sjo ¨gren’sandRaynaud’ssyndromes,musclefasciculation,vulvodynia,
dermatitis and cervical dysplasia. AC began 40 mg of olmesartan four
times daily in September 2009, less than 3 years after her initial dia-
gnosis. Prior to beginning treatment with olmesartan, AC reported
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104that on a scale of 1–10, with 10 being the most severe, high levels of
muscle (7), joint (8) and vulva (10) pain. Six months into treatment,
thosescoresdeclined:muscle(3),joint(3)andvulva(3).InSeptember
2010, 1 year after beginning treatment, she rates those symptoms,
respectively, as 1, 1 and 2. In February 2010, the patient’s bloodwork
wasnegativeforANA.RFhasnotbeenretestedsince.AChasreported
similar 12-month improvements in dry mouth (5–0), dry eye (6–3),
burning tongue (8–0) and noise intolerance (5–0). Only fissured ton-
gue (9–8) has remained unchanged at this point in therapy.
Cases like AC strongly suggest that the sooner an immunostimula-
tivetreatmentisstarted,thelessimmunopathologyapatientmayhave
to manage, and the quicker the potential recovery. This underscores
the importance of immunostimulatory therapies being researched in
further depth so thatthey might become increasingly used as first-line
treatment options for autoimmune disease.
SURROGATE OUTCOMES FOR DISEASE MUST BECAREFULLY
CHOSEN
Since microbes seem to play a significant role in the autoimmune
disease process, we must necessarily reconsider the role of the various
metabolites associated with the markers we use to assess those condi-
tions.Manyinflammatorydiseasestatesaremarkedbybothmetabolic
fluctuations and physical presentations that would not be considered
‘normal’. We observe shifts in white blood cell count, cholesterol
levels, blood pressure and measures of kidney function (such as blood
urea nitrogen (BUN) and creatinine) to be common.
In responding to elevated or depressed markers associated with
inflammatory disease, physicians have a broad range of available
therapeutic strategies. Statins, diuretics, hypoglycemics, tumor nec-
rosis factor-a antagonists, vitamin D and thyroid hormones each tar-
get a particular surrogate outcome associated with disease. Six of the
world’s 10 top-selling drugs in 2010 are marketed at targeting out-
comes that are surrogate outcomes.
Some physicians argue that autoimmune diseases should be treated
until laboratory abnormalities resolve.
100 However, while surrogate
outcomes have some utility in signaling the presence of inflammatory
disease, it has become increasingly less clear the extent to which chan-
ging a marker associated with disease alters the course of the disease
itself;‘fewsurrogatemarkers’havebeenshownto‘capturetheeffectof
a treatment’.
101
More and more researchers and physicians routinely deprecate
evidence devoid of outcomes that matter most to patients and their
caregivers (i.e., patient-important outcomes). This evolution in
approach is borne out of experience. According to Grimes and
Schulz, ‘thousands of useless and misleading reports on surrogate
end points litter the medical literature’.
101
While a number of drugs are highly effective at altering measurable
metabolites,theybarelyaffecttheprogressionofdisease.Forexample,
inlow-riskindividualswithhighcholesterol,statinshaveamarginal,if
not absent, effect in protecting against cardiovascular disease.
102
There are two possibilities in metabolite and disease interaction,
cause and effect. It is critical that we do not try to intervene to drive
purely associative metabolites back into range, as that may disrupt
systemic homeostasis and possibly delay disease resolution.
Markers of anemia
Thelowlevelsofbloodcellscharacteristicofanemiaofchronicdisease
(ACD) are relatively common among autoimmune conditions
103 and
obesity.
104 A related hallmark of ACD is increased uptake and reten-
tion of iron within cells.
105 In their New England Journal of Medicine
review,WeissandGoodnoughwritethatdespitetreatmentguidelines,
‘anemia of chronic disease remains underrecognized and under-
treated’. Anemia should be actively managed, they put forth, because
the condition ‘has been associated with a relatively poor prognosis’
and is associated with suboptimal oxygen delivery.
105
However, Zarychanski and Houston state that ACD is fundament-
allyanadaptivephysiologicresponsewhichbenefitsthepatientduring
times of infection
103 with Baker and Ghio offering a similar argu-
ment.
106 As a nutrient that is essential for the survival of many
microbes, increased iron availability promotes microbial growth.
107
In fact, the ability of a particular species of bacteria to glean iron from
its host is often a good indicator of its virulence. It is logical then that
the body sequesters iron in response to an infection. Kemna et al.
showed that injecting human volunteers with lipopolysaccharides, a
component of the cell walls of gram-negative bacteria, leads to a sig-
nificant decrease in serum iron.
108 In iron-deficient conditions, blood
plasma is moderately effective at inhibiting bacterial growth.
107,109,110
Ithasbeenourexperiencethatbothwhiteandredbloodcellcounts
surge and wane during therapy, tending to normalize as the inflam-
mation resolves. Therefore, while it might otherwise seem reasonable
for a clinician to directly manage ACD using iron supplements, doing
so may actually lead to microbial proliferation.
25-hydroxyvitamin D (25-D)
Lower than normal levels of the metabolite 25-D, which is widely
believed to serve as a marker of vitamin D status, have been indepen-
dently associated with all-cause mortality
111 and increased prevalence
of at least 40 different chronic inflammatory diseases. Over the last
decade, low levels of 25-D have generated interest among physicians,
with many concerned that failing to supplement puts the patient at
greater risk for further disease. Proponents of heavy supplementation
have statedthatadulthumanscantakeextraordinary levels ofvitamin
D for prolonged periods of time without risk of adverse effects.
112
However, the issue of what serum level of the secosteroid is optimal
for health may be less conclusive than some have suggested.
113
As previously discussed, microbes including M. tuberculosis,
Borrelia and EBV have been shown to downregulate the activity of
the VDR. As expression of CYP24A1 diminishes, 1,25-D levels rise.
When the hormone/secosteroid rises above a normal range, it may
downregulate, via the nuclear receptor pregnane X receptor, the
amount of pre-vitamin D converted into 25-D.
38 The result is that
25-D levels drop.
Thus, in patients suffering from VDR dysregulation, there is a
strong possibility that a low 25-D level is a result rather than a cause
of the disease process. A similar pattern has been demonstrated in
VDR knockout mice. While there are clear biological differences
between humans and rodents, VDR knockout mice also show a
marked increase, by a factor of 10, in serum 1,25-D and a clear reduc-
tion in serum 25-D to almost undetectable levels.
114
This challenges the entire concept of vitamin D ‘deficiency’ and
helps explain why many patients with inflammatory disease present
with low levels of 25-D even when they are consuming large amounts
of the secosteroid or are exposed to abundant sunlight.
115
Supplemental vitamin D has been widely lauded for conferring
immunosuppressive effects: Arnson et al. writes ‘[v]itamin D affects
the immune system at many levels and by a number of mechanisms....
Vitamin D has multiple immunosuppressant properties.... On the
whole, vitamin D confers an immunosuppressive effect’.
116 Indeed,
in a 2010 study of pregnancy-associated breast cancer, higher levels
of 25-D were positively correlated with serum antibodies to EBV,
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105suggesting that EBV is able to better proliferate in patients who take
vitamin D.
117 Further evidence for vitamin D’s activity as an immu-
nosuppressant comes in the range of reports of short-term symptom
resolution in autoimmune patients taking vitamin D.
118 In animal
models, administration of vitamin D has been shown to effectively
inhibit signs of autoimmunity, even when animals had ‘sufficient’
vitamin D.
118
Vitamin D may be a case where a substance has inadvertently
become popular in autoimmune disease because of its immunosup-
pressive properties and subsequent ability to lower inflammation and
immunopathology. Ingestion of an immunosuppressant would
counteract an immunostimulatory therapy, leading to treatment fail-
ure even while a patient experiences modest symptomatic improve-
ment in the short-term.
Blood pressure
Low bloodpressureisoftentaken tobeacauseof disease,butinmany
circumstances, hypotension is one of the net results of microbial
death. Hudgins found that injecting human volunteers with a small
amount of endotoxin—which typically enters the blood stream when
gram-negative bacteria are destroyed—not only produces fever and
activates coagulatory and inflammatory processes, but leads to a drop
in blood pressure.
63 One lab worker ingested very large amounts
of Salmonella endotoxin and found his blood pressure drop to
42/20 mmHg.
119
Unfortunately, artificially raising a patient’s blood pressure back to
the range normally correlated with health does not alter the bioavail-
ability of endotoxins or the underlying disease state. In many cases,
intervention to raise or lower the blood pressure is unnecessary, espe-
cially because additional medications may affect immune homeosta-
sis. We find that blood pressure surges and wanes during treatment,
but usually settles into the normal range as the inflammation wanes.
An illustrative case is that of AY, a 54-year-old female who began
treatment with a diagnosis of chronic fatigue syndrome in 1993 and a
numberofcomorbidities.InNovember2004,priortotreatment,AY’s
blood pressurewas measured as75/45mmHg. Thatmonth, shebegan
four times daily dosing of 40 mg of olmesartan. Initially, symptoms of
CFS and photosensitivity increased. Over the subsequent year, AY’s
blood pressure ranged between 65/45 and 75/50 mmHg. In January
2005, the patient was administered with 25 mg of minocycline every
otherday.Thedosewasslowlyincreaseduntilshereachedamaximum
of 100 mg every other day. Symptoms intensified including several
episodes of syncope. Starting in March 2005, the patient continued
rotating combinations of minocycline, clindamycin and azithromy-
cin, all taken in pulsed subinhibitory doses, which resulted in an
increase in nearly all disease symptoms. However, in January 2006,
A.Y’s blood pressure rose to 90/60 mmHg. In August 2006, she
reported increased tolerance to light and noise, less insomnia,
increased exercise tolerance but still limited functionality. In March
2008, AY became able to travel and reported greatly decreased photo-
sensitivity. Blood pressurewasmeasuredat100/65mmHg.InJanuary
2009, the patient’s blood pressure read 110/65 mmHg. In April 2010,
AY discontinued all antibiotics, remaining on 40 mg of olmesartan
taken three times daily. AY reported being able to exercise vigorously.
The latest blood pressure was taken at this time and read 120/75
mmHg.
It should be noted that AY was taking the same dose of olmesartan
whenherbloodpressurewas75/45mmHgaswhenitlaterstabilizedto
120/75mmHg,furthersuggestingthatheroriginallowbloodpressure
was not directly related to treatment medications.
Blood urea nitrogen and creatinine
Several studies have pointed to elevated markers of kidney function as
a risk factor for disease.
120 In the absence of further context, a physi-
cian administering an immunostimulatory therapy might be tempted
to withdraw treatment in the face of such measures. However,
increases in nitrogenous waste may also reflect host-defensive
measures.
121–124
During acute infections, proinflammatory cytokines and inter-
feron-gamma stimulate the production of nitric oxide
123 as do bac-
terial lipopolysaccharides
125. Nitric oxide acts as a highly potent
microbicidal and tumoricidal agent,
121 and has immunomodulatory
functions.
126
Research has also shown that nitric oxide acts as an effector of the
innate immune system targeting adenoviruses and other similar
viruses.
127 As a result, during acute infections we see a sudden and
dramaticincreaseinexcretionofurinarynitrite,
128astablemetabolite
of nitric oxide
129. Fever, the body’s evolutionarily conserved response
to infection, is also accompanied by urinary excretion of creatinine,
urea and ammonia.
130
A 2003 study found that among 117 hemodialysis patients, those
who had high serum values of BUN were less likely to have the acute
infection, Helicobacter pylori.
131 This clinical work suggests that tem-
porary markers of kidney stress may correlate with a robust and suc-
cessfulimmuneresponse.Incertaincases,elevatedkidneymetabolites
are associated with improved clinical outcomes. A recent Japanese
4-year follow-up study of 877 men found that lower serum creatinine
wassignificantlyassociatedwithanincreasedriskoftype2diabetes.
132
Studies of immunopathology indicate that the kidneys and liver
must deal with the burden of toxins released after microbial death.
This, in addition to the factors described above, may lead to a decline
in markers of kidney function. While the kidneys are under a certain
amount of stress, bringing such metabolites back into range would
require interfering with the immunopathological reaction. This
defeats the purpose of administering the treatment in the first place.
Therefore, to a certain extent, physicians may want to consider allow-
ing BUN, creatinine, or other kidney markers to remain out of range
provided that these metabolites are carefully monitored and immu-
nopathology is tolerable. As with blood pressure, we typically see that,
if left alone in this fashion, kidney metabolites will come back into
range as immunopathology eventually subsides.
EJ is a 53-year-old female diagnosed with CFS. She also complains
ofmusculoskeletalpain.EJbegan40mgofolmesartanfourtimesdaily
in May 2007. After starting subinhibitory doses of minocycline and
azithromycin, EJ reported increases in pain and fatigue while, around
the same time, her epidermal growth factor receptor (EGFR)
plummeted from 86 to 38 ml/min. After only normal readings, EJ’s
creatinine was first measured out of range 7 months into therapy at
1.53mg/dl.However,inthecourseofthenextyear,hereGFRclimbed
to 53 and eventually 80.3. During the same period of time, EJ’s crea-
tinine dropped to 0.76. As of September 2010, EJ reports her muscu-
loskeletal pain as 0, but still complains of fatigue
5–7 and cognitive
problems.
6,7 Her latest kidney readings are a creatinine of 0.79 and
eGFR of 75.9.
Although EJ’s creatinine and eGFR fluctuated substantially out of
the normal rangeduring some of the time onthe treatment, the meta-
bolites stabilized without intervention. As expected, her most pro-
nounced drop in eGFR corresponded to a period in which she
experienced very high levels of immunopathology.
A more extreme example is that of BB, a 56-year-old male with a
diagnosis of sarcoidosis. He began 40 mg of olmesartan four times
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bitory minocycline, azithromycin and clindamycin shortly thereafter.
As seen in Figure 3, several months after starting treatment, measures
of renal function initially declined sharply, reaching out-of-range
levels in BUN (18 of 21 measures), creatinine (19 of 22) and GFR
(14 previous tests). However, he is now 95% free of his previous
symptoms and no longer takes oral or inhaled steroids.
This case is interesting in that typically a patient with kidney meta-
bolites such as those of BB would likely be preparing for dialysis or
experiencing symptoms of kidney failure. Instead, BB is relatively
symptom-free. Again, his test results fluctuate in a way that suggests
they are tied to immunopathology. This implies that in BB’s case,
factors other than progressive kidney deterioration may be affecting
hisBUN,creatinineandGFR.Itisimportanttonotethateventhough
we have received many case histories in which patients’ kidney meta-
bolites fluctuate out of range, we have had no reports of patients
needing dialysis.
IMMUNOSTIMULATIVE THERAPIES NEED FURTHER STUDY
In studying therapeutic approaches designed to induce immuno-
pathology, we must grapple with several ethical issues that have
received minimal attention thus far.
Accepting discomfort
Physicians andresearchers, especiallyinthecontext ofclinical studies,
feel an acute imperative to relieve pain and discomfort whenever
possible. Anything less, many have argued, would be unethical or
immoral. Pullman writes ‘[t]he duties to relieve pain and suffering
are clearly matters of moral obligation’’.
133 Lohman writes that access
to pain treatment is a ‘human right’,
134 while Rollin states that neces-
sary suffering is any suffering which is ‘impossible to alleviate’.
135
However, medical providers have limited reservations with admin-
istering painful treatments or conducting uncomfortable procedures
thatleadtowell-characterizedpositiveoutcomes:sentinelnodebiopsy
in suspected cancer, major shoulder surgery, certain dental proce-
dures, etc. Nor are most clinicians categorically opposed to using
medicinesthathavearangeofserioussideeffects,chemotherapybeing
an obvious example. Given sufficient reason for causing near-term
discomfort, many patients and physicians are perfectly willing to ser-
iously consider these types of trade-offs.
Therapiesaretypicallythoughtofashavingtwocategoriesofeffects:
therapeutic effects and adverse effects. The former is intentional and
makes a patient feel better, and the latter is unintended and makes a
patient feel worse. Yet, certain therapies that induce immunopathol-
ogy have the potential to be a hybrid of the two: by necessity, the
treatment is intended to make a patient feel worse. In other words,
in the context of an immunopathology-inducing therapy, an adverse
effect is not so much a collateral effect of the treatment, but the treat-
ment itself.
As we have discussed, our immunopathology-inducing protocol
can cause a sustained exacerbation in symptoms over at least several
years.However,inspiteofthetreatment’slength,wehavefoundmany
patients are more than willing, considering the gravity of the pro-
gnoses they face, to commit themselves to such therapy.
It should be noted that the immune system may become healthier
over the course of treatment. As microbes dysregulating the nuclear
receptorsareincreasinglyeliminated,andinfectedcellsarereplacedby
their healthy counterparts, the immune response gains substantial
strength.Thus,insomecases,immunopathologymayactuallybecome
more severe several years into treatment. Physicians and patients
should be aware that symptomatic improvement on an immunosti-
mulatory treatment is rarely linear.
Blinding, randomization and study design
The randomized controlled trial is regarded as the gold standard of
measuring the efficacy of a therapy. Blinding the intervention to par-
ticipants and physicians further reduces the effect of treatment bias.
However, in the case of an immunopathology-inducing therapy, the
severity of the symptom response would invariably make blinding
impossible—patient and physician would know in short order the
treatment arm to which a participant had been assigned. Given that
therapies that generate immunopathology seem to be required at least
several years before sicker patients report substantial improvement,
randomization also poses a challenge. To be sure, subjects could be
Figure 3 Kidney metabolites in a 56-year-old male with sarcoidosis. BUN, blood urea nitrogen; GFR, glomerular filtration rate.
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107assigned to the immunopathology-inducing group, but the potential
for early withdrawal is clearly much higher for multiyear treatments
that necessitate symptom exacerbation, even if only in the short term.
The number of patients who decline to participate and withdraw
early may make an intention to treat analysis untenable. In any case,
any study design for a therapy which makes patients feel significantly
uncomfortable has the potential to incur self-selection bias: people
who commit themselves to a challenging multiyear therapy are quali-
tatively different from people who decline the treatment.
Another key consideration for study designis the lengthof the trial.
Trials that assess overall patient outcomes, such as improvement in
activities of daily living,would need tolastseveral years. Alternatively,
trials of efficacy (i.e., those looking at microbial death) could be con-
cluded in a month or 2. It has been reported that HIV/AIDS patients
on antiretroviral drugs experience IRIS within weeks of beginning
therapy.
136 This is consistent with our experience when using immu-
nostimulation in autoimmune disease.
An essential feature of the design of any clinical trial is informed
consent, and this is especially important in therapies that generate
immunopathology. Patients need to expect to experience temporary
well-defined increases in symptoms, markers of inflammation, and
disease state. They must also appreciate why such increases are neces-
sary, and how they would work with their physician to manage their
symptoms.
SUMMARY
Over the past decade, molecular sequencing technology and metage-
nomic analyses have revolutionized the field of microbiology. The
human body, once deemed largely sterile, is now known to harbor
thousands of genomes—many of which have still to be named and
characterized. These genomes continually interact with the human
genome in both health and disease. Not just single pathogens, but
entire communities of microbes differ substantially between healthy
individualsandthosewithautoimmunedisease.Thebodyislikelynot
creatingantibodiesagainstself,butinsteadinresponsetothesepatho-
genic genomes. Indeed, many ‘autoantibodies’ have already been
linked to the presence of pathogens.
Those pathogens that canpersist intracellularly have accessto DNA
translation and repair mechanisms, and can also affect gene express-
ion. This activity mandates a fundamental reconsideration of how
chronicdiseasesaretreated.Ratherthanimmunosuppression, immu-
nostimulation may be the true key to reversal of these conditions.
The symptoms of an acute infection result from a battle between
man and microbe. A similar battle, in which the immune system
releases cytokines and microbes form endotoxins or debris, would
occur if pathogens were killed in chronic disease. Thus, if chronic
microbes are successfully targeted, patients would necessarily be
expectedtoexperiencesymptomexacerbation.Ineffect,patientsreco-
vering from autoimmune disease may need to feel worse before they
feel better.
Interestingly, these responses have been described in the literature,
generally as being paradoxical.
137–141 Yet symptom exacerbation
resulting from an immunostimulative approach towards pathogens
is paradoxical only because it defies previously held intuition.
The immunostimulatory approach we have studied uses a putative
VDR agonist to reactivate the innate immune response. Case histories
suggest that patients with a variety of autoimmune diagnoses experi-
ence prolonged immunopathology. Many subjects additionally
experienced neurological immunopathology, often for several years
before improvement. This emphasizes the systemic nature of
autoimmune disease processes and the significant number of patho-
gens that seem to be involved in the development of these disease
states.
Abroadarrayofmedicationsandsupplementsareeffectiveatredu-
cing discomfort of patients with chronic disease. Our reports suggest
that many of these drugs, whose actions at the molecular level are not
fully understood, may generate feelings of clinical and subjective
improvement precisely because they suppress and slow activity of
the immune system.
In addition, accumulating evidence from metagenomic studies is
pushing physicians and researchers to reflect upon the wisdom of
using interventions in an attempt to alter the body’s metabolites.
The more prominently microbes figure in our understanding of the
pathogenesis of chronic disease, the more likely it is that therapies
should be tailored to support the body as it responds to infection. In
many cases, out-of-range markers seem to be a necessary part of the
healing process.
Nevertheless, there remains a need to identify microbe-specific
markers. Metabolomics is the emerging field which studies microbial
metabolites. As metabolomics and metagenomics evolve, we should
expecttheemergenceoftechnologiescapableofmoreoptimallydefin-
ing a treatment regime based on examination of specimens from
blood, urine and swabs.
Thereneedstobemorecollaborationbetween researchersandclin-
icians in order to more tightly define the immunopathology we have
observed.
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Summary and link to General Discussion 
 
In  this  chapter  “Immunostimulation  in  the  era  of  the  metagenome”,  we  discussed  an 
immunostimulative therapy that attempts to increase innate immune activity via a drug aimed 
at  re-activating  the  VDR.  The  putative  VDR  agonist  olmesartan  may  correct  VDR 
dysregulation and prime the immune system to kill the intracellular pathogens driving the 
autoimmune disease process. In parallel, pulsed low-dose bacteriostatic antibiotics would 
assist  in  bacterial  eradication.  We  have  presented  ten  case  reports  of  patients  whose 
physicians had used this immune therapy in order to illustrate the paradigm shifts when 
immunostimulative medications are used in the place of immunosuppressants. We examined 
the  effects  of  the  treatment  in  a  variety  of  autoimmune  diagnoses,  most  showing 
improvement and/or reversal of disease symptoms. 
 
The  most  important  observation  made  was  that  when  the  innate  immune  system  was 
invigorated to target chronic pathogens, the resulting storm of cytokines and chemokines led 
to a temporary rise in disease inflammation and symptoms. We refer to this process as 
immunopathology.  In  this  chapter,  we  have  described  the  different  forms  of 
immunopathology observed in treated patients. We also discussed some challenges that 
physicians and scientists will need to face as they attempt to optimize potential curative 
treatments for autoimmune disease in the future. 
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General Discussion 
 
This  thesis  presents  a  working  hypothesis  describing  the  pathogenesis  of  many  serious 
idiopathic diseases. To the best of my knowledge, this thesis is the first body of original work 
to  propose  a  model  for  autoimmune  disease  informed  by  metagenomics.  We  synthesize 
data and concepts from metagenomic biological research, in silico emulations, and data from 
clinical studies of autoimmune disease. If the pathogenic description described in this thesis 
is valid, it will significantly change both the description and understanding of autoimmune 
disease. 
 
Key Points 
 
1.  The  human  body  is  not  a  sterile  compartment  but  harbors  a  prolific  microbiota.  The 
number of microbial cells in the body exceeds human cells by a factor of at least ten. While 
the  human  genome  consists  of  23,000  genes,  the  number  of  unique  genes  in  the 
microbiome is known to be at least 100 times greater. 
 
2. The human microbiome exists not only in the gut and other mucosal surfaces but also in 
tissues,  blood,  and  inside  the  cells.  Key  to  disease  is  that  the  RNA  and  proteins  from 
intracellular  microbes  directly  interfere  with  transcription,  translation,  and  cellular  repair 
mechanisms. 
 
3. Koch’s postulates stipulate that a given infectious disease must be caused by a given 
species  of  microbe.  Yet  it  is  now  more  plausible  that  autoimmune  disease  results  from 
dysbiosis of whole communities of microbes - microbes that interact so extensively that the 
line between species is unclear. 
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4.In order to survive in the face of the human immune response, persistent components of 
the microbiota must necessarily employ survival mechanisms. Those mechanisms, which 
weaken  the  host  innate  immune  system,  including  expression  by  the  human  VDR  of 
cathelicidin and TLR2, provide a significant survival advantage. 
 
5. The exact composition of a given person’s microbiota varies according to several factors 
including familial exposure, site and duration of exposure to infections, blood transfusions, 
and  use  of  antibiotics  or  immunosuppressants.  The  sum  of  a  person’s  infectious  history 
determines the level and type of interference between the host and parasitic proteomes and 
metagenomes. This drives the uniqueness of each disease presentation, no two of which are 
exactly alike. Embracing the co-morbidities allow us to focus on the shared mechanisms by 
which microbes disrupt the body’s pathways. 
 
6.  In  order  to  restore  microbial  homeostasis,  the  body’s  immune  response  must  be 
reinvigorated  to  recognize  persistent  pathogens.  Therefore,  immunosuppression  is 
counterproductive if one wishes to target the underlying causes of autoimmune disease. At 
best, it can lead to short term symptomatic relief with relapse in the longer term. 
 
7. When the immune system is killing pathogens inside a cell, the likelihood of killing the cell 
through apoptosis or autophagy is very high. Additionally, the storm of inflammatory and 
toxic  byproducts  resulting  from  microbial  death  is  significant.  The  resulting  surge  in 
symptoms (immunopathology) causes patients to initially feel worse before they start to feel 
better. It follows that feel-good substances therefore cannot be targeting the causal microbes 
and are most likely acting through immunosuppressive pathways. Any claimed long-term 
efficacy of such substances must be very suspect. The substances in question include the 
secosteroid transcriptional activator called vitamin D.  
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8.  Hormonal  differences  between  women  and  men  cause  the  sexes  to  express  different 
antimicrobial  defenses.  In  addition,  the  VDR  is  expressed  in  the  cycling  endometrium, 
potentially  causing  women  to  suffer  more  from  VDR  dysregulation  than  their  male 
counterparts. These differences suggest that over time, women may be more susceptible to 
certain microbes than men and may acquire them more easily. This would partially account 
for the higher prevalence of autoimmune disease in women. 
 
9. The body sets up a different metabolic homeostasis in disease than in health. Thus, low 
levels of 25-D in patients with inflammatory disease are likely a result rather than a cause of 
the disease process. This disturbance of homeostasis is observed with other metabolites 
such  as  cortisol  and  cholesterol.  This  means  that  a  physician  may  have  to  allow  these 
metabolites, and others, to remain out of range during periods of immunopathology in order 
for the body to attempt to return to a state of homeostasis. 
 
10. Autoantibodies are notoriously polyspecific. Increasingly the evidence is showing that 
they are created in response to the disease-causing microbiota. Thus, autoimmune activity 
may be collateral damage from the immune system's fight against chronic infection rather 
than the result of a hyperactive adaptive immune response. Ultimately, Ehrlich’s instinct was 
at least partially correct: there is no such thing as autoimmunity. 
 
11. The human genome can no longer be studied in isolation. Rather, it must be analyzed in 
the context of or how it interacts with the metagenome and with the metatranscriptome. 
 
Translating the science into practice 
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In 2010, J. Craig Venter, who first sequenced the human genome, commented, “If anything, 
we don't really know how to read the genome and it can't tell us very much right now... We 
couldn't even be certain from my genome what my eye color was. Isn't that sad? Everyone 
was looking for miracle 'yes/no' answers in the genome. ‘Yes, you'll have cancer.’ Or ‘No, 
you won't have cancer.’ But that's just not the way it is.... [The Human Genome Project has 
had] close to zero [medical benefit]. We have, in truth, learned nothing from the genome 
other than probabilities. How does a 1 or 3 percent increased risk for something translate 
into the clinic? It is useless information.” 
 
Venter's genome is “useless” because it has not yet been interpreted in concert with the 
microbial genomes that also persist in his body. Mainstream medicine has yet to embrace 
the  clinical  utility  of  the  metatranscriptome,  which  impacts  nearly  all  areas  of  medicine 
including how we react to vaccines, medications, and environmental toxins. In the same 
vein,  the  human  superorganism  is  often  viewed  as  more  of  a  fascinating  factoid  than  a 
paradigm  on  which  to  base  or  reinterpret  research.  While  it  is  widely  assumed  that 
inflammatory  disease  is  caused  by  a  combination  of  genetic  and  environmental  factors, 
researchers studying the human genome often have little contact with those studying the 
microbiome. Much of the lack of utility described by Venter is due to this disconnect. 
 
As the importance of the metatranscriptome becomes more fully appreciated, researchers 
attempting to set a “correct” level for vitamin D intake will need to interpret their findings in 
the context of how VDR expression is continually altered by a number of major pathogens. 
Moreover, the traditional concept that intake of probiotics is beneficial must be re-examined 
now that microbes such as Bifidobacteria and Lactobacillus are known to directly impact 
pathways associated with autoimmune disease.
1 To reduce mistakes in characterization of  
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the human genome, it is important to make sure that tools do not mistakenly amplify RNA 
from intracellular microbial genomes. 
 
Moving away from reductionist approaches 
 
Recently Schutzer et al. used mass spectroscopy proteomics to analyze the cerebrospinal 
fluid  of  patients  with  Chronic  Fatigue  Syndrome  (CFS),  Post  Treatment  Lyme  Disease 
(nPTLS) and so-called healthy subjects.
2
 The group detected more than 2,600 proteins in 
each group with 692 proteins unique to the Lyme patients and 738 unique to the CFS group. 
CFS and nPTLS groups shared significantly more proteins (305) than either group shared 
with healthy controls. 
 
In  discussing  the  study  the  team  wrote,  “As  with  most  technologic  methods  we  expect 
multiple replicate analyses of the highly fractionated samples would result in a reduction of 
the number of seemingly unique proteins identified for each disease group.” However, if the 
results were interpreted in the context of our model, our team would seek to do the exact 
opposite.  We  would  hope  that  future  studies  would  investigate  even  more  proteins 
associated with each disease state, as this would expand our understanding of the microbes 
capable of contributing to each condition. We would also be more interested in the proteins 
associated with both nPTLS and CFS, as such overlap would support our hypothesis that 
any one microbe can contribute to a variety of disease states. This approach would require 
us to accept the complexity inherent to each disease state and, as we have tried to do with 
our current work, focus our efforts on identifying new ways to describe and analyze the 
system.” 
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Some metagenomic researchers have suggested that studies with larger sample sizes and 
more in-depth analyses of specific genomes might better inform our understanding of the 
metagenome in health and disease. This resembles the approach currently being employed 
by many GWAS (genome-wide association studies) investigators. These researchers believe 
that GWAS with staggering sample sizes and an increased focus on a growing number of 
SNPs may finally lead to an understanding of the “missing heritability.” Unfortunately these 
GWAS  have  only  bogged  down  the  field  of  genomics  in  a  morass  of  complexity.  An 
increasing number of SNPs are identified but few show more than a minimal association with 
any specific diagnosis. 
 
It would be a shame if future metagenomic researchers decide to adhere exclusively to a 
similar path in which reams of new data are generated absent context of how this might 
transfer to the clinic. The reason that our immunostimulative therapy has the potential to help 
patients with inflammatory disease today is that we have chosen not to fixate on the complex 
interplay between the microbes in any given disease state. Instead, we identified a common 
pathway  that,  if  stimulated,  enables  the  innate  immune  system  to  decide  which  species 
should be eliminated in order to restore health. 
 
Other considerations 
 
1. Health and disease are not discrete states. 
 
The  medical  community  traditionally  divides  people  into  two  categories:  healthy  or  sick. 
However,  a  person's  microbiota  continually  changes  over  time  as  new  microbes  are 
incorporated  into  the  superorganism.  As  described  in  Chapter  6,  in  some  people,  the 
accumulation leads to chronic symptoms at an early or middle age, while others will not 
suffer until "aging" in their later years. Thus, health and disease are not discrete states; there  
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is  a  continuum  between  the  two.  For  example,  most  studies  that  look  for  microbes  in 
chronically ill individuals find that members of the control group harbor them as well, albeit 
usually with differing incidence. This should not be a surprise but an expected outcome. It 
follows that people who are not yet overtly ill may also need to take measures to maintain 
the homeostasis and healthy trajectory of their microbiotas. This would provide an entirely 
new avenue for preventative medicine. 
 
2. We must study antibiotics more critically. 
 
Antibiotics have saved countless lives over the past century. However, this may have also 
engendered a false sense of confidence that we fully understand the manner in which they 
work  and  should  be  used.  For  example,  as  described  in  Chapter  5,  one  of  the  most 
important, yet virtually ignored properties of the beta-lactam antibiotics, is that while they 
effectively  target  acute  bacterial  forms,  they  foster  the  development  of  chronic  variants 
without cell walls. This alone could account for much of the increase in chronic disease over 
the last decades, but is not commonly used to inform clinical practice. 
 
In  the  same  vein,  high-dose  antibiotics  have  been  shown  to  have  profound  effects  on 
immune function in addition to their actions on any microbes. This means that, paradoxically, 
patients  taking  high  doses  of  antibiotics  frequently  exhibit  symptoms  characteristic  of 
immunosuppression.  They  generally  feel  better  while  the  high  dose  antibiotic  is  being 
administered  but  relapse  after  it  is  discontinued.  At  least  one  study  has  shown  that 
intravenous cephalosporin is purely palliative.
3
 
 
Other studies are just beginning to reveal that commonly used antibiotics have many more 
actions  at  the  molecular  level  than  previously  realized.  For  example,  the  bacteriostatic 
antibiotics  minocycline  and  clindamycin  may  be  a  direct  agonist  of  the  PXR  nuclear  
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receptor.
4
  Concerns  about  antibiotic  resistance  continue  to  grow,  but  perhaps  a  better 
understanding of the full spectrum of an antibioticʼs actions at the molecular level could help 
us better dose and design these drugs. If used in a more informed and careful fashion, they 
would form a more powerful part of our arsenal against bacterial pathogens. 
 
3. Use of probiotics may have unintended effects. 
 
In the 1930's cane beetles in Australia were found to be destroying much of the country's 
sugar cane crop. It was decided that cane toads (Bufo marinus) should be bred in Hawaii 
and subsequently transferred to Australia in an effort to control the beetles. Hundreds of 
toads  were  released  into  the  Australian  tropics  in  1935.  Unfortunately,  it  soon  became 
apparent that the toads could not jump high enough to eat the beetles, which persisted on 
the upper stalks of the cane plants. Furthermore, the toad population quickly burgeoned and 
began to outcompete and decimate many native species. The cane toads were also toxic to 
would-be predators such as native snakes.  
 
The gut harbors a microbial ecosystem. The equivalent of the toads in the above example of 
biological  pest  control  could  be  certain  strains  of  probiotic  bacteria.  It  is  seductive  yet 
simplistic to assume that dumping large amounts of so called beneficial microbes into the gut 
will simply kill "bad" microbes. Instead, introducing "beneficial" bacteria into a sick patient 
may actually cause such species to swap genes with pathogenic microbes. This could alter 
the interactions between the microbial genomes and the human genome, creating a different 
microbiota that the immune system may have difficulty managing. As described in Chapter 5, 
because of the size of their genomes, "good" microbes may well have undesirable properties 
as well.  
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Patients often do report feeling better after taking probiotics. However, it may be that adding 
new microbes into the gut simply diverts the immune system away from dealing with other 
pathogenic  species.  This  would  temporarily  decrease  immunopathology  and  disease 
symptoms but not target the root cause of the problem. 
 
4. Physicians must be on the alert for neurological immunopathology. 
 
It is clear from our case reports that immunopathology does not just occur in the body but 
also  in  the  brain.  It  is  now  understood  that  microbes  can  cross  the  blood-brain  barrier 
transcellularly, paracellularly, and intracellularly.
5
 Microbes have already been implicated in 
diseases including Alzheimer's, autism spectrum disorder, and schizophrenia. A very high 
number of patients with inflammatory disease exhibit mental co-morbidities. Furthermore, it 
appears that microbes in other parts of the body can impact the brain. For example, the 
composition of bacteria in the gut has been linked to depression and anxiety. 
 
This means that patients on immunostimulatory therapy will almost certainly have to contend 
with changes in the way they think and feel. We have found that physicians must continually 
monitor  their  patients  mental  as  well  as  physical  health.  Patients  who  undertake 
immunostimulative therapy must have a support system in place, which would help them 
manage immunopathology and become educated about the wide range of symptoms they 
may encounter due to immunopathology. 
 
5. Chronic components of the microbiome affect susceptibility to acute infection. 
 
It is well known that the immune system weakens with age and in chronic disease. Our 
model of successive infection offers stronger explanatory power of this phenomenon at the  
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molecular level. Since the health of the microbiome is continually altered over a lifetime, its 
composition at any point in time significantly impacts how a person will respond to an acute 
infection.  If  the  proteome  and  innate  immune  response  are  already  dysregulated  by  the 
persistent microbiota, risk of morbidity and mortality by acute pathogens also becomes much 
higher. 
 
During the recent outbreak E. coli O104:H4 strain in Germany, the preponderance of cases 
occurred  in  women.
6  As  described  in  Chapter  1,  women  have  an  extra  site  of  VDR 
expression in the cycling endometrium. This could account for why several pregnant women 
also developed the more serious forms of the illness. 
 
Many immunologists predict that it is only a matter of time before more acute pathogens 
mutate into forms that might lead to serious, worldwide epidemics. Already thousands have 
died from SARS, HIV, tuberculosis and other “super bugs.” If preventative measures were 
available  to  maintain  the  health  and  homeostasis  of  an  individual's  chronic  microbiota, 
priming the body to best deal with these acute invaders, then control of these epidemics 
might  well  become  easier.  At  the  very  least,  a  move  away  from  the  regular  use  of 
immunosuppressive medications towards immunostimulative medications could prove very 
useful in the control of acute pathogens. 
 
6. We must learn to explore more alternative hypotheses. 
 
This thesis repeatedly invokes the alternative hypothesis. Our model opens up numerous 
avenues of inquiry that will be valuable in allowing other research teams to also examine 
their data in a new light. For example, studies which draw the conclusion that subjects with a 
particular inflammatory condition have low 25-D levels and are thus suffering from "vitamin D  
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deficiency" also fit our alternative model. The 25-D levels may actually be a result of the 
disease process. 
 
On their website
7, the supplementation advocacy group Vitamin D Council asked, “One of 
the great mysteries in human biology is the fact that most human breast milk is deficient in 
vitamin D. How could Nature overlook such an important nutrient in the 'perfect food'?” Many 
studies have shown that breast-fed infants tend to perform better on standardized tests and 
display higher overall levels of intelligence than their formula-fed counterparts. This is almost 
invariably  interpreted  as  a  sign  that  breast  milk  contains  a  substance  that  baby  formula 
lacks. Instead, the converse may be true – the intelligence discrepancy could be due to the 
fact that formula contains an extra ingredient with potential immunosuppressive properties: 
the secosteroid vitamin D. 
 
Continued support 
 
To be truly useful our model needs to be continually tested against data accumulating from 
new  studies.  Since  the  2011  publication  of  “Immunostimulation  in  the  era  of  the 
metagenome,”  dysbiosis  of  microbial  communities  has  been  further  reported  in  chronic 
inflammatory  diseases  including  type  1  diabetes,
8
  autism,  and  COPD
9.  We  continue  to 
receive physician case reports that are consistent with our model. 
 
In 2009, the US Institute of Medicine (IOM) commissioned a report on vitamin D research by 
the Tufts Medical Center Evidence-based Practice Center. According to the report’s abstract: 
“The  majority  of  the  findings  concerning  vitamin  D,  calcium,  or  a  combination  of  both 
nutrients on the different health outcomes were inconsistent.”
10
 For a variety of diseases, the 
report repeatedly finds few or no controlled studies showing an association between vitamin  
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D intake and disease.” Based on this assessment and speeches from several vitamin D 
researchers  (including  myself),  IOM  opted  not  to  raise  the  daily  recommended  intake 
towards the high levels recommended by many top “experts” in the field. Instead, as we 
have,  they  called  for  a  shift  away  from  epidemiological  observation  towards  more 
comprehensive studies and long-term results. 
 
Weaknesses 
 
Several aspects of this model require further validation. This includes data derived from in 
silico emulations, such as those that suggest that elevated 1,25-D can alter expression of 
thyroid beta and other nuclear receptors. To some extent, case studies of patients on our 
immunostimulative therapy offer validation of our model. Several reports demonstrate that 
thyroid, adrenal, and sex hormone levels return to range after 1,25-D levels drop. Yet these 
reports  are  not  being  collected  in  a  controlled  setting.  Nor  can  we  assume  that  these 
metabolite changes are due to the same mechanisms suggested by our model. 
 
Another  challenge  lies  in  more  accurately  characterizing  immunopathology.  Physician 
reports  indicate  that  the  reaction  is  often  extremely  profound  and  sustained.  Yet  at  the 
moment, what appears to be a dramatic change in inflammation and cell death is poorly 
detected by standard laboratory tests. While physicians have reported changes in markers 
such as CRP, white blood cell count, and “autoantibody” levels, such changes vary among 
patients and not in a reliable manner. With such inconsistencies in signs and symptoms of 
immunopathology,  it  is  no  wonder  that  the  phenomenon  has  previously  gone  essentially 
unrecognized.  Indeed  the  best  biomarker  that  we  have  identified  as  an  indicator  of  the 
dysregulated microbiota is higher than normal levels of 1,25-dihydroxyvitamin-D. 
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It  is  critical  then  that  researchers  identify  new,  unique  biomarkers  that  would  allow 
physicians to specifically track immunopathology. We anticipate that new immunopathology-
specific markers might be identified in the metabolome or the proteome since the micriobiota 
and  the  immune  response  both  alter  the  body’s  protein  expression  and  microbial 
composition. Hopefully this would only require analysis of blood or urine, rather than the 
cerebrospinal fluid as in the Schutzer study
2. 
 
Assuming that immunopathology is indeed an inevitable response to immunostimulation, it is 
very important that we develop new ways to manage the reaction. At present, there are very 
few drugs that can temper immunopathology since the vast majority of common palliatives 
impair the immune response. If used too often, palliatives call into question the rationale for 
stimulating  the  innate  immune  response  in  the  first  place.  That  said,  our  case  studies 
suggest that the best way to prevent severe immunopathology is to start patients on an 
immunostimulative  treatment  at  an  early  stage  in  the  disease  process  –  before  the 
microbiota becomes dominant. 
 
Challenges in testing 
 
Testing  our  pathogenesis/model  is  not  as  straightforward  as  it  might  seem.  Testing  and 
improving our model has presented us with many challenges. As explored in the section 
“Men are not large mice without tails”, in Chapter 5, there are a host of difficulties in trying to 
use an animal model to recreate a system in which our model might be accurately tested. 
The most obvious problem is that many pathways, including the VDR system, are different in 
mice and man (and even between higher primates and man). Thus, the manner in which the 
murine microbiota has evolved to persist in its host is undoubtedly different from the manner 
in which the human microbiota has evolved to persist. Also, to date, it has not been possible  
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to re-create the process of successive infection in mice in order to induce a human chronic 
disease.  This  means  that  although  the  symptoms  of  an  “autoimmune”  condition  can 
sometimes be re-created in a mouse model, the pathogenesis or reason for the appearance 
of those symptoms is almost certainly different from the reason similar symptoms appear in 
Homo  sapiens.  However,  despite  these  issues,  some  regulatory  agencies  will  not  give 
permission  for  in  vivo  studies  to  proceed  in  the  absence  of  evidence  generated  from 
experimental  animal  models.  This  represents  a  serious  barrier  to  the  pace  of  scientific 
change. 
 
In vitro research also presents certain difficulties. Researchers are accustomed to testing the 
effects of drugs on ready-made cell lines. However such cell lines do not account for the 
effects  of  an  intracellular  microbiota.  Given  that  the  microbiota  varies  between  people, 
among  people,  and  over  time,  it  may  be  impossible  to  duplicate  the  microbiota,  and  its 
interaction with the human genome, in an in vitro setting. For example, we can try to test the 
effects  of  various  compounds  on  VDR  expression.  However,  in  vivo  the  VDR  is  likely 
compromised by the microbiota leading towards inflammatory disease. If we are unable to 
duplicate these variables in the laboratory, is such an experiment even worth conducting? 
 
In order to perform a successful in vitro study it is also essential that we understand the mark 
we plan to measure. There are currently 51 identified nuclear receptors and the function of 
most of them is still unknown. The VDR plays a critical role in the expression of numerous 
important  genes,  and  yet  mice  that  are  VDR-null  still  survive.  Clearly  there  are  a  great 
number of redundant functions in a mammal. There will remain a huge gap in our ability to 
understand  the  underlying  mechanisms  of  clinical  phenomena  until  more  nuclear 
transcriptomes become available. 
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The optimal way to test our model is in an in vivo environment, yet working with human 
subjects  presents  its  own  set  of  obstacles.  As  mentioned  in  Chapter  6,  we  have  found 
institutional review boards (IRBs) are often uncomfortable allowing patients to feel worse as 
a result of immunopathology. Several years ago we attempted to begin a clinical trial at West 
China Hospital (WCH) in Chengdu, China in an effort to test our immunostimulative model in 
the  therapy  of  patients  with  ankylosing  spondylitis.  Although  our  clinical  collaborators 
understood the need for patients to experience immunopathology, they were still generally 
uncomfortable.  West  China  Hospitalʼs  review  board  took  the  issue  further,  stating  that 
patients  on  any  treatment  should  not  feel  worse.  We  were  told  that  every  symptom  of 
immunopathology would have to be palliated with a medicine that attempted to reverse the 
symptom. Furthermore, if any measure of the patient's blood work went out of range, even 
temporarily, the patient would be given a medication to bring the metabolite back into range, 
or possibly be excluded from the study. 
 
We  agree  that  the  symptoms  of  immunopathology  are  very  difficult  to  manage  and  that 
palliation will be necessary in some cases. However, treating the patient in this manner 
would result in the inevitable prescription of many medications with numerous confounding 
side effects. Our ability to observe the immune response to olmesartan most likely would 
have been greatly reduced. This intervention would then negate the utility and outcome of 
the study. Consequently we did not proceed with the WCH study. However, until the clinical 
community  is  ready  to  work  within  a  new  paradigm  that  does  not  require 
immunosuppression, pursuing such a study may be quite difficult. 
 
In  the  meantime,  we  continue  to  gather  case  reports  and  series  from  our  clinical 
collaborators. While some have argued that such anecdotal reports are of no value, we have  
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learned a great deal from them. For example, it is clear that the immunopathological reaction 
appears to be consistent across a wide variety of inflammatory diagnoses. 
 
Rethinking assumptions about the human microbiota 
 
Most  physicians  have  little,  if  any,  training  in  metagenomics.  This  makes  our  work  very 
difficult, as physicians ultimately have to interpret the manner in which to optimally move our 
metagenomic  model  from  bench  to  bedside.  The  Faculty  of  1000  rated  my  2009  paper 
"Autoimmune disease in the era of the metagenome” as a "must read":  
 
The clear message of this article is that molecular genetic studies of diseases must 
include  analysis  of  resident  bacterial  genomes  and  not  focus  solely  on  the  human 
genome.  The  observations  presented  in  this  review  are  thought-provoking  and  offer 
new ways of thinking about the origin of diseases and possible novel treatments. 
 
The essence of this eye-opening article is that 90% of the cells in the human body are 
bacterial, that bacterial genomes are expressed in humans and that they have profound 
positive  or  negative  influences  on  health.  Compelling  evidence  is  presented  that 
humans  are  'superorganisms'  whose  molecular  functions  result  from  the  sum  of 
interactions between the human genome and a multitude of microbial genomes. The 
advantages of bacterial colonization and its profound influence on the diversity of the 
human  metagenome  are  emphasized.  The  human  genome  is  composed  of  about 
30,000  genes,  while  the  endogenous  microbial  flora  contribute  millions  of  genes.  In 
addition, transcription of the human genome is altered by the presence or absence of 
bacterial products. Differences in bacterial colonization account for individual variations  
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in gene expression. Lastly, the potential pivotal role of endogenous microbial genomes 
on the induction and persistence of autoimmune disease is emphasized. 
 
Even so, the clinical infectious disease expert, Mark Crislip, M.D., is on record as saying that 
the publication exaggerates the number of potential disease-causing pathogens capable of 
causing disease stating, “Of our thousand bacterial species, I only have to worry about a 
couple dozen.” 
 
At the same time, researchers in the metagenomics community are not making a compelling 
case to clinicians explaining why their work should be taken seriously. Metagenomic findings 
that  offer  compelling  new  connections  to  disease  progression  and  proliferation  are 
overshadowed  by  assertions  that  the  microbiota  is  largely  helpful  and  innocuous.  For 
example,  in  2010  Gordon  et  al.  decoded  viral  DNA  in  stool  samples  provided  by  four 
identical  twin  pairs  and  their  mothers.
11
  They  sequenced  the  DNA  from  stool  samples 
collected at three different times over a one-year period. Amazingly, more than 80% of the 
viral genetic sequences found, which included sequences characteristic of both animal and 
bacterial  viruses,  had  never  been  previously  reported.  When  asked  about  the  findings 
Gordon commented, "This is a largely unexplored world." He did not rule out the possibility 
that the viruses could, at least under certain conditions, contribute to disease processes. 
However the message the team communicated in the press release, and subsequently to 
the public, was very different. Despite the fact that the majority of these viruses had never 
been studied, they were repeatedly described as harmless and even beneficial. Yet Edward 
DeLong  of  MIT  commented  that,  in  oceans,  the  modality  of  viruses  has  tended  to  be 
predatory.  In  his  opinion,  Gordon’s  work  was  interesting  because  the  “faecal  microbiota 
seems to be driven by prophages, which tend to basically integrate their genetic material into 
the host genome and hide there — it's a much more stable situation."  
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Our model allows us to interpret prophage action a little differently. The integration of viral 
DNA into a host genome offers significant potential for some pathogenicity and genomic 
instability, albeit this is more likely over the long term. It is certainly premature to assume 
stability when the study was only of one-year duration. Yet apparently, because subjects 
were not acutely ill at the time of the study, it was decided that their fecal viral loads would 
best be described as innocuous. 
 
In our experience, researchers who stray from this tone may be accused of unnecessarily 
scaring  the  public.  To  some  extent,  metagenomic  researchers  are  wise  in  avoiding  the 
pitfalls  of  their  colleagues  who  jumped  to  premature  conclusions  in  studying  the  human 
genome. However, there is no need to swing to the other extreme and soft pedal the serious 
implications of many metagenomic discoveries. 
 
Final thoughts 
 
In the United States, the number of people with chronic diseases is projected to increase 
steadily for the next 30 years. Partnership for Solutions National Program Office estimates 
that it will reach 157 million by 2010. In 2004, almost half of all Americans, or 133 million 
people, lived with a chronic condition. At that time, people with chronic conditions accounted 
for 83 percent of health care spending, and those with five or more chronic conditions had an 
average  of  almost  fifteen  physician  visits  and  filled  over  50  prescriptions  each  year.
12 
According to the World Health Organization, deaths from “noncommunicable” diseases are 
projected to increase by 15% globally between 2010 and 2020.
13 
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The rate of chronic health conditions among children in the United States increased from 
12.8% in 1994 to 26.6% in 2006, particularly for asthma, obesity, and behavior and learning 
problems, according to results of a new prospective study published in the 2010 paper in 
Journal  of  the  American  Medical  Association.
14
  One  team  concluded  in  a  recent  meta-
analysis that if Americans keep gaining weight at the current rate, 75 percent of U.S. adults 
will be overweight and 41 percent obese by the year 2015.
15
 
 
Chronic disease prevalence is increasing at the same time that the theory of "autoimmunity" 
still  guides  our  clinical  approaches.  Meanwhile,  the  majority  of  autoimmune  researchers 
continue to look for answers to disease in the human genome alone. Rates of autoimmune 
disease  are  escalating  as  the  metagenomic  and  autoimmune  research  communities 
continue  to  operate  in  virtual  isolation.  These  trends  persist  as  substances  such  as  the 
secosteroid vitamin D are added to an increasing number of foods and supplements. 
 
Consequently, there is an urgent need for the novel paradigms, including those in our model, 
to  be  further  explored  and  tested.  Ultimately,  as  we  factor  the  microbiota  and  the 
metatranscriptome into our understanding of chronic disease we must make a choice. We 
can continue to use immunosuppressive substances that offer short-term palliation at the 
cost of long-term relapse. Or, we can move towards immunostimulatory approaches. While 
difficult in the short-term, these measures may improve long-term preventative and curative 
outcomes. 
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